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Abstract
Alpha-2 agonists for sedation of mechanically ventilated
adults in intensive care units: a systematic review
Moira Cruickshank,1 Lorna Henderson,1 Graeme MacLennan,1
Cynthia Fraser,1 Marion Campbell,1 Bronagh Blackwood,2
Anthony Gordon3 and Miriam Brazzelli1*
1Health Services Research Unit, University of Aberdeen, Aberdeen, UK
2Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences,
Queen’s University Belfast, Belfast, UK
3Faculty of Medicine, Department of Surgery and Cancer, Charing Cross Hospital,
Imperial College London, London, UK
*Corresponding author m.brazzelli@abdn.ac.uk
Background: Care of critically ill patients in intensive care units (ICUs) often requires potentially invasive
or uncomfortable procedures, such as mechanical ventilation (MV). Sedation can alleviate pain and
discomfort, provide protection from stressful or harmful events, prevent anxiety and promote sleep.
Various sedative agents are available for use in ICUs. In the UK, the most commonly used sedatives are
propofol (Diprivan®, AstraZeneca), benzodiazepines [e.g. midazolam (Hypnovel®, Roche) and lorazepam
(Ativan®, Pfizer)] and alpha-2 adrenergic receptor agonists [e.g. dexmedetomidine (Dexdor®, Orion
Corporation) and clonidine (Catapres®, Boehringer Ingelheim)]. Sedative agents vary in onset/duration of
effects and in their side effects. The pattern of sedation of alpha-2 agonists is quite different from that
of other sedatives in that patients can be aroused readily and their cognitive performance on psychometric
tests is usually preserved. Moreover, respiratory depression is less frequent after alpha-2 agonists than after
other sedative agents.
Objectives: To conduct a systematic review to evaluate the comparative effects of alpha-2 agonists
(dexmedetomidine and clonidine) and propofol or benzodiazepines (midazolam and lorazepam) in
mechanically ventilated adults admitted to ICUs.
Data sources: We searched major electronic databases (e.g. MEDLINE without revisions, MEDLINE
In-Process & Other Non-Indexed Citations, EMBASE and Cochrane Central Register of Controlled Trials)
from 1999 to 2014.
Methods: Evidence was considered from randomised controlled trials (RCTs) comparing dexmedetomidine
with clonidine or dexmedetomidine or clonidine with propofol or benzodiazepines such as midazolam,
lorazepam and diazepam (Diazemuls®, Actavis UK Limited). Primary outcomes included mortality, duration
of MV, length of ICU stay and adverse events. One reviewer extracted data and assessed the risk of bias of
included trials. A second reviewer cross-checked all the data extracted. Random-effects meta-analyses were
used for data synthesis.
Results: Eighteen RCTs (2489 adult patients) were included. One trial at unclear risk of bias compared
dexmedetomidine with clonidine and found that target sedation was achieved in a higher number of
patients treated with dexmedetomidine with lesser need for additional sedation. The remaining 17 trials
compared dexmedetomidine with propofol or benzodiazepines (midazolam or lorazepam). Trials varied
considerably with regard to clinical population, type of comparators, dose of sedative agents, outcome
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measures and length of follow-up. Overall, risk of bias was generally high or unclear. In particular,
few trials blinded outcome assessors. Compared with propofol or benzodiazepines (midazolam or
lorazepam), dexmedetomidine had no significant effects on mortality [risk ratio (RR) 1.03, 95% confidence
interval (CI) 0.85 to 1.24, I2= 0%; p= 0.78]. Length of ICU stay (mean difference –1.26 days, 95% CI
–1.96 to –0.55 days, I2= 31%; p= 0.0004) and time to extubation (mean difference –1.85 days, 95% CI
–2.61 to –1.09 days, I2= 0%; p< 0.00001) were significantly shorter among patients who received
dexmedetomidine. No difference in time to target sedation range was observed between sedative
interventions (I2= 0%; p= 0.14). Dexmedetomidine was associated with a higher risk of bradycardia
(RR 1.88, 95% CI 1.28 to 2.77, I2= 46%; p= 0.001).
Limitations: Trials varied considerably with regard to participants, type of comparators, dose of sedative
agents, outcome measures and length of follow-up. Overall, risk of bias was generally high or unclear.
In particular, few trials blinded assessors.
Conclusions: Evidence on the use of clonidine in ICUs is very limited. Dexmedetomidine may be effective
in reducing ICU length of stay and time to extubation in critically ill ICU patients. Risk of bradycardia but
not of overall mortality is higher among patients treated with dexmedetomidine. Well-designed RCTs are
needed to assess the use of clonidine in ICUs and identify subgroups of patients that are more likely to
benefit from the use of dexmedetomidine.
Study registration: This study is registered as PROSPERO CRD42014014101.
Funding: The National Institute for Health Research Health Technology Assessment programme.
The Health Services Research Unit is core funded by the Chief Scientist Office of the Scottish Government
Health and Social Care Directorates.
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Plain English summary
Sedation involves the use of drugs to produce a state of calm or sleep in patients admitted to intensivecare units (ICUs).
The most common drugs used in ICUs fall into three groups: (1) propofol (Diprivan®, AstraZeneca);
(2) benzodiazepines [including midazolam (Hypnovel®, Roche) and lorazepam (Ativan®, Pfizer)];
and (3) alpha-2 adrenergic receptor agonists [including clonidine (Catapres®, Boehringer Ingelheim) and
dexmedetomidine (Dexdor®, Orion Corporation)]. The effects of sedation vary between drugs and none
has been shown to be clearly better than the others. The drugs called alpha-2 agonists (clonidine and
dexmedetomidine) appear to be different in that patients can be awakened more easily, are better able to
communicate and do not suffer from breathing problems which can occur with other drugs.
We looked at all clinical studies that have been done on these drugs in people admitted to ICUs who
required assistance with breathing on a ventilator. We assessed (1) the effects of dexmedetomidine
compared with clonidine and (2) the effects of dexmedetomidine compared with propofol and
benzodiazepines. Results from 18 clinical studies (2489 patients) showed that, compared with other drugs,
dexmedetomidine reduced the length of stay in ICUs and the time until the patient was ready to have the
breathing tube removed. More people treated with dexmedetomidine, however, suffered from a slow
heart rate. The numbers of deaths and other bad effects were similar regardless of the drug used. Overall,
the quality of the clinical studies was low and there were some uncertainties regarding the data used for
the analyses. Further clinical studies are needed to evaluate the effects of clonidine and to identify which
patients are more likely to benefit from dexmedetomidine.
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Scientific summary
Background
Sedation is a key component of the care of critically ill patients who may need invasive or uncomfortable
procedures, such as mechanical ventilation (MV). In the intensive care unit (ICU), indications for sedation
include pain control, to allow use of distressing procedures and minimise patient discomfort, to provide
protection from stressful and harmful stimuli, reduction and control of agitation, and to enable nocturnal
sleep and induce amnesia.
Evidence from randomised controlled trials (RCTs) and current clinical guidelines support the use of
minimum possible sedation levels to achieve the desired effects, while preserving patient comfort and
safety. Indeed, the recent trend has been towards lighter levels of sedation, with only a minority of
patients requiring continuous deep sedation. Optimal sedation level varies widely between patients,
depending on their clinical condition and treatment requirements. Prevalence of anxiety and agitation
in critically ill patients undergoing MV has been reported to be > 70%. Therefore, assessment and
monitoring of sedation level should be routinely performed in ICUs. Usually, sedation level is measured by
means of scoring sedation scales. The most commonly used scales are the Richmond Agitation–Sedation
Scale and the Ramsay Sedation Scale.
Often, sedation requirements are not optimally managed, and oversedation or undersedation may occur with
important deleterious effects, such as cardiorespiratory depression, prolonged MV, hypertension and
tachycardia. The recent Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in
Adult Patients in the Intensive Care Unit [pain, agitation and delirium (PAD) guidelines] recommend routine
monitoring of the depth of sedation to address suboptimal sedation levels, use of sedation protocols and light
target sedation levels using either daily sedation interruptions or titration of sedatives.
These guidelines also stress the importance of routine assessment of pain with provision of adequate
analgesia to all critically ill patients and routine monitoring of delirium. Pain is the main stressor reported
by patients and the most common memory patients have of their ICU stay. Delirium may occur in up to
80% of mechanically ventilated ICU patients and is associated with higher mortality, longer MV and
hospital stay, and increased risk of cognitive impairment.
A variety of sedative agents are available for the management of critically ill patients in ICUs. The choice
of sedative or analgesic agents to achieve appropriate levels of sedation and pain relief can be quite
challenging and must take account of the pharmacological properties of the different drugs as well as the
individual patient’s characteristics and needs. In the UK, the most commonly used drugs are propofol
(Diprivan®, AstraZeneca), benzodiazepines [midazolam (Hypnovel®, Roche) and lorazepam (Ativan®, Pfizer)]
and alpha-2 adrenergic receptor agonists [dexmedetomidine (Dexdor®, Orion Corporation) and clonidine
(Catapres®, Boehringer Ingelheim)]. A shift from benzodiazepines to propofol has been recently observed in
ICU practice. The PAD guidelines suggest that use of non-benzodiazepines (propofol or dexmedetomidine)
may improve clinical outcomes over benzodiazepine-based sedation strategies (midazolam or lorazepam).
The 2014 Intensive Care National Audit and Research Centre national survey conducted among 235 adult
general ICUs in the UK showed that propofol was the most widely used sedative agent, with 88% of
the units reporting it as their first choice of sedative agent. Although approximately one-third of the
surveyed units (32%) reported frequent use of midazolam, only a small proportion (6%) reported that
midazolam was their first choice of sedative agent. Less than 1% of the units reported use of lorazepam.
Around one-third of ICUs (33%) reported frequent use of clonidine and 10% reported frequent use
of dexmedetomidine.
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The ideal sedation strategy for critically ill patients in ICUs should address pain, sedation and anxiety; have
favourable kinetics and clinical effects; be easily titrated and monitored; have a tolerable side effect profile;
and be affordable. None of the commonly used sedative agents fulfils all these criteria or has been shown
to be clearly superior to the others.
Objectives
The purpose of this assessment was to review the evidence from existing RCTs on the effects of alpha-2
agonists compared with each other and compared with alternative sedative agents in intensive care
practice, with the purpose of informing any future RCT.
The specific objectives of this assessment were (1) to assess the effects of sedation using dexmedetomidine
compared with clonidine in mechanically ventilated adults admitted to ICUs; and (2) to assess the effects of
sedation using dexmedetomidine or clonidine compared with other most commonly used sedative agents
(i.e. propofol and benzodiazepines) in mechanically ventilated adults admitted to ICUs.
Methods
This assessment was conducted according to current methodological standards. Comprehensive literature
searches were conducted to identify reports of RCTs assessing the effects of alpha-2 agonists, propofol and
benzodiazepines for sedation in ICUs. We searched major electronic databases including MEDLINE without
revisions, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Science Citation Index, Bioscience
Information Service and the Cochrane Central Register of Controlled Trials, for publications from 1999
onwards. Reports of relevant evidence synthesis were sought from the Cochrane Database of Systematic
Reviews and Database of Abstracts of Reviews of Effects. The World Health Organization International Clinical
Trials Registry Platform, metaRegister of Controlled Trials and ClinicalTrials.gov were searched for evidence of
ongoing studies. Final searches were carried out between 12 and 15 November 2014. Evidence for clinical
effectiveness was considered from fully published RCTs comparing dexmedetomidine with clonidine or
dexmedetomidine or clonidine with propofol or benzodiazepines (i.e. midazolam or lorazepam).
The population considered was critically ill adults admitted to ICUs who required MV. Primary outcomes of
interest were mortality, duration of MV, ventilator-free days, length of ICU stay, adverse events and unpleasant
side effects. Secondary outcomes were duration of weaning, time spent in target sedation range, proportion of
patients in target sedation range, extubation readiness, discharge readiness, length of hospital stay, quality of
life and costs. Data were extracted by one reviewer and double-checked by a second reviewer. The Cochrane
risk-of-bias tool was used to assess the risk of bias of the included RCTs. Random-effects meta-analyses were
performed when suitable data were available.
Results
Eighteen trials, with a total of 2489 patients, were included in the clinical effectiveness review. One trial
(70 patients) compared dexmedetomidine with clonidine; nine trials (1134 patients) compared
dexmedetomidine with propofol; four trials (939 patients) compared dexmedetomidine with midazolam;
one trial (118 patients) compared dexmedetomidine with propofol and midazolam (three treatment arms);
two trials (122 patients) compared dexmedetomidine with standard care (i.e. propofol and/or midazolam);
and one trial (106 participants) compared dexmedetomidine with lorazepam. Overall, four trials were
judged to be at low risk of bias, seven were judged to be at high risk of bias and the remaining seven trials
did not provide sufficient information on which to base a judgement. Clinical heterogeneity among trials
was mainly because of patient population (i.e. patients admitted to ICUs following elective surgery and
general ICU patients), comparator interventions, dosage of sedative agents, outcome measures and units
of measurements, and timing of follow-up assessments. Follow-up was short term (24 to 72 hours) in
most trials.
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Both clonidine and dexmedetomidine produced effective sedation. However, target sedation, with less
need for additional sedation, was achieved in more patients who received dexmedetomidine than in those
who received clonidine. Haemodynamic parameters appeared to be more stable among patients treated
with dexmedetomidine.
Compared with propofol or benzodiazepines (midazolam or lorazepam), dexmedetomidine had no
significant effects on mortality [risk ratio (RR) 1.03, 95% confidence interval (CI) 0.85 to 1.24, I2= 0%;
p= 0.78]. Length of ICU stay (mean difference –1.26 days, 95% CI –1.96 to –0.55 days, I2= 31%;
p= 0.0004) and time to extubation (mean difference –1.85 days, 95% CI –2.61 to –1.09 days, I2= 0%;
p< 0.00001) were significantly shorter among patients who received dexmedetomidine than among those
who received alternative sedative agents. The proportion of time spent in adequate sedation range was
not significantly different between sedative interventions (mean difference 2.53, 95% CI –0.82 to 5.87,
I2= 0%; p= 0.14), but dexmedetomidine was associated with a higher risk of bradycardia (RR 1.88,
95% CI 1.28 to 2.77, I2= 46%; p= 0.001). We did not find any difference between dexmedetomidine and
alternative sedative agents with regard to other adverse events such as hypotension, hypertension and
tachycardia. There was no clear evidence that dexmedetomidine could reduce the risk of delirium (RR 0.83,
95% CI 0.65 to 1.06, I2= 60%; p= 0.14), but statistical heterogeneity was observed in the analysis.
In general, patients treated with dexmedetomidine were reported to be more easily arousable, more
co-operative and better able to communicate than those treated with alternative sedative agents.
Subgroup analyses according to type of comparator were generally consistent with those of the
overall population.
Limitations
The majority of the included trials assessed the effects of dexmedetomidine compared with propofol or
midazolam. Data on the effects of dexmedetomidine compared with clonidine were limited (one trial).
There was considerable clinical heterogeneity among included trials, and most were at high or unclear risk
of bias. Few trials blinded outcome assessors.
There was substantial variation in the choice, definitions and measurements of outcome measures,
especially measures of ventilator dependence.
Transformation/imputation of data was required to combine results from included trials, as units of
measurements and methods for analysing results varied considerably between trials.
Subgroup analyses were performed according to the type of comparators, but subgroups were usually too
small to provide reliable conclusions.
Conclusions
There is an indication that dexmedetomidine may have a better cardiovascular safety profile than clonidine,
but evidence is limited. Length of stay in ICUs and time to extubation were significantly shorter among
patients who received dexmedetomidine than among those who received other sedative agents other than
clonidine. No difference was observed in time in target sedation range between dexmedetomidine and
alternative sedative interventions.
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Incidence of bradycardia was significantly higher for dexmedetomidine, but did not impact on mortality.
There was no clear evidence that dexmedetomidine was superior to other sedative agents in reducing the
risk of delirium. Considerable clinical heterogeneity between trials was observed, and the overall risk of
bias was high or unclear.
Recommendations for future research
Large, well-designed clinical trials are needed to (1) evaluate the long-term effects of clonidine for sedation
in ICUs; and (2) identify subgroups of patients who are more likely to benefit from dexmedetomidine.
Main subgroups of interest would be patients who require short-term sedation after elective surgery and
general critically ill patients who require long-term sedation.
Ideally, such trials would include relevant clinical outcomes sets, proper outcome definitions, validated
instruments to assess level of sedation and incidence of events such as delirium and coma, longer
follow-ups and a full economic evaluation. Relevant clinical outcomes from an ICU perspective would
comprise MV, length of ICU stay and incidence of delirium, bradycardia and hypotension. Patient-relevant
outcomes such as the patients’ ability to communicate with health-care personnel and the patients’
perspective of quality of sedation would also require consideration in future trials.
Study registration
This study is registered as PROSPERO CRD42014014101.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. The Health Services Research Unit is core funded by the Chief Scientist Office
of the Scottish Government Health and Social Care Directorates.
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Chapter 1 Background and research question
Description of health problem
Introduction
Sedation is ‘a drug-induced depression of consciousness, a continuum culminating in general
anaesthesia’.1 Sedation is a key component of care of critically ill patients, who often need to undergo
potentially invasive or uncomfortable procedures such as mechanical ventilation (MV).2–6 Indications for the
use of sedation in the intensive care unit (ICU) include: to alleviate pain; to facilitate use of distressing
procedures and minimise patient discomfort; to provide protection from stressful and harmful stimuli; to
reduce agitation and control agitation; and to enable nocturnal sleep and, when necessary, amnesia.6–11
Sedation requirements vary widely between patients and sedative regimens should be tailored to individual
patient’s needs [Sheila Harvey, Intensive Care National Audit and Research Centre (ICNARC), 2014].
Evidence from randomised controlled trials (RCTs) and current guidelines supports the use of the minimum
possible level of sedation to achieve the desired effects without compromising patient comfort and
safety.12,13 A review of international surveys of critical care clinicians published between 1999 and 2009
confirmed that the trend was towards lighter levels of sedation,4 with only a minority of patients in need
of continuous deep sedation.13–15
The optimal level of sedation varies according to patients’ clinical conditions and treatment requirements.
The prevalence of anxiety and agitation in critically ill patients undergoing MV in the ICU has been
reported to be > 70%. Hence, assessment of sedation level should be routinely performed in ICUs.14,16
Sedation level is usually measured by ICU staff by means of scoring sedation scales. Several scales have
been developed to monitor sedation levels in critically ill patients. The first standardised measurement for
sedation was the Ramsay Sedation Scale (RSS),17 which has been more recently superseded by the
Richmond Agitation–Sedation Scale (RASS)18,19 and the Riker Sedation–Agitation Scale (SAS).20 Scores on
the RASS range from 4 (combative) to –5 (cannot be aroused). Riker SAS scores range from 7 (dangerous
agitation) to 1 (cannot be aroused). For mechanically ventilated critically ill patients, target scores of
between –2 and 0 for the RASS and between 3 and 4 for the Riker SAS are considered appropriate.13
These scales have been shown to have good reliability and validity in the ICU setting, with neither being
definitively superior.12,14,21 Physiological methods to measure the level of sedation include heart rate
variability, auditory-evoked potentials and electroencephalogram.12,22 Among these, one of the most
developed is the bispectral index, which measures the level of consciousness by an algorithmic analysis of
the patient’s electroencephalographic and haemodynamic parameters, such as heart rate and arterial
pressure.11,23,24 Current UK and US guidelines do not recommend the use of physiological measures of
brain function (e.g. bispectral index) as the primary method to monitor level of sedation in non-comatose,
non-paralysed critically ill ICU patients, as these measures cannot adequately replace the existing subjective
sedation scoring systems.12,22
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Sedation requirements are often not optimally managed, and poor sedation practice, which encompasses
oversedation and undersedation, may have important deleterious effects.3,6,25 Oversedation can result in
cardiorespiratory depression, decreased gastrointestinal motility, immunosuppression and prolonged MV.
Undersedation can cause hypertension, tachycardia and discomfort.6 A variety of strategies have been
proposed to address suboptimal management of levels of sedation of critically ill patients in ICUs, including
use of sedation guidelines, protocols and goal-directed sedation algorithms,26–29 light target level of
sedation and daily sedation interruptions (DSIs),30–34 and regular monitoring of sedation requirements.35–37
The current Clinical Practice Guidelines from the Society of Critical Care Medicine for the Management of
Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit12 [pain, agitation and delirium
(PAD) guidelines] strongly recommend the use of management guidelines and protocols. Protocolised
target-based sedation and analgesia may be regarded as the cornerstone of effective sedation practice.38
The PAD guidelines also recommend DSI or a light level of sedation in mechanically ventilated adults
in ICUs.12 Current evidence on the use of DSIs is far from conclusive. A RCT conducted by Girard and
colleagues39 in four tertiary care hospitals found that a strategy comprising both daily spontaneous
breathing attempts and daily spontaneous awakening attempts (i.e. DSIs) resulted in better outcomes
(such as days breathing without assistance and length of stay in ICUs and hospital) than standard care.
A meta-analysis of five trials published in 201140 highlighted the need for further RCTs with long-term
survival follow-up before DSI could become standard sedation practice for critically ill patients.
A multicentre RCT by Mehta and colleagues36 found that, in mechanically ventilated patients receiving
continuous sedation, the combined use of protocol-guided sedation and DSI did not improve the clinical
outcomes observed with the use of protocol-guided sedation alone. Similarly, a recent Cochrane systematic
review35 did not find strong evidence that DSIs influence the duration of MV, mortality, length of stay,
drug consumption, quality of life or adverse events compared with sedation strategies that do not involve
the use of DSIs. The authors, however, considered the results to be unstable because of the small number
of identified trials, the clinical and statistical heterogeneity observed among them and the marginally
significant overall estimate of effect. Moreover, a reduction in duration of MV was detected when the
analyses were restricted to trials conducted in North America.35
Prior to initiating sedation, it is important to provide appropriate analgesia to all critically ill patients.3,11,15
Adequate pain control can reduce the need for sedative drugs.41 Pain can be experienced at rest by
patients in the ICU42 or because of a number of other factors, including routine care, underlying disease
processes, invasive procedures and immobility.13,43 Pain is reported as the principal stressor by patients and
is the most common memory they have of their ICU stay.13,44,45 The PAD guidelines stress the importance
of routine assessment of pain and provision of pre-emptive analgesia.12 Analgesics and sedatives work in
synergy but actually have discrete targets,6 and some analgesics also have a secondary sedative effect.3
For example, remifentanil (Ultiva®, GlaxoSmithKline UK Ltd), an opioid, can be administered as a sole agent
because of its sedative effects, although it is not commonly used in most ICUs.13
Clonidine (Catapres®, Boehringer Ingelheim) also has both sedative and analgesic effects.46 Patient’s
requirements for analgesia and sedation should be thoughtfully balanced11 and sedation should never be
given as a substitute for analgesia (Sheila Harvey, ICNARC, 2014).
Alongside assessment of pain, the PAD guidelines recommend the routine monitoring of delirium,12
which occurs in around 60–80% of mechanically ventilated patients in ICUs.47–50 Delirium is associated
with higher mortality, prolonged duration of MV, longer hospital stay and an increased risk of cognitive
impairment among adult ICU patients 47,51,52 The Confusion Assessment Method for the Intensive Care Unit
(CAM-ICU)53 and the Intensive Care Delirium Screening Checklist54 are the two most reliable instruments to
assess delirium and their use is recommended by current guidelines.12
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Current service provision
Management of critically ill patients in intensive care units in the UK
A variety of medication is available to treat critically ill patients in ICUs. The choice of sedative or analgesic
agents to achieve appropriate levels of sedation and pain relief can be quite challenging and must take account
of the pharmacological properties of the different drugs as well as the individual patient’s characteristics and
needs.4,11,55 Sedative agents commonly used in ICUs include propofol (Diprivan®, AstraZeneca), benzodiazepines
[midazolam and lorazepam (Ativan®, Pfizer)] and alpha-2 adrenergic receptor agonists [clonidine and
dexmedetomidine (Dexdor®, Orion Corporation)].34 Commonly used analgesic agents include alfentanil,
fentanyl, morphine and remifentanil.4,15 The current general trend in the UK, and internationally, is a shift from
benzodiazepines to propofol and from morphine to alfentanil and fentanyl.4,56,57 The 2013 PAD guidelines
suggest that sedation strategies using non-benzodiazepines (either propofol or dexmedetomidine) may improve
clinical outcomes in mechanically ventilated ICU patients over sedation strategies based on benzodiazepines
(either midazolam or lorazepam).12
Ideally, the optimal sedative regimen for critically ill patients in ICUs should adequately address pain,
sedation and anxiety; have favourable kinetics and clinical effects; be easily titrated and monitored; have a
tolerable adverse effects profile; and be affordable.4 At present, none of the commonly used sedative
agents fulfil all of these criteria and none of them has demonstrated to be clearly superior to the others.4,13,56
Variation in services and/or uncertainty about best practice
A recent UK national survey conducted by the ICNARC among 235 adult general critical care units together
with a point-prevalence study conducted among 52 adult general critical care units (Sheila Harvey,
ICNARC, 2014) showed that just over half of the surveyed units (57%) reported the use of a written
sedation or sedation/analgesia protocol and, of those that did, fewer than one-quarter assessed compliance
with the protocol. Level of compliance with sedation protocols varied considerably across units, ranging
from 26% to 100%. There was considerable variation with regard to the elements of pain, sedation and
delirium management that were included in each protocol and the level of details provided. The majority of
the units (94%) used a sedation scale/score for assessing the depth of sedation in patients. The RASS was
the most frequently reported scale in use (65% of units), followed by the RSS (25%). Small proportions of
units reported the use of the Riker SAS (3.5%), the modified RSS (3%), the Bloomsbury Sedation Scale (1%)
and other local or modified scales. Most patients (88%) in the point-prevalence study were assessed using
the same sedation scale/score reported in the survey, although variations were observed across units (from
63% to 100%). Seventy per cent of units reported screening for delirium daily and, of these, most (92%)
reported using the CAM-ICU tool. Most units (94%) reported that a sedation hold was considered daily for
sedated patients. The findings of the point-prevalence study indicate, however, that compliance with
sedation holding may be quite low. Overall, only 53% of sedated patients who had been in the unit for at
least 24 hours had been considered for a sedation hold during the previous 24 hours.
Despite the existence of numerous published studies and clinical guidelines for sedation and analgesia,
there is still a great variation between units in terms of actual intensive care, suggesting that there are still
some barriers to the implementation of all relevant recommendations into routine clinical practice.
Relevant national guidelines
The current clinical pathway for analgosedation in the ICU was published by the UK Intensive Care Society
in 2014 and recommends sequential assessment and treatment of pain, sedation and delirium, with
regular monitoring built into the pathway.22 These guidelines are in line with the current US12 and
German58 guidelines. The UK framework is presented in Figure 1.
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The National Institute for Health and Care Excellence Clinical Guidance Number 103,59 published in
July 2010, provides general recommendations for the diagnosis, prevention and management of delirium.
The only specific recommendations for people in critical care are that the CAM-ICU should be used if
indicators of delirium are identified and that consideration should be given to provision of 24-hour clocks
to patients to address cognitive impairment and/or disorientation. The UK Intensive Care Society guidelines
also provide recommendations for managing delirium.22 The suggested framework consists of three stages:
assess (pain, discomfort, constipation, hunger, delirium, attempts to communicate); treat (analgesia,
aperients, feed, drug withdrawal, change or stop sedative regimen); and prevent (alternative analgesia,
sleep, quiet and calm environment, diligent and targeted sedation, communication).
Description of technologies under assessment
Alpha-2 agonists
Dexmedetomidine is a newer, selective alpha-2 receptor agonist which has sedative, analgesic, anxiolytic
and sympatholytic effects.11,12,60 The sedative effects are mediated through decreased firing of the locus
coeruleus, the predominant noradrenergic nucleus, situated in the brainstem.61 The pattern of sedation
of the alpha-2 agonists is quite different from that of other sedative agents in that patients can be
aroused readily and their performance on psychometric tests is usually well preserved.22,62,63 Moreover,
dexmedetomidine does not depress the respiratory system, unlike other sedative agents.64,65
The dexmedetomidine terminal elimination half-life is around 2 hours.12,13 Main adverse effects related to
dexmedetomidine are hypotension and bradycardia.11,13,66 Transient hypertension may occur during
loading infusion.13
Patient
comfortable?
NO YES Reassess – at
least hourly
Propofol /
Midazolam /
Dexmedetomidine
Morphine /
Remifentanil
Dopamine
Antagonist (e.g.
Haloperidol /
Chlorpromazine)
Non-Pharmacological
Intervention
Delirium
Pain
Sedation
FIGURE 1 General framework for analgosedation in ICUs (the list of drugs is not exhaustive).22 Reproduced from
Grounds M, Snelson C, Whitehouse T, Wilson J, Tulloch L, Linhartova L, et al. Intensive Care Society Review of Best
Practice for Analgesia and Sedation in the Critical Care with permission from UK Intensive Care Society (www.ics.ac.uk).
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Dexmedetomidine was granted UK marketing authorisation in September 2011 for ‘sedation of adult ICU
patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding
to RASS 0 to –3)’.67 According to the summary of product characteristics,61 dexmedetomidine is for hospital
use only and should be administrated by a health-care professional skilled in managing patients requiring
intensive care. It should be administered by intravenous infusion only, using a controlled infusion device.
Doses are adjusted until the required level of sedation is attained. A loading dose is not recommended, as it
is associated with increased adverse reactions. The maximum dose of dexmedetomidine is 1.4 µg/kg/hour.
During infusion, all patients should undergo continuous cardiac monitoring, and respiration should be
monitored in non-intubated patients. Use of dexmedetomidine for > 14 days requires monitoring and
regular assessments. The combined use of dexmedetomidine with anaesthetics, other sedatives, hypnotics
or opioids is likely to enhance pharmacological effects and, consequently, a reduced dosage of
dexmedetomidine or the concomitant drug may be necessary.61 In the USA, dexmedetomidine is authorised
for infusion of up to 24 hours only in intubated and mechanically ventilated patients.68
In clinical trials, dexmedetomidine has been shown to be similar to midazolam and propofol on the time in
target sedation range in a predominantly medical population requiring prolonged light to moderate
sedation (RASS score of 0 to –3) in the ICU for up to 14 days.61,69 In addition, dexmedetomidine reduced
the duration of MV compared with midazolam61,70,71 and reduced the time to extubation compared
with midazolam and propofol. Compared with both propofol and midazolam, patients receiving
dexmedetomidine were more easily aroused, were more co-operative and better able to communicate
whether or not they had pain,61,70 and showed a lower rate of post-operative delirium.20,64,72 The sedative
benefits of dexmedetomidine compared with midazolam are, however, not conclusive. A systematic review
of six RCTs (1031 intensive care patients) published in 2013 has highlighted the need for further, more
robust, research as, so far, the evidence of the advantages of dexmedetomidine compared with midazolam
in the ICU setting is limited.2 A meta-analysis of 14 trials (3029 critically ill patients) published in 2014
showed that the use of dexmedetomidine in ICUs is associated with a significant reduction in the incidence
of delirium, agitation and confusion compared with other sedative agents.73 Another meta-analysis of
27 RCTs, assessing dexmedetomidine compared with any other comparator in 3648 mechanically
ventilated ICU patients, indicated that dexmedetomidine could be useful in reducing ICU stay and time
to extubation, although heterogeneity was detected among included studies.73 Similarly, a Cochrane
systematic review published in January 2015 and based on seven RCTs with a total of 1624 patients,
concluded that, compared with traditional sedative agents, long-term sedation with dexmedetomidine in
critically ill patients may reduce the duration of MV and the length of ICU stay. However, the general
methodological quality of evidence was low and there was clinical and statistical heterogeneity
among studies.74
Clonidine is an alpha-2 agonist agent that produces a reduction in sympathetic tone and resultant fall in
diastolic and systolic blood pressure and heart rate.75 Originally marketed as an antihypertensive agent,
clonidine has demonstrated sedative and analgesic-sparing properties. The current therapeutic indications
include the treatment of hypertensive crises,76 the prophylactic management of migraine or recurrent
vascular headache and the management of vasomotor conditions commonly associated with the
menopause and characterised by flushing.75 There is no current marketing authorisation for clonidine as a
sedative agent and no dosage recommendation for sedation in the summary of product characteristics.76
In the ICU setting, clonidine has been used as a treatment for delirium and as a second-line sedative
agent.77–79 The pharmacodynamics pattern of clonidine is broadly similar to that of dexmedetomidine,
but clonidine is less specific for alpha-2 receptors and has a lower affinity for alpha-2 receptors than
dexmedetomidine.60,78 Clonidine has been shown to be effective in controlling delirium and withdrawal
symptoms from opioids, benzodiazepines, nicotine and alcohol.78,80–83 Clonidine is a very lipid-soluble
agent. Its peak action occurs after 10 minutes and lasts for 3–7 hours after a single intravenous dose.84
Clonidine is metabolised in the liver and is eliminated primarily through the kidney. The elimination of the
half-life of clonidine is 6–23 hours (average 7.7 hours) (Sheila Harvey, ICNARC, 2014), a key difference
from dexmedetomidine which has an elimination half-life of around one-quarter the length of clonidine.85
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Sudden cessation of clonidine after prolonged use may cause a withdrawal syndrome leading to rebound
hypertension and tachycardia in susceptible patients.15,77,86 The main adverse effects of clonidine include
bradycardia, hypotension and xerostomia (dry mouth).15
Evidence on the use of clonidine in ICU settings is limited. A recent placebo-controlled RCT found a
significant reduction in the need for benzodiazepines and opioids, but not propofol, in mechanically
ventilated ICU patients treated with clonidine compared with those receiving placebo. No significant
differences in the incidence of adverse events were observed between the groups.87
A retrospective review of mechanically ventilated ICU patients’ clinical records showed a significantly lower
mortality index and no important adverse effects for patients receiving clonidine rather than other
sedatives.88 A prospective study assessing the effects of clonidine among mechanically ventilated ICU
patients with withdrawal symptoms after sedation interruption for ventilator weaning showed that the
majority responded positively to clonidine and were weaned in a median of 2 days. In addition, clonidine
decreased the haemodynamic, metabolic and respiratory parameters to near those observed with sedation.82
The role of alpha-2 agonists (clonidine and dexmedetomidine) in the sedation of ICU patients has yet to be
fully established.
Intravenous anaesthetic agents
Propofol is a short-acting intravenous general anaesthetic agent commonly used in ICUs since the 1980s.
It activates gamma-aminobutyric acid (GABA) receptors and has shown a considerable array of effects
including anxiolysis, anticonvulsant activity, antiemesis and the ability to reduce intracranial pressure.13,89–93
Propofol is a lipid-soluble compound with a rapid onset of action (from seconds to minutes) and a short
duration of effect following short-term administration.12,90,94 Owing to its short duration of sedative effect,
propofol may be indicated for patients who require frequent awakening and DSIs.12,95 The half-life of
propofol ranges from 30 to 60 minutes after short-term infusion, but is longer after prolonged infusion
(up to 50± 18.6 hours).12,13 The rapid onset and offset are specific features of propofol compared with
other common sedative drugs.96 The most significant side effects of propofol include hypotension as a
result of systemic vasodilation and dose-dependent respiratory depression.
Other side effects include hypertriglyceridaemia, acute pancreatitis, arrhythmia, bradycardia and cardiac
arrest.11–13 Propofol administration may rarely cause propofol infusion syndrome, an adverse reaction
characterised by lactic acidosis, hypertriglyceridaemia, hypotension and arrhythmia.12
A systematic review of 16 RCTs with a total of 1386 critically ill adult patients, which compared propofol
with alternative sedative agents for medium- or long-term sedation, concluded that propofol is safe and
can reduce the duration of MV. In addition, propofol also reduced the length of ICU stay when compared
with long-acting benzodiazepines but not when compared with midazolam.97
Benzodiazepines
Benzodiazepines bind to the GABA receptor complex modulating GABA release in the central nervous
system, causing downregulation of neuronal excitation (neurons become less excitable).11 Depending
on the dose used, they can cause sedation, anxiolysis or hypnosis (Sheila Harvey, ICNARC, 2014).
Benzodiazepines vary in their potency, onset and duration of effect, uptake, distribution, metabolism and
presence or absence of active metabolites.15,94 Lorazepam is more potent than midazolam, which, in turn,
is more potent than diazepam (Diazemuls®, Actavis UK Ltd). As midazolam and diazepam are more lipid
soluble than lorazepam, they cross the blood–brain barrier quicker and result in a more rapid onset of
action (from 2 to 10 minutes) than lorazepam (from 5 to 20 minutes).11,13,98–100 The half-life of midazolam is
3–11 hours, compared with 8–15 hours for lorazepam and 20–120 hours for diazepam.12,13 Midazolam
and diazepam metabolites are active and tend to accumulate with prolonged administration, especially in
patients with renal dysfunction.11,101 Lorazepam metabolites are not active and, for this reason, it is the
preferred benzodiazepine in patients with renal failure.11 As all benzodiazepines are metabolised
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predominantly in the liver, clearance is reduced in patients with hepatic dysfunction.12 Adverse effects of
benzodiazepines include hypotension, respiratory depression, paradoxical agitation, tolerance with acute
discontinuation and delirium.13,15,102
A recent systematic review of six trials (1235 patients) concluded that the use of a dexmedetomidine- or
propofol-based sedation regimen rather than a benzodiazepine-based regimen in critically ill patients may
reduce ICU length of stay and duration of MV.103 Indeed, current PAD guidelines suggest that sedation
strategies using non-benzodiazepines (either propofol or dexmedetomidine) may be preferred over
sedation with benzodiazepines (either midazolam or lorazepam) to improve outcomes in mechanically
ventilated adult ICU patients.12
Identification of important subgroups
Specific subgroups of interests are usually based on severity of disease, primary reasons for admission to
the ICU (e.g. admission after elective surgery) and duration of MV. Severity of disease is usually assessed
by means of severity scores and risk prediction models. One of the most commonly used methods is the
Acute Physiology and Chronic Health Evaluation (APACHE) II severity score system, which uses a point
score based on initial values of 12 routine physiological measurements, age and previous health status to
provide a general measure of severity of disease. Scores can range from 0 to 71, with higher scores
indicating more severe disease and a higher risk of mortality. This severity index has been used to evaluate
the use of hospital resources and compare the efficacy of intensive care over time and across different
hospitals. The APACHE II scores combined with an accurate description of disease can also be used to
stratify, prognostically, acutely ill patients and compare the success of new or differing forms of therapy.104
Current usage in the NHS
The 2014 ICNARC national survey, conducted among 235 adult general ICUs, together with a point
prevalence study conducted among 52 ICUs in the UK, showed that propofol was the most widely used
sedative agent, with 88% of the units reporting it as their first choice of agent. Although approximately
one-third of the surveyed units (32%) reported frequent use of midazolam, only a small proportion (6%)
reported that midazolam was their first choice of sedative agent. Less than 1% of the units reported use
of lorazepam. Approximately one-third of the ICUs reported frequent use of clonidine and 10% reported
frequent use of dexmedetomidine. The most frequently used agents for analgesia were alfentanil (51% of the
units), morphine (42%) and fentanyl (36%). The largest proportion of units (40%) reported that alfentanil
was their first choice of analgesic agent. In general, the trend was away from morphine, the first choice of
analgesic agent in 20% of the ICUs, towards alfentanil and fentanyl (Sheila Harvey, ICNARC, 2014).
With regard to the strategies on how sedatives and analgesics were used, 66% of surveyed units reported
that they occasionally or rarely opted for a single sedative agent and 76% of units for multiple sedative
agents together. Most units (82.7%) reported that their first and preferred approach was to use one
or more sedatives in combination with one or more analgesics. The expected duration for sedation and/or
analgesia was reported to be an important determinant in the choice of sedative and/or analgesic agent.
In the point prevalence study, 69% of sedated patients had received both a sedative agent and an
analgesic agent in the previous 24 hours and the most frequent choice was propofol combined with either
alfentanil or fentanyl (Sheila Harvey, ICNARC, 2014).
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Chapter 2 Definition of the decision problem
This chapter defines the main components of this assessment. The current clinical pathway foranalgosedation in the ICU is that of the UK Intensive Care Society, shown in Figure 1.22 The clinical
characteristics of the interventions under investigation were reported in Chapter 1. Detailed information on
the population, interventions, comparators and relevant outcomes considered for this assessment will be
presented in Chapter 3.
Population
The population considered for this assessment was critically ill adults admitted to ICUs who require MV.
People with primary brain injuries such as trauma or intracerebral bleed/infarct are not deemed suitable for
inclusion, as their clinical conditions require very specific ICU management and, often, a deeper level
of sedation.
Interventions assessed
Dexmedetomidine and clonidine for sedation in ICUs.
Relevant comparators
Propofol and benzodiazepines (e.g. midazolam and lorazepam) for sedation in ICUs.
In this assessment, the term ‘standard care’ refers to the use of propofol and/or midazolam, at the
discretion of the treating clinician, for sedation of critically ill patients admitted to ICUs, who require MV.
The specific use of sedation interruptions and sedation protocols is not included in this definition.
Relevant outcomes
The main outcomes of interest were mortality, duration of MV, ventilator-free days, length of ICU stay,
adverse events and unpleasant side effects. Secondary outcomes of interest include duration of weaning,
time spent in target sedation range, proportion of patients in target sedation range, discharge readiness,
extubation readiness, length of hospital stay, quality of life and cost.
Overall aims and objectives of the assessment
The purpose of this assessment was to systematically review the evidence of the clinical effectiveness of
the alpha-2 agonists, propofol and benzodiazepines in ICUs, with the purpose of informing future RCTs.
The specific objectives of this assessment were to (1) compare the effects of dexmedetomidine with those
of clonidine in mechanically ventilated adults admitted to ICUs and (2) compare the sedative effects of
dexmedetomidine or clonidine with those of other most commonly used sedatives (i.e. propofol and
benzodiazepines) in mechanically ventilated adults admitted to ICUs. The structure of this assessment will
be that of a Health Technology Assessment short report.
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Chapter 3 Assessment of clinical effectiveness
This chapter reports the evidence of the clinical effectiveness of dexmedetomidine compared withclonidine and of dexmedetomidine or clonidine compared with propofol or benzodiazepines
(midazolam or lorazepam) in mechanically ventilated adults admitted to ICUs.
Methods for assessing the outcomes arising from the use of the
intervention
The methods for this assessment were prespecified in a research protocol (www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42014014101).105
Identification of studies (search strategy and information sources/dates)
Highly sensitive literature searches, using an appropriate combination of controlled vocabulary and text word
terms, were developed to identify reports of published, ongoing and unpublished studies reporting the
clinical effectiveness of dexmedetomidine or clonidine in comparison with propofol and benzodiazepines
(e.g. midazolam, lorazepam and diazepam) in mechanically ventilated adults admitted to ICUs. Literature
searches were carried out from 12 to 15 November 2014 for publications from 1999 onwards. Details of the
search strategies are reported in Appendix 1. Major electronic databases were searched including MEDLINE
without revisions, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Science Citation Index,
Bioscience Information Service and the Cochrane Central Register of Controlled Trials. Reports of relevant
evidence synthesis were sought from the Cochrane Database of Systematic Reviews and Database of Abstracts
of Reviews of Effects. The World Health Organization International Clinical Trials Registry Platform,
metaRegister of Controlled Trials and ClinicalTrials.gov were searched for evidence of ongoing studies.
Websites of regulatory bodies and Health Technology Assessment agencies were checked for relevant
unpublished reports, while websites of relevant pharmaceutical companies and professional organisations
were searched for further pertinent information and reports.
In addition, reference lists of all included studies were perused for further citations.
Inclusion and exclusion criteria
Types of studies
Evidence was considered from RCTs comparing dexmedetomidine with clonidine or dexmedetomidine or
clonidine with propofol or benzodiazepines such as midazolam, lorazepam and diazepam.
The following types of reports were excluded:
l narrative reviews, editorials and opinions
l case reports
l conference abstracts for which a full publication or further methodological information could not
be found
l non-English-language reports for which a translation could not be organised
l studies that focused predominantly on people with primary brain injuries.
Types of participants
The types of participants considered were critically ill adults in ICUs who required MV. We did not
prespecify definitions for ‘critically ill’ or ‘adults’, so any study population described as such was deemed
suitable for inclusion.
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Interventions
The sedative interventions considered were dexmedetomidine and clonidine.
Comparator interventions
The comparator interventions assessed were propofol and benzodiazepines such as midazolam, lorazepam
and diazepam.
Outcomes
The following primary outcomes were considered:
l mortality
l duration of MV
l ventilator-free days
l length of ICU stay
l adverse events as reported by trial investigators and including the rate of:
¢ hypotension
¢ hypertension
¢ bradycardia
¢ respiratory depression
¢ delirium
¢ coma
¢ non-planned or accidental removal of lines (e.g. extubation) or catheters
l unpleasant side effects as reported by trial investigators (e.g. unpleasant memories, constipation
or diarrhoea).
Secondary outcomes considered were:
l duration of weaning
l time spent in target sedation range
l proportion of patients in target sedation range
l discharge readiness
l extubation readiness
l length of hospital stay
l quality of life
l cost.
Data extraction strategy (study selection and data collection)
One reviewer (MC) screened all titles and abstracts identified by the search strategies. A second reviewer
(MB) independently double-screened the first 100 abstracts and titles of the 2011–14 list. Agreement
between the two reviewers was 100%.
All potentially relevant reports were retrieved in full and assessed independently by one reviewer (MC).
A total of 40 reports were double-assessed by a second reviewer (Pawana Sharma or MB). Any
disagreements were resolved by consensus. The full-text screening form is presented in Appendix 2.
A data extraction spreadsheet (Microsoft Excel®, 2013; Microsoft Corporation, Redmond, WA, USA)
was developed specifically for the purpose of this assessment, piloted and amended as necessary.
From each study, one reviewer (MC) extracted information on geographical location, sponsor, study
design, participants’ characteristics, setting and characteristics of ICU practice, characteristics of sedative
intervention and outcome measures. Data extraction was double-checked by a second reviewer (MB).
Any disagreements were resolved by discussion.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Critical appraisal strategy
The risk of bias of included RCTs was initially assessed by one reviewer (MC) using Cochrane’s
risk-of-bias tool106 and, subsequently, cross-checked by a second reviewer (MB). The following domains
were assessed: sequence generation, allocation concealment, blinding of participants and medical
personnel, blinding of outcome assessors, incomplete outcome data and selective outcome reporting.
Assessment of ‘other bias’ was based on the funding source, and a study was judged to be at high risk of
bias if it was funded by the manufacturer(s) of the sedative agent(s) under investigation. Individual
outcomes were judged as being at ‘high’, ‘low’ or ‘unclear’ risk of bias. Overall, risk of bias for each study
was based on the findings of three key domains: sequence generation, allocation concealment and
blinding of outcome assessor.
Studies were classified as follows: (1) high risk of bias if one or more key domains were at high risk;
(2) unclear risk of bias if one or more key domains were judged to be at unclear risk; and (3) low risk of
bias if all key domains were judged to be at low risk. Any disagreements between reviewers were resolved
by discussion.
Method of analysis/synthesis
The general approach recommended by Cochrane was used for data analysis and synthesis.106 For binary
outcomes, the Mantel–Haenszel approach was used to pool risk ratios (RRs) derived from each study.
A random-effects model was used to calculate the pooled estimates of effect. For continuous outcomes
(duration of MV, ICU length of stay, hospital length of stay, time to extubation, time in target sedation
range and ventilator-free days), mean differences between groups were pooled when possible using the
inverse variance weighted mean difference method and a random-effects model. Random-effects
methods, rather than fixed-effects methods, as outlined in the original protocol, were chosen because of
the clinical and statistical heterogeneity observed among included studies.
For each continuous outcome, an initial analysis was conducted using only studies where the mean and
standard deviation (SD) were provided. In studies that did not report a mean and SD [and we could not
derive these summary measures from reported p-values, standard errors or confidence intervals (CIs)],
we tried to impute these from the data reported. The imputation strategy was as follows:
i. Where the median, range and n for each group were available, we used the formulae reported by
Hozo and colleagues107 to estimate the mean and SD.
ii. Where this method proved unfeasible, we imputed a SD from the available data using the methods
outlined by Furukawa and colleagues.108
iii. In studies where a median and interquartile range were reported, we used two methods to calculate
the mean. If the sample size was < 25, then first the median was used and second the value midway
between the lower quartile and upper quartile was used. If the two methods yielded results that
reversed the direction of treatment effect for a certain outcome within a study, then the study was
excluded from the pooled analysis of that outcome.
For each outcome where the above provided extra data, a second analysis was done using the
imputed data.
Heterogeneity across studies was explored by visual inspection of forest plots and using the chi-squared
test and I2-statistics.
When data were available, subgroup analyses were performed according to type of comparator intervention.
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Results of the evidence synthesis
Quantity of the evidence (studies included and excluded)
The literature searches identified 1182 potentially relevant citations, of which 83 were selected for full-text
assessment and 107 for background information. Of these, 59 were subsequently excluded because the
patient population, study design, outcomes reported or publication type were not eligible. A total of 18
RCTs published in 24 papers with a total of 2489 people were included in this assessment.5,52,69–72,102,109–125
It is worth noting that the results of the two large multicentre trials of PROpofol compared with
DEXmedetomidine (the PRODEX trial) and of MIdazolam compared with DEXmedetomidine (the MIDEX
trial) were published in a single report by Jakob and colleagues70 for the Dexmedetomidine for Long-Term
Sedation investigators. Figure 2 presents the flow chart of the selection process. Appendix 3 provides the
details of the 18 included trials and related secondary publications. Appendix 4 categorises the excluded
studies according to the main reasons for their exclusion.
Study characteristics
Appendix 5 details the study characteristics of the 18 included trials. All 18 trials were published in full.
Four different comparators were assessed. One trial, with a total of 70 randomised patients, compared the
effects and safety of dexmedetomidine with clonidine;55 nine trials, with a total of 1134 randomised
patients, compared dexmedetomidine with propofol;70,109–111,114,117,120,122,123 four trials, with a total of
939 randomised patients, compared dexmedetomidine with midazolam;70,71,112,116 one trial, with a total of
118 randomised patients, compared dexmedetomidine with propofol or midazolam (three arms);72 two
trials, with a total of 122 randomised patients, compared dexmedetomidine with ‘standard care’ (i.e.
propofol and/or midazolam);69,121 and one trial with a total of 106 randomised patients, compared
dexmedetomidine with lorazepam.102 A total of 2446 patients were analysed in the 18 included trials.
Titles/abstracts identified by
primary searches
(n = 1182)
Selected for full-text screening
(n = 83)
Retrieved for background
(n = 107)
Excluded
(n = 59)
• Not a RCT, n = 30
• Ineligible participants, n = 10
• No relevant outcomes, n = 5
• Foreign language, n = 11
• Unable to locate full text, n = 1
• Abstract only, n = 2
Excluded
(n = 992)
Included studies
(n = 18 RCTs published in
24 papers)
FIGURE 2 Flow chart of the study selection process.
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Six trials assessed dexmedetomidine in patients admitted to ICUs following elective surgery,72,110,111,114,120,123
whereas the remaining trials included general ICU patients.
Four trials were conducted in the USA,72,102,110,116 two in India,55,120 three in Turkey,112,117,122 two in
Egypt,109,111 one in the UK,123 one in North America (USA and Canada),114 one in Finland and Switzerland,69
and one in Australia and New Zealand.121 The MIDEX multicentre trial70 was conducted in nine European
countries; the PRODEX multicentre trial70 was conducted in six European countries and in Russia; and the
SEDCOM71 (Safety and Efficacy of Dexmedetomidine COmpared with Midazolam) multicentre trial was
conducted in the USA, Argentina, Brazil, Australia and New Zealand. All included trials involved
prospective collection of data.
Three trials assessed patients up to 45 days69,70 and one up to 90 days.121 In one trial,102 participants were
observed in the hospital from enrolment until discharge from hospital or death, and survivors were
observed for vital status until 1 year after enrolment using hospitals’ electronic record systems and a
commercial version of the Social Security Death Master File (http://ssdi.rootsweb.com). One trial114 followed
up patients for 24 hours after discharge from ICUs and another trial71 for 48 hours after study drug
cessation. One trial72 reported that patients were followed up for 3 days post operatively. In one trial,109
length of follow-up was reported to be 6 hours, in two trials55,120 it was 24 hours and in another trial123
it was 48–72 hours. Two trials reported follow-up in terms of time post extubation: one trial110 assessed
patients at least 24 hours post extubation and another trial116 at least 72 hours post extubation. Length of
follow-up was not reported in four trials.111,112,117,122
Appendix 6 presents details of dosage and route of administration of the respective sedative agents.
In general, dexmedetomidine was initiated with a loading dose of 1 µg/kg, administered intravenously over
a period of 10–20 minutes.109,110,112,114,117,120,122 Some trials involved lower55,72,102,116 or higher111,123 loading
doses, four trials did not use a loading dose69,70,121 and, in one trial, the loading dose was optional.71
Dexmedetomidine maintenance doses were fixed in two trials: 0.4 µg/kg/hour110 or 0.7 µg/kg/hour.112 The
remaining trials specified lower and upper limits for maintenance doses, with lower limits ranging from
0 µg/kg/hour121 to 0.015 µg/kg/hour,102,116 0.2 µg/kg/hour,55,70,72,111,114,117,120,122,123 0.4 µg/kg/hour,110
0.5 µg/kg/hour109 and 0.7 µg/kg/hour.112 The maximum allowable dose was 2.5 µg/kg/hour.117,122,123
Clonidine was used in one trial. Patients received an infusion of clonidine at 1 µg/kg/hour. Titration was
achieved with dosage increments up to 2 µg/kg/hour.55
Of the 12 trials that included a propofol arm, four trials reported a loading dose: an initial bolus dose
of 1mg/kg in one trial111 and 1mg/kg over 10–15 minutes in three trials.117,122,123 Six trials did not use a
loading dose69,70,72,109,110,120 and two trials did not provide information on dosage.114,121 Maintenance
infusions of propofol ranged from 0.5–1mg/kg/hour111 to 4mg/kg/hour across trials.69,70
Out of the seven trials that included a midazolam arm, one trial reported a loading dose of 0.05mg/kg112
and another trial reported an optional loading dose of the same level.71 The remaining trials did not use a
loading dose. One trial did not specify dosage of midazolam.121 Maintenance doses of midazolam were
between 0.03mg/kg/hour70 and 10mg/hour across trials.116
In one trial, lorazepam infusion started at 1mg/hour and was titrated to a maximum of 10mg/hour.102
All trials titrated sedatives to a target sedation level.55,69–72,102,109–112,114,116,117,120–123 Target sedation level was
measured by means of the RSS score in 11 trials,55,72,109–112,114,117,120,122,123 the RASS in six trials69–71,102,121
and the Riker SAS score in one trial.116
The main characteristics of the 18 included studies are shown in Table 1.
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Participant characteristics
The 18 included trials randomised a total of 1283 participants to dexmedetomidine and 1206 participants
to a control intervention. The sample sizes of included studies ranged from 23 to 501 participants.
There was some doubt whether or not the trial by Memis and colleagues (40 patients in total)117 and that
by Tasdogan and colleagues (40 patients in total)122 were mutually exclusive with regard to participants.
Even though a number of similarities between the two trials were observed, the characteristics of the two
patient populations were clearly not identical and, therefore, we treated them as two separate trials.
Correspondence with the trials investigators (Dr Dilek Memis named as corresponding author for both
trials) proved unsuccessful and did not elicit any response.
The mean age was reported in 12 trials.71,72,109–112,114,116,117,120–122 With the exception of one trial112 that focused
exclusively on young pregnant women (mean age 25.1 years in the dexmedetomidine group and 26.8 years
in the control intervention group), the 11 remaining trials mean age ranged from 43 to 65 years for
dexmedetomidine and from 40 to 67 years for the comparator interventions. The median age was reported
in six trials55,69,70,102,123 and ranged from 49 to 65 years for dexmedetomidine and from 46 to 67 years for the
comparator interventions.
Sixteen studies reported information regarding the sex of participants.55,69–72,102,109,110,112,114,116,117,120–122 Study
populations tended to involve more men than women, with the exception of one trial that involved only
pregnant women112 (see Appendix 5 for further details).
The severity of illness at baseline was reported in eight trials55,71,102,112,117,121–123 by means of the APACHE II
scores or APACHE III scores (one trial).116 The APACHE II scores have a possible range of 0–71, whereas the
APACHE III scores can range from 0 to 299. In both cases, higher scores indicate more severe disease and
a higher risk of death.104 Across the eight trials that used APACHE II, scores ranged from a mean of 5.1112
to a mean of 22 for dexmedetomidine117 and a mean of 6112 to a mean of 20117 for the control sedative
intervention. One trial102 reported a median APACHE II score of 29 for dexmedetomidine and of 27 for the
control sedative intervention. The trial116 that assessed severity of disease using the APACHE III scores
reported mean scores of 74.1 for dexmedetomidine and of 70.4 for midazolam.
Table 2 presents an overview of the participants’ characteristics of the 18 included trials. It is worth noting
that not all trials provided the same participant details or used the same measures to assess them.
Risk-of-bias assessment of included studies
Figure 3 presents the summary of the risk-of-bias assessments for all included trials. The risk of bias of
individual studies is presented in Figure 4.
Overall, out of the 18 included trials, four were judged to be at low risk of bias70,71,102 and seven at high
risk of bias.72,111,114,117,120–122 For the remaining seven trials, there was not sufficient information to make an
overall judgement.55,69,109,110,112,116,123
With regard to the assessment of selection bias, around half of the trials were judged to be at low risk
(i.e. adequate sequence generation and allocation concealment),55,70,71,102,110,112,116,117,122 whereas the remaining
eight trials did not provide sufficient information to formulate a proper judgement.69,72,109,111,114,120,121,123
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TABLE 2 Summary of main participants’ characteristics (for trials that reported this information)
Characteristic
Dexmedetomidine compared
with propofol RCTs
Dexmedetomidine compared
with midazolam RCTs
Dexmedetomidine compared
with other comparators
Total number
of participants
randomised
1134 (n= 9 trials) 939 (n= 4 trials) Dexmedetomidine compared
with clonidine: 70 (n= 1 trial)
Dexmedetomidine compared
with propofol and midazolam:
118 (n= 1 trial)
Dexmedetomidine compared
with standard care: 122 (n= 2
trials)
Dexmedetomidine compared
with lorazepam: 106 (n= 1
trial)
Age (years),
median of
means (range)
Dexmedetomidine: 60 (43–65);
propofol: 58 (40–67) (n= 9
trials)
Dexmedetomidine: 41.7
(25.1–58.3); midazolam: 42.3
(26.8–57.8) (n= 2 trials)
Dexmedetomidine: 65;
standard care: 61.6 (n= 1 trial)
Sex (% men),
median of
means (range)
65.5 (51.5–89.9) (n= 7 trials) 52.7 (0–65.6) (n= 4 trials) Dexmedetomidine compared
with clonidine: 54.3 (n= 1 trial)
Dexmedetomidine compared
with lorazepam: 51.4 (n= 1
trial)
Dexmedetomidine compared
with propofol and midazolam:
61.5 (n= 1 trial)
Dexmedetomidine compared
with standard care: 68.3
(54.4–82.2) (n= 2 trials)
APACHE II
scores, median
of means (range)
Dexmedetomidine: 19 (18–22);
propofol: 18 (16.5–20) (n= 3
trials)
Dexmedetomidine: 12.1
(5.1–19.1); midazolam: 12.2
(6–18.3) (n= 2 trials)
Dexmedetomidine (median 15)
compared with clonidine
(median 16.5) (n= 1 trial)
Dexmedetomidine (median 29)
compared with lorazepam
(median 27) (n= 1 trial)
Dexmedetomidine (median
20.2) compared with standard
care (median 18.6) (n= 1 trial)
Note
Owing to incomplete reporting or differences in the way this information was summarised in some included trials, the
number of trials varies between rows.
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Venn 2001123 PROPOFOL
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FIGURE 4 Risk-of-bias assessments of individual studies. CLON, clonidine compared with dexmedetomidine,
LORAZ, lorazepam compared with dexmedetomidine; MIDAZOLAM, midazolam compared with dexmedetomidine;
PROPOFOL, propofol compared with dexmedetomidine; SC, standard care compared with dexmedetomidine.
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In eight of the included trials, participants were reported to be blinded to the intervention
received,69–71,102,109,111,116 whereas in six trials they were not.72,114,117,120–122 The remaining four trials did not
report information on blinding of participants.55,110,112,123 Blinding of outcome assessor was addressed
adequately in five trials,69–71,102 not adequately in seven trials72,111,114,117,120–122 and not reported in
six trials.55,109,110,112,116,123
With regard to ‘incomplete outcome data’,10 trials had low withdrawal/discontinuation rates, which were
balanced between intervention groups and, therefore, judged to be at low risk of bias.69,71,72,102,112,116,117,120–122
Two trials reported significantly higher discontinuation rates, owing to lack of efficacy, among people
treated with dexmedetomidine, and were judged to be at high risk of bias.70 The remaining six trials did not
provide sufficient information on which to make a definitive judgement.55,109–111,114,123
There was no evidence of selective reporting in any of the included trials, with the exception of one trial111
in which data on hypotension and bradycardia were mentioned only in the discussion section of the
published paper and not properly reported in the results section. For this reason, the study was judged to
be at high risk of selective reporting.
With regard to ‘other sources of bias’, nine trials declared financial support by manufacturers of sedative
agents and were, therefore, judged to be at high risk of bias.69–71,102,116,120,121,123 One trial was judged at
low risk of bias, as the authors clearly stated that no funding was received from manufacturers.55 The
remaining eight studies were judged to be at unclear risk of bias, as the authors did not explicitly report
their source of funding.72,109–112,114,117,122
Summary of clinical effectiveness
Random-effects meta-analyses of relevant clinical outcomes were performed when appropriate.
We had initially planned to perform subgroup analyses according to the type of clinical setting (patients
admitted to ICUs following elective surgery compared with general ICU patients) if enough data had been
available. However, only 6 of the 18 studies included patients who were admitted to the ICU after elective
surgery, and not all of them provided data for all efficacy outcomes. Therefore, because of the dearth
of suitable data, subgroup analyses according to the type of clinical setting were deemed unfeasible.
As patients admitted to the ICU after elective surgery represent a distinct type of patient population (short
duration of sedation and MV, and lower mortality rate), we deemed it inappropriate to combine trials that
included patients after elective surgery with those that enrolled more general, critically ill ICU patients.
The results of trials that enrolled patients after elective surgery were instead summarised narratively.
It is worth pointing out that there was considerable variation among included trials in the choice,
definitions and measurements of outcomes, especially with regard to measures of ventilator dependence
such as duration of MV, ventilator-free days, time to extubation or duration of weaning. Often, trials that
assessed duration of MV did not report ventilator-free days as an outcome. The number of ventilator-free
days was available from three trials, but details on measurement were lacking.69,118,121 Information on time
to extubation was reported in six trials,70,71,111,114,123 but definition and criteria for extubation were not
consistent across trials. Two large trials (MIDEX and PRODEX)70 reported both duration of MV and time to
extubation, but did not provide a clear definition or measurement criteria for time to extubation and
failed to discuss the clinical difference between the two measures. Similarly, duration of weaning was
reported by two trials,69,114 but only one provided a proper outcome definition and a description of the
measurement criteria.114
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Clonidine compared with dexmedetomidine
One trial, at unclear risk of bias, randomised a total of 70 general ICU patients requiring MV to
dexmedetomidine (35 patients) or to clonidine (35 patients).55 Both clonidine and dexmedetomidine
produced effective sedation. Target sedation was achieved in 86% of observations among patients who
received dexmedetomidine and in 62% of observations among patients who received clonidine (p= 0.04).
Additional sedation was needed by more patients treated with clonidine than those treated with
dexmedetomidine (14 patients and 8 patients, respectively; p= 0.034). Hypotension was observed
significantly more frequently among patients who received clonidine (11 out of 35 patients) than among
patients who received dexmedetomidine (3 out of 35) (p= 0.02). Rebound hypertension was seen only in
four patients receiving clonidine. The authors concluded that both clonidine and dexmedetomidine
produced effective sedation. However, the haemodynamic stability provided by dexmedetomidine makes it
a preferable option over clonidine for short-term sedation of ICU patients.
Propofol and benzodiazepines (i.e. midazolam and lorazepam)
compared with dexmedetomidine
Primary outcomes
Mortality
Nine trials reported mortality data (Figure 5).69–71,102,116,117,120,121 A total of 196 out of 909 (22%) patients
who received dexmedetomidine and 162 out of 783 (21%) of patients who received a control intervention
died. Compared with alternative sedative agents, dexmedetomidine had no significant effects on mortality
(RR 1.03, 95% CI 0.85 to 1.24, I2= 0%; p= 0.78).
Two trials assessing patients after elective surgery reported mortality data.72,123 In one trial,72 two deaths
not attributable to sedation occurred among patients who received the control intervention (propofol),
whereas in the other trial123 two patients receiving dexmedetomidine died, compared with one patient
receiving the control intervention (propofol).
Duration of mechanical ventilation
Two trials reported mean duration of MV (Figure 6).70 There were no significant differences in the duration
of MV between dexmedetomidine and control interventions (mean difference –0.36, 95% CI –1.59 to
0.86, I2= 0%; p= 0.56).
Similarly, there was no difference (mean difference –0.30, 95% CI –1.70 to 1.11; p= 0.68) in the duration
of MV between dexmedetomidine and control interventions (Figure 7) when all available data suitable for
the analysis were considered (including transformed and imputed data). Statistical heterogeneity was
observed among trials (I2= 70%).
One trial that assessed patients after elective surgery110 reported no difference between dexmedetomidine
and propofol (p> 0.05) with regard to length of intubation.
Ventilator-free days
One trial provided suitable data for ventilator-free days (Figure 8).121 There was no evidence of a statistically
significant difference (mean difference 1.20, 95% CI –5.12 to 7.52; p= 0.71) between patients who
received dexmedetomidine and those who received standard care (propofol or midazolam).
When all available data suitable for the analysis were considered (including transformed and imputed data)
(Figure 9), the mean difference was 3.28 ventilator-free days (95% CI 0.06 to 6.49 ventilator-free days,
I2= 0%; p= 0.046) favouring dexmedetomidine.
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Intensive care unit length of stay
One trial provided mean length of ICU stay data (Figure 10).117 There was no evidence of a significant
difference between sedative agents (mean difference 2.00 days, 95% CI –3.12 to 7.12 days; p= 0.44).
However, Figure 11 shows that when all available data suitable for the analysis were considered (including
transformed and imputed data), ICU length of stay was significantly shorter among patients who received
dexmedetomidine than among those who received an alternative sedative agent (mean difference
–1.26 days, 95% CI –1.96 to –0.55 days, I2= 31%; p= 0.0004).
Hypotension
Five trials provided suitable data to assess the incidence of hypotension (Figure 12).69–71,116 There were no
statistically significant differences between participants who received dexmedetomidine (232 out of 789,
29%) and those who received an alternative sedative agent (137 out of 675, 20%) (RR 1.28, 95% CI 0.93
to 1.75, I2= 55%; p= 0.12).
The proportion of patients who developed hypotension was reported in two trials that assessed patients
after elective surgery.110,114 No statistically significant differences were found. In one trial,110 35 out of
43 patients who received dexmedetomidine experienced severe hypotension, compared with 31 out of
46 of those who received propofol (p= 0.132). In the other trial,114 hypotension occurred in 36 out of
148 (24%) participants who received dexmedetomidine and in 24 out of 147 (16%) participants who
received propofol (p= 0.111).
Hypertension
Three trials reported the incidence of hypertension during sedation (Figure 13).70,71 There was no evidence
of statistically significant differences (RR 1.09, 95% CI 0.89 to 1.33, I2= 21%; p= 0.43) between
dexmedetomidine (211 out of 737, 29%) and alternative sedative agents (143 out of 619, 23%).
In one trial, in which patients were sedated after elective coronary artery bypass graft (CABG) surgery,114
hypertension occurred more frequently among patients who received dexmedetomidine than among those
who received propofol (p= 0.018).
Bradycardia
Six trials assessed the incidence of bradycardia during sedation (Figure 14).69–71,102,116 Significantly more
participants who received dexmedetomidine (189 out of 841, 22%) experienced bradycardia than those
who received alternative sedative agents (70 out of 726, 10%) (RR 1.88, 95% CI 1.28 to 2.77,
I2= 46%; p= 0.001).
In one trial, which enrolled patients after elective coronary artery bypass graft surgery,114 the frequency of
bradycardia was similar between intervention groups [5 out of 148 (3%) in the dexmedetomidine group,
compared with 2 out of 147 (1%) in the propofol group; p= 0.448].
Delirium
Seven trials reported the proportion of patients who experienced episodes of delirium during
sedation.69–71,102,116,121 A total of 234 out of 862 (27%) participants who received dexmedetomidine and
209 out of 742 (28%) participants who received an alternative sedative agent experienced delirium
(Figure 15). The difference between sedatives was not statistically significant (RR 0.83, 95% CI 0.65 to
1.06, I2= 60%; p= 0.14). Statistical heterogeneity was observed among trials (I2= 60%).
Two trials, which enrolled patients after elective surgery, reported the proportion of patients with episodes
of delirium.72,110 In one trial,110 the number of patients with episodes of delirium was similar in both
intervention groups (1 out of 43 in the dexmedetomidine group compared with 1 out of 46 in the
propofol group). In the other trial,72 the incidence of delirium was 10% (4 out of 40) among patients
who received dexmedetomidine, 44% (16 out of 36) among those who received propofol and 44%
(17 out of 40) for those who received midazolam.
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Self-extubation
Four trials reported episodes of self-extubation during sedation (Figure 16).70,102,121 Self-extubation occurred
in 12 out of 566 (2%) of patients who received dexmedetomidine and 3 out of 564 (< 1%) of those who
received an alternative sedative agent. There was no clear evidence of a statistically significant difference
between sedative interventions (RR 2.95, 95% CI 0.96 to 9.06, I2= 0%; p= 0.06).
One trial, which assessed patients after elective surgery,110 reported one episode of self-extubation among
participants who received propofol (1 out of 46) and none among those who received dexmedetomidine
(0 out of 43).
Tachycardia
Five trials assessed the incidence of tachycardia among patients receiving sedation (Figure 17).70,71,102,116
There was no evidence of a significant difference (RR 0.93, 95% CI 0.63 to 1.39; p= 0.73) between
sedative interventions [187 out of 800 (23%) of those who received dexmedetomidine compared with
178 out of 682 (26%) of those who received alternative sedative agents]. Substantial statistical
heterogeneity was observed among trials (I2= 82%).
Rate of respiratory depression
Rate of respiratory depression was not reported by any of the included trials. However, respiratory rate was
reported by two trials.109,120 In both trials, no significant differences were observed between sedatives.
One trial109 recorded mean breaths per minute of 28 (SD 4 breaths per minute), 28 (SD 3 breaths per minute)
and 29 (SD 4 breaths per minute) among patients who received dexmedetomidine and 29 (SD 3 breaths per
minute), 30 (SD 3 breaths per minute) and 30 (SD 4 breaths per minute) among those who received propofol
at 2 hours, 4 hours and 6 hours after infusion of study drug, respectively. The other trial120 reported mean
respiratory rate per minute pre and post operatively. For patients who received dexmedetomidine, the
pre- and post-operative values were 16.53 (SD 3.83) and 17.07 (SD 3.47) breaths per minute, whereas for
those who received propofol the values were 17.25 (SD 3.58) and 20 (SD 4.0) breaths per minute, respectively.
Incidence of coma
One trial assessed the incidence of coma during a 12-day evaluation period.102 Significantly fewer patients who
received dexmedetomidine (63%) than those who received lorazepam (92%) experienced coma (p< 0.001).
Secondary outcomes and other reported outcomes
It is worth noting that no data were available from the included trials for extubation readiness, discharge
readiness and quality of life.
Duration of weaning
Two trials reported duration of weaning.69,114 Ruokonen and colleagues69 did not observe any difference
(p= 0.27) between patients who received dexmedetomidine (median 59.4 hours) and those who received
propofol and/or midazolam (median 78 hours). Similarly, Herr and colleagues,114 who enrolled patients after
elective surgery, found that there was no difference between sedative interventions in median times to
weaning. Median time to the start of weaning was 259 minutes (25th–75th percentiles 215–410 minutes)
for dexmedetomidine and 300 minutes (25th–75th percentiles 210–482 minutes) for propofol.
Time in target sedation range
Three trials provided data on percentage of total time in target sedation range (Figure 18).70,71 There was
no evidence of a significant difference between sedative interventions (mean difference 1.94% of total
time in target sedation range, 95% CI –1.70 to 5.57% of total time in target sedation range, I2= 0%).
Similarly, Figure 19 shows that no significant differences were evident between dexmedetomidine and
alternative sedative agents (mean difference 2.53% of total time in target sedation range, 95% CI –0.82
to 5.87% of total time in target sedation range, I2= 0%; p= 0.14) when all available data suitable for the
analysis (including transformed and imputed data) were considered.
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Two trials, which enrolled patients after elective surgery, assessed time in target sedation range.111,123
Both trials showed that the proportion of time spent at adequate depth of sedation was similar for
sedative interventions (46.3% for dexmedetomidine and 49.1% for propofol in one trial,123 and 93% for
dexmedetomidine and 92% for propofol in the other trial).111
Hospital length of stay
Three trials reported overall length of hospital stay and did not find any significant difference between
dexmedetomidine and alternative sedative interventions.70,121 In the MIDEX trial, the median duration of
study hospital stay was 35 days (range 14–45 days) for dexmedetomidine and 27 days (range 17–45 days)
for midazolam (p= 0.370). In the PRODEX trial, the median duration of study hospital stay was 25 days
(range 13–45 days) for dexmedetomidine and 28 days (range 14–45 days) for propofol (p= 0.760).70
Shehabi and collegues121 reported a median of 16.1 days (interquartile range 9.3–33.3 days) for
dexmedetomidine and 17 days (interquartile range 4.0–29.0 days) for standard sedative
treatments (p= 0.49).
Time to extubation
Two trials reported time to extubation (Figure 20).70 Time to extubation was significantly shorter among
patients who received dexmedetomidine than among those who received an alternative sedative agent
(mean difference –1.83 days, 95% CI –2.70 to –0.95 days, I2= 0%; p< 0.0001).
Similarly, time to extubation was significantly shorter for patients who received dexmedetomidine than
for those who received an alternative sedative agent (Figure 21) when all available data suitable for the
analysis (including transformed and imputed data) were considered (mean difference –1.85 days, 95% CI
–2.61 to –1.09 days, I2= 0%; p< 0.00001).
Three trials, which enrolled patients after elective surgery, assessed time to extubation.111,114,123 All three
trials showed that times to extubation were similar between sedative interventions. Elbaradie and
colleagues111 reported mean times to extubation of 30 minutes (SD 15 minutes) for dexmedetomidine
compared with 35 minutes (SD 12 minutes) for propofol. Herr and colleagues114 reported median times
to extubation of 410 minutes (25th–75th percentiles 310 to 584 minutes) for dexmedetomidine and
462 minutes (25th–75th percentiles 323–808 minutes) for propofol. In the trial by Venn and Grounds,123
mean extubation times were 29 minutes (range 15–50 minutes) for dexmedetomidine and 28 minutes
(range 20–50 minutes) for propofol (p= 0.63).
Cost of care
Three trials71,72,102 reported costs related to sedation. The trial by Pandharipande and colleagues, published in
2007,102 reported median costs of US$4675 for dexmedetomidine and US$2335 for lorazepam. The median
total hospital cost was approximately US$22,500 higher, but not significantly higher, for dexmedetomidine.
This difference was attributed to costs that occurred prior to enrolment and randomisation.
The trial by Maldonado and colleagues, published in 2009,72 reported an average total cost for
post-operative care of US$7025 for dexmedetomidine, compared with US$9875 and US$9570
for propofol and midazolam, respectively. There were no significant differences between sedative
interventions. For patients who developed delirium, the average cost was US$12,965, compared with
an average cost of US$6763 for those who did not (p= 0.004).
The SEDCOM trial by Riker and colleagues, published in 2009,71 reported overall economic costs (expressed
in Canadian dollars) of CA$7022 for dexmedetomidine and of CA$7680 for midazolam; medication costs
of CA$1929.57 for dexmedetomidine and CA$180.10 for midazolam; costs associated with delirium of
CA$2127.49 for dexmedetomidine and CA$3012.30 for midazolam; and MV costs were CA$2938.62 for
dexmedetomidine and CA$4447.64 for midazolam.
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Co-operation and communication
In four multicentre trials with a total of 1461 patients69–71 that compared dexmedetomidine with midazolam
or propofol, secondary efficacy outcomes included nurses’ assessment of arousal, co-operation and ability to
communicate pain using visual analogue scales. In all four trials,69–71 patients who received dexmedetomidine
were significantly more arousable, more co-operative and better able to communicate their pain than those
who received an alternative sedative agent (propofol or midazolam) (p≤ 0.001 in all cases).
Neuropsychological testing
In the trial by Pandharipande and colleagues102 (103 patients in total), neuropsychological tests were
administered within 72 hours of discharge from the ICU. A higher proportion of patients who received
dexmedetomidine (42%), but not significantly higher, were able to complete the post-ICU neuropsychological
testing than those who received lorazepam (31%) (p= 0.61). The median Mini-Mental State Examination
score, which evaluates global cognitive ability, was 28 for dexmedetomidine and 27 for lorazepam (p= 0.23),
whereas the median Trails-B scores, which assesses motor speed and attention functions corrected for age and
level of education, were 18 for dexmedetomidine and 19 for lorazepam (p= 0.75).
Anxiety and depression
The trial by MacLaren and colleagues116 assessed the rates of post-ICU anxiety, depression and acute stress
disorder manifestations among 23 mechanically ventilated patients admitted to ICUs. Validated assessment
scales were administered 72 hours after extubation but before hospital discharge. Eight patients in each
intervention group (midazolam compared with dexmedetomidine) completed the questionnaires.
Manifestations of anxiety and depression were similar between sedative interventions. Five patients (62.5%)
who received dexmedetomidine and one patient (12.5%) who received midazolam manifested acute stress
disorder (p= 0.063).
Memory of intensive care unit experience
Three trials provided information on patients’ ICU recall.110,116,123 MacLaren and colleagues,116 who assessed
a total of 23 patients, reported that the median number of ICU experiences remembered by patients
who received dexmedetomidine was significantly higher than that of patients who received midazolam
(18.5 compared with 8.5; p= 0.015).
Venn and Grounds123 enrolled a total of 20 patients after elective surgery and assessed recall 48–72 hours
after discharge from ICUs. The majority of patients who received dexmedetomidine remembered their length
of stay in ICU accurately, compared with those who received propofol (8 out of 10 compared with 2 out of 10
remembered their length of stay in the ICU; p= 0.023), but few remembered the duration of MV (3 out of
10 compared with 2 out of 10). Sleeping difficulty and noise were more often reported by patients who received
propofol and discomfort on the ventilator by those who received dexmedetomidine. No patient recorded pain.
Corbett and colleagues,110 who enrolled a total of 89 patients after elective surgery, evaluated patients’
perception regarding their ICU experience. A validated questionnaire was administered after ICU discharge
[mean time between discharge and administration of 46.5 hours (SD 24.5 hours) for dexmedetomidine and
45.5 hours (SD 20.7 hours) for propofol; p= 0.847]. Level of overall awareness as a marker to amnesia was
similar between sedative interventions as well as the overall level of discomfort and pain. Participants who
received dexmedetomidine perceived a significantly shorter length of intubation than those who received
propofol (p= 0.044). Perceptions in length of stay were similar between patient groups (p= 0.767). Patients
who received dexmedetomidine reported greater difficulty in resting or sleeping than those who received
propofol (p= 0.051).
Subgroup analyses
We were able to perform subgroup analyses of primary and secondary outcomes according to type of
comparator (see Appendix 7). Generally, results of subgroup analyses were consistent with those of the
overall population. However, subgroups were usually too small to provide reliable conclusions and caution
should be applied in their interpretation.
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No subgroup analyses were possible for age, severity of disease, different duration of MV, type of clinical
setting and nurse/patient ratio because of the paucity of suitable data.
Duration of MV was significantly longer for participants treated with dexmedetomidine than for those
treated with propofol, but it was significantly shorter than for those who received standard care. There
were no differences between participants who received dexmedetomidine and those who received
midazolam. Overall, duration of MV was significantly different across the various subgroups. A high level
of heterogeneity was evident in the analyses (I2= 78.1%).
Incidence of delirium was significantly lower in participants treated with dexmedetomidine than among
those treated with propofol or midazolam. There were no differences between participants treated with
dexmedetomidine than for those treated with standard care or lorazepam. Overall, there were significant
differences in the incidence of delirium across the comparator subgroups and there was evidence of high
heterogeneity (I2= 76.9%). The incidence of tachycardia was significantly lower for participants treated
with propofol than for those treated with dexmedetomidine. There were no differences between
participants who received dexmedetomidine and those who received midazolam or lorazepam. Overall,
there were significant differences in the incidence of tachycardia between the comparator subgroups and,
again, there was evidence of substantial heterogeneity (I2= 77.6%).
Table 3 presents an overview of all meta-analyses results including both main analyses and
subgroup analyses.
TABLE 3 Summary of meta-analyses results
Outcome or subgroup Number of studies Number of participants RR (95% CI)
Mortality 9 1692 1.02 (0.85 to 1.24)
Propofol 3 578 0.86 (0.60 to 1.23)
Midazolam 3 889 1.11 (0.82 to 1.50)
Standard care 2 122 1.62 (0.76 to 3.43)
Lorazepam 1 103 0.63 (0.30 to 1.33)
Duration of MV 4 1120 –0.30 (–1.70 to 1.11)
Propofol 2 535 a0.84 (0.11 to 1.57)**
Midazolam 1 500 –0.88 (–2.65 to 0.88)**
Standard care 1 85 a–2.36 (–4.62 to –0.10)**
Ventilator-free days 2 140 3.28 (0.06 to 6.49)b
Lorazepam 1 103 4.00 (0.27 to 7.73)a
Standard care 1 37 1.20 (–5.12 to 7.52)
ICU length of stay 8 1662 –1.26 (–1.96 to –0.55)*
Propofol 3 568 –0.40 (–1.41 to 0.61)
Midazolam 3 906 –1.86 (–2.71 to –1.01)
Lorazepam 1 103 –1.50 (–3.97 to 0.97)
Standard care 1 85 –1.00 (–3.44 to 1.44)
Hypotension 5 1464 1.28 (0.93 to 1.75)
Propofol 1 493 0.97 (0.62 to 1.53)
Midazolam 3 886 1.41 (0.90 to 2.22)
Standard care 1 85 2.15 (0.20 to 22.79)
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
TABLE 3 Summary of meta-analyses results (continued )
Outcome or subgroup Number of studies Number of participants RR (95% CI)
Hypertension 3 1356 1.09 (0.89 to 1.33)
Propofol 1 493 1.41 (0.96 to 2.07)
Midazolam 2 863 1.00 (0.82 to 1.22)
Bradycardia 6 1567 1.88 (1.28 to 2.77)*
Propofol 1 493 1.29 (0.79 to 2.10)a
Midazolam 3 886 1.94 (1.20 to 3.13)
Standard care 1 85 7.50 (0.40 to 140.91)
Lorazepam 1 103 4.41 (1.00 to 19.44)c
Delirium 7 1604 0.83 (0.65 to 1.06)
Propofol 1 493 a0.50 (0.26 to 0.98)**
Midazolam 3 886 a0.71 (0.61 to 0.82)**
Standard care 2 122 1.44 (0.86 to 2.41)**
Lorazepam 1 103 0.96 (0.79 to 1.16)**
Self-extubation 4 1130 2.95 (0.96 to 9.06)
Propofol 1 493 3.01 (0.12 to 73.58)
Midazolam 1 497 5.06 (0.60 to 43.01)
Standard care 1 37 3.86 (0.20 to 75.28)
Lorazepam 1 103 1.96 (0.38 to 10.24)
Tachycardia 5 1482 0.93 (0.63 to 1.39)
Propofol 1 493 a1.72 (1.12 to 2.65)**
Midazolam 3 886 0.71 (0.47 to 1.07)**
Lorazepam 1 103 0.95 (0.74 to 1.22)**
Time in target sedation range 5 1445 2.53 (–0.82 to 5.87)
Propofol 1 437 –0.10 (–6.68 to 6.48)
Midazolam 2 826 2.83 (–1.53 to 7.20)
Lorazepam 1 103 13.00 (–0.52 to 26.52)
Standard care 1 79 1.00 (–9.98 to 11.98)
Time to extubation 3 1364 –1.85 (–2.61 to –1.09)*
Propofol 1 498 –1.83 (–3.06 to –0.59)a
Midazolam 2 866 –1.86 (–2.83 to –0.89)a
*p< 0.05 for overall effect; **p< 0.05 for subgroup differences.
a p< 0.05 within subgroup.
b p= 0.05.
c p= 0.05 within subgroup.
Note
Results of continuous outcomes reported using all available data plus data imputed from range plus SD imputed from
available information; data from Maldonado and colleagues72 included in both propofol compared with dexmedetomidine
and midazolam compared with dexmedetomidine analyses.
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Chapter 4 Discussion
Statement of principal findings
The purpose of this assessment was to systematically review the available evidence of the effects of alpha-2
agonists (dexmedetomidine and clonidine) compared with alternative sedative agents in UK ICU clinical
practice. We included evidence from published RCTs comparing (1) dexmedetomidine with clonidine,
or (2) dexmedetomidine or clonidine with propofol or benzodiazepines in critically ill adults admitted to ICUs
who required MV. Relevant RCTs were identified through comprehensive literature searches. We considered
the following primary outcomes: mortality, duration of MV, ventilator-free days, length of ICU stay and
adverse events (e.g. hypotension, hypertension, bradycardia, delirium or coma). We also considered
the following secondary outcomes: time spent in target sedation range, length of hospital stay, extubation
readiness, discharge readiness, duration of weaning, quality of life and economic costs. When possible,
outcome data across included trials were statistically combined in a formal meta-analysis.
Clinical effectiveness
This assessment is based on evidence from 18 RCTs with a total of 2489 critically ill mechanically ventilated
ICU patients. Only 1 of the 18 identified trials compared dexmedetomidine directly with clonidine, while
the remaining trials assessed the effects and safety of dexmedetomidine compared with propofol or
compared with benzodiazepines (i.e. midazolam or lorazepam). Not all trials provided data for the
assessment of all primary and secondary outcomes under consideration. Clinical heterogeneity among trials
was mostly because of type of patient population (e.g. general ICU patients and patients admitted to ICU
following elective surgical); type of comparator treatment (i.e. propofol, midazolam or lorazepam); type of
outcome measures; and length of follow-up. Overall, trials were at high or unclear risk of bias.
Clonidine compared with dexmedetomidine
Srivastava and colleagues5 assessed 70 patients on short-term MV in ICUs and showed that target sedation
was achieved in a higher number of patients treated with dexmedetomidine with a lesser need for
additional sedation. Haemodynamic/cardiovascular parameters appeared to be more stable among patients
who received dexmedetomidine than among those who received clonidine.
Clonidine does not currently have a UK marketing authorisation for use as a sedative agent in ICUs and
there is no recommendation or consensus on best dose regimen for sedation. Nevertheless, the recent
findings of the UK national survey conducted by the ICNARC (Sheila Harvey, ICNARC, 2014) among 235
adult general ICUs have shown that around one-third of the units (32.7%) reported very frequent use of
clonidine while 10.3% reported very frequent use of dexmedetomidine. Occasional use of clonidine was
reported by 60.3% of the units, with only 3.7% indicating that it was never used.
Clonidine compared with propofol or benzodiazepines (i.e. midazolam
or lorazepam)
No trials of clonidine compared with alternative sedative agents were identified in the included studies.
Propofol or benzodiazepines (i.e. midazolam or lorazepam) compared
with dexmedetomidine
Seventeen trials compared the effects of dexmedetomidine with an alternative sedative agent other than
clonidine. Nine trials (1134 patients) assessed propofol compared with dexmedetomidine, four trials
(939 patients) compared midazolam with dexmedetomidine, one trial (118 patients) compared both
propofol and midazolam with dexmedetomidine (three treatment arms), two trials (122 patients) compared
‘standard care’ (i.e. propofol and/or midazolam) with dexmedetomidine (i.e. propofol and/or midazolam)
and one trial (106 patients) compared lorazepam with dexmedetomidine.
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When all available data were combined in meta-analyses, length of ICU stay and time to extubation were
significantly shorter among patients who received dexmedetomidine than among those who received an
alternative sedative agent (see Figures 11 and 21). In contrast, we did not observe a significant reduction in
duration of MV or ventilator-free days with the use of dexmedetomidine. A reduction in ICU length of stay
has been reported consistently in recently published systematic reviews,10,66,73,74,126 while results for other
efficacy outcomes have not. Pasin and colleagues,73 in line with our findings, observed a reduction in time
to extubation. Chen and colleagues74 demonstrated a significant reduction in the duration of MV after
dexmedetomidine while Tan and Ho,66 Xia and colleagues10 and Zhuo and colleagues126 did not. It is worth
noting that the inclusion/exclusion criteria and number of assessed studies varied considerably among
these previous systematic reviews.
In line with the findings of a recent systematic review that has assessed how outcomes are defined in
clinical trials of mechanically ventilated adults and children,127 we found that outcome sets and especially
measures of ventilator dependence (e.g. duration of MV, ventilation-free days and time to extubation)
differed among included trials. In particular, we observed a considerable variation among trials with regard
to outcome definitions, measurement criteria and time of assessment.
The proportion of time spent in adequate sedation range was not different between sedative interventions
(see Figure 19), indicating that dexmedetomidine was as effective as common sedative agents.
With regard to the incidence of adverse events, the results of our meta-analyses show an increased risk
of bradycardia after dexmedetomidine compared with alternative sedative agents (see Figure 14), but no
evidence of an increased risk of hypotension, hypertension or tachycardia. However, bradycardia did not
impact negatively on mortality, which showed no evidence of differences between sedative interventions
(see Figure 5). In most of the trials that contributed to the meta-analyses, bradycardia required relatively
standard intervention and rarely interruption of treatment. Riker and colleagues,71 for example, stated that
bradycardia required titration or interruption in 4.9% of the treated patients. Similarly, Ruokonen and
colleagues69 indicated that 4.8% of the patients discontinued dexmedetomidine because of bradycardia.
Moreover, akin to the findings of the meta-analysis by Tan and Ho,66 bradycardia in our assessment was
not observed to be accompanied by an increased risk of hypotension.
We did not observe a reduced risk of delirium among patients treated with dexmedetomidine. However,
delirium was not consistently defined in the included studies, different tools were used for its assessment
and most trials excluded patients with pre-existing neurological conditions and substance abuse. These
inconsistencies across trials may have contributed to the observed level of statistical heterogeneity.
In the literature, the systematic reviews by Pasin and colleagues73 and by Zhuo and colleagues126 have
suggested a lower incidence of delirium for dexmedetomidine. It is worth noting, however, that the
meta-analysis conducted by Pasin and colleagues73 demonstrated a reduced risk for dexmedetomidine
compared with other sedative agents when all clinical settings were considered, but not when only trials
based on general ICU settings were analysed (p= 0.05). Moreover, their analyses were not limited to
mechanically ventilated patients but included all patients admitted to ICUs and statistical heterogeneity
was evident in all the analyses. In addition, the systematic reviews by Chen and colleagues74 and by
Tan and Ho66 did not show any clear beneficial effect of dexmedetomidine in reducing the risk of delirium.
We observed more episodes of self-extubation among patients treated with dexmedetomidine; however,
we could not find clear evidence of a difference between sedative interventions (see Figure 16).
There were not enough data to assess the incidence of coma reliably.
Subgroup analyses according to type of comparator were generally consistent with those of the overall
population. However, subgroups were usually too small to provide reliable conclusions.
DISCUSSION
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Only limited data were available for duration of weaning and length of hospital stay, and no data were
available for extubation readiness, discharge readiness and quality of life.
Overall, across trials, patients treated with dexmedetomidine were reported to be more arousable, more
co-operative and better able to communicate than those who received alternative sedative agents (four trials).
A cost-minimisation analysis conducted by Dasta and colleagues,128 on the results of the Riker and
colleagues’ trial,71 showed that compared with midazolam, sedation with dexmedetomidine resulted in
significantly lower total ICU costs, mainly resulting from reduced length of ICU stay and lower MV costs.
Uncertainties from the assessment
This assessment was conducted according to current methodological standards and the methods were
specified a priori in a research protocol, which was informed by an advisory group established for the
purpose of this assessment. In particular, we performed comprehensive literature searches of the major
electronic databases and we contacted experts in the field to identify all existing relevant evidence.
We reviewed all potential eligible studies for inclusion and assessed their methodological quality using the
best recommended risk-of-bias tool. We developed specific data extraction forms on prespecified outcome
parameters and data extraction was performed by one reviewer and chekced by a second reviewer.
Despite all these efforts, there is still the possibility that some relevant evidence may have been missed.
Furthermore, we need to acknowledge the following limitations:
l This assessment provides mainly evidence on the use of dexmedetomidine as sedative agent in ICUs.
The evidence on the effects of clonidine in ICUs was scant (only one trial comparing clonidine with
dexmedetomidine was identified in our included studies). Nevertheless, one-third of UK ICUs have
reported frequent or very frequent use of clonidine and nearly two-thirds have reported occasional or
rare use of clonidine to sedate critically ill adults (Sheila Harvey, ICNARC, 2014). Clonidine appears to
be used off-label and evidence regarding its effectiveness and safety profile is clearly needed.
l The included trials were clinically heterogeneous. In particular, patient populations, comparator
interventions, dose of sedative agents, length of follow-up assessments, and choice and definitions of
outcome measures varied considerably across trials.
l The overall risk of bias was high or unclear in the majority of included trials. Only four trials were
judged to be at low risk of bias. In particular, blinding of outcome assessors was reported in only
5 of the 18 included trials.
l Length of follow-up after discharge from ICUs varied among included trials. Apart from one trial in
which survivors were followed up for 1 year after discharge from ICUs, none of the remaining trials
reported the long-term outcomes of patients receiving dexmedetomidine (generally, length of
follow-up ranged from 24 to 72 hours in most trials).
l Units of measurement, especially for continuous data, varied considerably among trials. This required
data transformation and imputation, and it hampered our ability to combine data across trials reliably.
l Subgroup analyses according to type of comparator were not very informative as subgroups were
too small. There were not enough data to perform subgroup analyses according to type of patient
population, which is likely to impact on the effects of sedation (e.g. elective ICU setting compared with
general ICU setting).
l There was substantial variation in the choice and definitions of outcome measures among included
trials. No trials reported information on extubation readiness, discharge readiness or quality of life.
l A number of trials and, in particular, all the largest included trials excluded patients with bradycardia
and hypotension. This may impact on the generalisability of our findings.
l In two large multicentre trials (MIDEX and PRODEX, with a total of 1001 patients), discontinuation
because of a lack of efficacy was observed significantly more frequently among patients treated with
dexmedetomidine. However, patients in these trials received standard sedation prior to randomisation
and this may have potentially masked the benefits of dexmedetomidine because a change of sedative
drug (from that received prior to randomisation) might have negatively affected the subsequent efficacy
of dexmedetomidine.
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Chapter 5 Conclusions
This assessment summarised evidence from 18 RCTs, including data from 2489 patients. Data wereavailable to make summary conclusions about several aspects of the use of dexmedetomidine; however,
the methodological quality of identified evidence was variable, with many studies at high or unclear risk of
bias. Evidence on the use of clonidine as a sedative agent in ICUs was limited. Dexmedetomidine was
observed to be as effective as propofol and commonly used benzodiazepines (i.e. midazolam and
lorazepam) in ensuring an adequate light sedation level of critically ill, mechanically ventilated adults
admitted to ICUs. Compared with propofol and benzodiazepines, dexmedetomidine was also observed to
be effective in reducing the ICU length of stay and time to extubation.
Use of dexmedetomidine, however, was associated with an increased risk of bradycardia but not of overall
mortality. There was not enough evidence to assess the risk of coma and not clear evidence of a reduced
risk of delirium.
Implications for health care
l Dexmedetomidine was observed to be effective in reducing the ICU length of stay and time to
extubation. Use of dexmedetomidine, however, was associated with an increased risk of bradycardia,
but not of overall mortality.
l Owing to the observed heterogeneity among included trials with regard to patients’ characteristics,
clinical setting, doses of sedative agents, outcome measures and length of follow-up, our results need
to be interpreted with caution and may not be easily generalisable. Moreover, all included trials
enrolled adult patients. Therefore, our findings cannot be generalised to paediatric ICU populations.
l Many trials excluded patients with bradycardia, hypotension, liver disease and neurological conditions
and, therefore, we do not know the full effects of dexmedetomidine in these categories of patients.
l Most of the included trials have reported only short-term outcomes and, therefore, the long-term
effects of the use of dexmedetomidine for ICU patients are still to be fully established.
l Only a few trials included DSI within their study protocol. It is possible that the effects of
dexmedetomidine are different when DSIs are implemented in ICU practice.
Recommendations for research
The main gap in the current evidence is the dearth of RCTs comparing clonidine with dexmedetomidine,
as well as clonidine with traditional alternative sedative agents (propofol and midazolam).
Larger well-designed RCTs are needed:
l To assess the use of clonidine as main sedative agent.
l To define which subgroups of ICU patients are more likely to benefit from dexmedetomidine as main
sedative agent. The two main subgroups of interest are patients who require short-term sedation after
elective surgery and general critically ill patients who require long-term sedation.
l To assess the effects of alpha-2 agonists in children admitted to ICUs. This would need to include
dose-ranging trials, as different weight-based doses may be required in this patient population.
Future trials should be multicentre, use proper blinding procedures (in particular blinding of outcome
assessors), include a common set of relevant outcome measures, define how outcomes will be measured,
use validated instruments to assess the level of sedation and the incidence of events such as delirium and
coma, assess long-term effects of alpha-2 agonists and include a full economic evaluation.
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With regard to the choice of relevant outcome measures, time to extubation, duration of MV, length of
ICU stay and incidence of delirium, bradycardia and hypotension are most relevant from an ICU
perspective. On the basis of our observed data, mortality remains important but less so as the primary
outcome of interest in future trials. Moreover, future trials should assess patients’ ability to communicate
with health-care personnel as well as patients’ perspective of quality of sedation (e.g. perception of pain
and discomfort, anxiety and memories of ICU experience).
Ideally, future trials should consider the core outcome set for ventilation studies that is currently under
development as part of the COMET (Core Outcome Measures in Effectiveness Trials) initiative.129
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Appendix 1 Literature search strategies
Database: EMBASE (1996 to 2014 week 45), MEDLINE without
Revisions (1996 to November week 1 2014), MEDLINE In-Process
& Other Non-Indexed Citations (12 November 2014)
Ovid Multifile Search URL: https://shibboleth.ovid.com/.
Date of search: 12 November 2014.
Search strategy
1. Conscious Sedation/
2. exp Respiration, Artificial/ use medf
3. exp artificial ventilation/ use emef
4. exp Critical Care/ use medf
5. Intensive Care/ use emef
6. Critical Illness/
7. (sedation or sedate?).tw.
8. ((mechanical$ or artificial$) adj5 ventilat$).tw.
9. or/1-8
10. Dexmedetomidine/
11. (dexmedetomidine or dexdor or precedex or primadex or dexdomitor or mpv1440 or mpv 1440).tw,rn.
12. Clonidine/
13. (clonidine or clofenil or klofenil or m5041t or m 5041t or catapres$ or st155 or st 155).tw,rn.
14. or/10-13
15. exp clinical trial/ use emef
16. randomized controlled trial.pt.
17. controlled clinical trial.pt
18. randomization/ use emef
19. randomi?ed.ab.
20. placebo.ab.
21. drug therapy.fs.
22. randomly.ab.
23. trial.ab.
24. groups.ab.
25. or/15-24
26. exp animals/ not humans/
27. nonhuman/ not human/
28. exp child/ not exp adult/
29. (conference abstract or letter).pt.
30. 25 not (26 or 27 or 28 or 29)
31. 9 and 14 and 30
32. limit 30 to yr=“1999 -Current”
33. remove duplicates from 31
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Science Citation Index (1999 to 13 November 2014)
Bioscience Information Service (1999 to 13 November 2014).
ISI Web of Knowledge URL: http://wok.mimas.ac.uk/.
Date of search: 13 November 2014.
Search strategy
1. (TS=critical illness) AND DOCUMENT TYPES: (Article)
2. (TS=critical care) AND DOCUMENT TYPES: (Article)
3. (TS=intensive care) AND DOCUMENT TYPES: (Article)
4. (TS=(sedation or sedate*)) AND DOCUMENT TYPES: (Article)
5. (TS=((mechanical* or artificial*) NEAR/3 ventilat*)) AND DOCUMENT TYPES: (Article)
6. #5 OR #4 OR #3 OR #2 OR #1
7. (TS=(dexmedetomidine or dexdor or precedex or primadex or dexdomitor or mpv1440 or
“mpv1440”)) AND DOCUMENT TYPES: (Article)
8. (TS=(clonidine or clofenil or klofenil or m5041t or “m 5041t” or catapres$ or st155 or “st 155”))
AND DOCUMENT TYPES: (Article)
9. #8 OR #7
10. #9 AND #6
11. (TS=trial*) AND DOCUMENT TYPES: (Article)
12. (TS=randomized) AND DOCUMENT TYPES: (Article)
13. (TS=randomised) AND DOCUMENT TYPES: (Article)
14. (TS=randomly) AND DOCUMENT TYPES: (Article)
15. #14 OR #13 OR #12 OR #11
16. #15 AND #10 Refined by: [excluding] WEB OF SCIENCE CATEGORIES: (PEDIATRICS)
Scopus (14 November 2014)
URL: www.scopus.com/home.url.
Date of search: 14 November 2014.
Search strategy
#1 (Dexmedetomidine or Clonidine).ti [In press articles].
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The Cochrane Library [Cochrane Central Register of Controlled
Trials (Issue 10 October 2014), Cochrane Database of Systematic
Reviews (Issue 11 November 2014)]
URL: www3.interscience.wiley.com/.
Date of search: 13 November 2014.
Search strategy
1. MeSH descriptor: [Conscious Sedation] explode all tree
2. MeSH descriptor: [Respiration, Artificial] explode all trees
3. MeSH descriptor: [Critical Care] explode all trees
4. MeSH descriptor: [Critical Illness] explode all trees
5. (sedation or sedate*):ti,ab,kw (Word variations have been searched)
6. ((mechanical* or artificial*) near/5 ventilat*):ti,ab,kw (Word variations have been searched)
7. #1 or #2 or #3 or #4 or #5 or #6
8. MeSH descriptor: [Dexmedetomidine] explode all trees
9. MeSH descriptor: [Clonidine] explode all trees
10. dexmedetomidine or dexdor or precedex or primadex or dexdomitor or mpv1440 or “mpv1440”:ti,ab,
kw (Word variations have been searched)
11. clonidine or clofenil or klofenil or m5041t or “m 5041t” or catapres$ or st155 or “st 155”:ti,ab,kw
(Word variations have been searched)
12. #8 or #9 or #10 or #11
13. #7 and #12
14. MeSH descriptor: [Child] explode all trees
15. MeSH descriptor: [Adult] explode all trees
16. #14 not #15
17. #13 not #16
Health Technology Assessment Database/Database of Abstracts
of Reviews of Effects
Centre for Reviews and Dissemination URL: http://nhscrd.york.ac.uk/welcome.htm.
Date of search: 12 November 2014.
Search strategy
1. MeSH DESCRIPTOR Conscious Sedation
2. MeSH DESCRIPTOR Respiration, Artificial EXPLODE ALL TREES
3. MeSH DESCRIPTOR Critical Illness
4. MeSH DESCRIPTOR Critical Care EXPLODE ALL TREES
5. #1 OR #2 OR #3 OR #4
6. MeSH DESCRIPTOR Clonidine EXPLODE ALL TREES
7. MeSH DESCRIPTOR D exmedetomidineEXPLODE ALL TREES
8. #6 OR #7
9. #5 AND #8
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Clinical Trials.gov
URL: http://clinicaltrials.gov/ct/gui/c/r.
Date of search: 15 November 2014.
Search strategy
Interventions=Dexmedetomidine or Clonidine
International Clinical Trials Registry Platform
World Health Organization URL: www.who.int/ictrp/en/.
Date of search: 15 November 2014.
Search strategy
Intervention= Dexmedetomidine or Clonidine
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Appendix 2 Full-text screening form
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Appendix 3 List of included studies
(including secondary publications)
Abdulatif 2004
Abdulatif M, Hamed HM, el-Borolossy K, Teima DO. A comparative study of the use of dexmedetomidine
and propofol as sedatives for mechanically ventilated patients in ICU. Egypt J Anaesthes 2004;20:437–42.
Corbett 2005
Corbett SM, Rebuck JA, Greene CM, Callas PW, Neale BW, Healey MA, et al. Dexmedetomidine does not
improve patient satisfaction when compared with propofol during mechanical ventilation. Crit Care Med
2005;33:940–5.
Elbaradie 2004
Elbaradie S, El Mahalawy FH, Solyman AH. Dexmedetomidine vs. propofol for short-term sedation of
postoperative mechanically ventilated patients. J Egypt Nat Cancer Inst 2004;16:153–8.
Esmaoglu 2009
Esmaoglu A, Ulgey A, Akin A, Boyaci A. Comparison between dexmedetomidine and midazolam for
sedation of eclampsia patients in the intensive care unit. J Crit Care 2009;24:551–5.
Herr 2003
Herr DL, Sum-Ping ST, England M. ICU sedation after coronary artery bypass graft surgery:
dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesthes
2003;17:576–84.
Jakob 2012
Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, et al. Dexmedetomidine vs
midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled
trials. JAMA 2012;307:1151–60.
MacLaren 2013
MacLaren R, Preslaski CR, Mueller SW, Kiser TH, Fish DN, Lavelle JC, et al. A randomized, double-blind
pilot study of dexmedetomidine versus midazolam for intensive care unit sedation: patient recall of their
experiences and short-term psychological outcomes. J Intensive Care Med 2013;30:167–75.
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Maldonado 2009
Maldonado JR, Wysong A, van der Starre PJ, Block T, Miller C, Reitz BA. Dexmedetomidine and the
reduction of postoperative delirium after cardiac surgery. Psychosomatics 2009;50:206–17.
Memis 2009
Memis D, Kargi M, Sut N. Effects of propofol and dexmedetomidine on indocyanine green elimination
assessed with LIMON to patients with early septic shock: a pilot study. J Crit Care 2009;24:603–8.
Pandharipande 2007
Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, et al. Effect of sedation with
dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS
randomized controlled trial. JAMA 2007;298:2644–53.
Secondary reports
Pandharipande PP, Sanders RD, Girard TD, McGrane S, Thompson JL, Shintani AK, et al. Effect of
dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis
of the MENDS randomized controlled trial. Crit Care 2010;14:R38.
Fine PG. Sedation in mechanically ventilated patients. J Pain Palliat Care Pharmacother 2008;22:15.
Riker 2009
Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs
midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009;301:489–99.
Secondary reports
Lachaine J, Beauchemin C. Economic evaluation of dexmedetomidine relative to midazolam for sedation in
the intensive care unit. Can J Hosp Pharm 2012;65:103–10.
Shehabi Y, Riker RR, Bokesch PM, Wisemandle W, Shintani A, Ely EW, et al. Delirium duration and mortality
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Riker R, Shehabi Y, Wisemandle W, Bokesch PM, Rocha MG, Bradt J. Dexmedetomidine improves
outcomes for long term ICU sedation when compared to midazolam: the Sedcom study. Chest
2008;134:34003s.
Ruokonen 2009
Ruokonen E, Parviainen I, Jakob SM, Nunes S, Kaukonen M, Shepherd ST, et al. Dexmedetomidine versus
propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med
2009;35:282–90.
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Takala J, Nunes S, Parviainen I, Jakob S, Kaukonen M, Shepherd S. Comparison of dexmedetomidine with
propofol/midazolam in sedation of long-stay intensive care patients: a prospective randomized, controlled,
multicenter trial. Crit Care 2007;11:P423.
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Shah 2014
Shah PN, Dongre V, Patil V, Pandya S, Mungantiwar A, Choulwar A. Comparison of post-operative ICU
sedation between dexmedetomidine and propofol in Indian population. Ind J Crit Care Med
2014;18:291–6.
Shehabi 2013
Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, et al. Early goal-directed sedation versus
standard sedation in mechanically ventilated critically ill patients: a pilot study. Crit Care Med
2013;41:1983–91.
Srivastava 2014
Srivastava U, Sarkar ME, Kumar A, Gupta A, Agarwal A, Singh TK, et al. Comparison of clonidine and
dexmedetomidine for short-term sedation of intensive care unit patients. Ind J Crit Care Med
2014;18:431–6.
Tasdogan 2009
Tasdogan M, Memis D, Sut N, Yuksel M. Results of a pilot study on the effects of propofol and
dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis. J Clin Anesth
2009;21:394–400.
Venn 2001
Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive
care unit: patient and clinician perceptions. Br J Anaesth 2001;87:684–90.
Secondary report
Venn RM, Bryant A, Hall GM, Grounds RM. Effects of dexmedetomidine on adrenocortical function, and
the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in
the intensive care unit. Br J Anaesth 2001;86:650–6.
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65

Appendix 4 Excluded studies grouped according
to the rationale for exclusion
Study not a randomised controlled trial (n= 30)
Abd Aziz N, Chue MC, Yong CY, Hassan Y, Awaisu A, Hassan J, et al. Efficacy and safety of
dexmedetomidine versus morphine in post-operative cardiac surgery patients. Int J Clin Pharm
2011;33:150–4.
Ahmed S, Murugan R. Dexmedetomidine use in the ICU: are we there yet? Crit Care 2013;17:320.
Akin S, Aribogan A, Arslan G. Dexmedetomidine as an adjunct to epidural analgesia after abdominal
surgery in elderly intensive care patients: a prospective, double-blind, clinical trial. Curr Ther Res Clin Exp
2008;69:16–28.
Anger KE, Szumita PM, Baroletti SA, Labreche MJ, Fanikos J. Evaluation of dexmedetomidine versus
propofol-based sedation therapy in mechanically ventilated cardiac surgery patients at a tertiary academic
medical center. Crit Pathway Cardiol 2010;9:221–6.
Barletta JF, Miedema SL, Wiseman D, Heiser JC, McAllen KJ. Impact of dexmedetomidine on analgesic
requirements in patients after cardiac surgery in a fast-track recovery room setting. Pharmacotherapy
2009;29:1427–32.
Bliesener B, Kleinschmidt S. [Incidence and duration of postoperative delirium after cardiac surgery:
comparison between dexmedetomidine and morphine for postoperative sedation and analgesia.]
Anaesthesist 2010;59:256–7.
Brar NK. Dexmedetomidine takes on propofol and midazolam. Clin Pulm Med 2012;19:237.
Cox CE, Govert JA. Assessing the comparative value of sedatives in the intensive care unit. Crit Care Med
2010;38:709–11.
Curtis JA, Hollinger MK, Jain HB. Propofol-based versus dexmedetomidine-based sedation in cardiac
surgery patients. J Cardiothorac Vasc Anesthes 2013;27:1289–94.
Devabhakthuni S, Pajoumand M, Williams C, Kufera JA, Watson K, Stein DM. Evaluation of
dexmedetomidine: safety and clinical outcomes in critically ill trauma patients. J Trauma Injury Infect Crit
Care 2011;71:1164–71.
Devlin JW, Al-Qadheeb NS, Chi A, Roberts RJ, Qawi I, Garpestad E, et al. Efficacy and safety of early
dexmedetomidine during noninvasive ventilation for patients with acute respiratory failure: a randomized,
double-blind, placebo-controlled pilot study. Chest 2014;145:1204–12.
Kopel L, Carvalho RT, Araujo H-BN, Fagundes AA, Ribeiro M, Bastos J. Dexmedetomidine for sedation
following cardiovascular surgery: a two different loading doses. Crit Care 2005;9:P120.
Liatsi D, Tsapas B, Pampori S, Tsagourias M, Pneumatikos I, Matamis D. Respiratory, metabolic and
hemodynamic effects of clonidine in ventilated patients presenting with withdrawal syndrome.
Intens Care Med 2009;35:275–81.
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
Martin E, Ramsay G, Mantz J, Sum-Ping ST. The role of the alpha2-adrenoceptor agonist dexmedetomidine
in postsurgical sedation in the intensive care unit. J Intens Care Med 2003;18:29–41.
Mehta S, Burry L, Cook D, Fergusson D, Steinberg M, Granton J, et al. Daily sedation interruption in
mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled
trial. JAMA 2012;308:1985–92.
Moritz RD, Machado FO, Pinto EP, Cardoso GS, Nassar SM. [Evaluate the clonidine use for sedoanalgesia in
intensive care unit patients under prolonged mechanical ventilation.] Rev Brasil Terap Inten 2008;20:24–30.
Nader ND, Li CM, Dosluoglu HH, Ignatowski TA, Spengler RN. Adjuvant therapy with intrathecal clonidine
improves postoperative pain in patients undergoing coronary artery bypass graft. Clin J Pain 2009;25:101–6.
Nour El-Din BM. Clinical evaluation of dexmedetomidine following ultra-fast track off-pump coronary
artery bypass grafting. Egypt J Anaesthes 2004;20:253–9.
Ozaki M, Takeda J, Tanaka K, Shiokawa Y, Nishi S, Matsuda K, et al. Safety and efficacy of
dexmedetomidine for long-term sedation in critically ill patients. J Anesthes 2014;28:38–50.
Pasin L, Landoni G, Nardelli P, Belletti A, Di Prima AL, Taddeo D, et al. Dexmedetomidine reduces the risk
of delirium, agitation and confusion in critically ill patients: a meta-analysis of randomized controlled trials.
J Cardiothorac Vasc Anesth 2014;28:1459–66.
Perez-Rada FJ, Franco-Calderon JL, Torres CM. Comparison of cerebral hemodynamic variables in
hemorrhagic stroke using dexmedetomidine-propofol versus dexmedetomidine-midazolam. Crit Care
2009;13(Suppl. 1):P402.
Prause A, Wappler F, Scholz J, Bause H, Schulte am EJ. Respiratory depression under long-term sedation with
sufentanil, midazolam and clonidine has no clinical significance. Intens Care Med 2000;26:1454–61.
Shehabi Y, Grant P, Wolfenden H, Hammond N, Bass F, Campbell M, et al. Prevalence of delirium with
dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled
trial (DEXmedetomidine COmpared to Morphine – DEXCOM Study). Anesthesiology 2009;111:1075–84.
Shehabi Y, Chan L, Kadiman S, Alias A, Ismail WN, Tan MATI, et al. Sedation depth and long-term
mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study.
Intens Care Med 2013;39:910–18.
Short J. Use of dexmedetomidine for primary sedation in a general intensive care unit. Crit Care Nurse
2010;30:29–38.
Spiegler P. It is time to wake up in the intensive care unit. Clin Pulmon Med 2008;15:232–3.
Tanaka LMS, Azevedo LCP, Park M, Schettino G, Nassar AP, Rea-Neto A, et al. Early sedation and clinical
outcomes of mechanically ventilated patients: a prospective multicenter cohort study. Crit Care
2014;18:R156.
Triltsch AE, Welte M, von HP, Grosse J, Genahr A, Moshirzadeh M, et al. Bispectral index-guided sedation
with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled
phase II study. Crit Care Med 2002;30:1007–14.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E, Naughton C, et al. Preliminary UK experience
of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia
1999;54:1136–42.
Wajida G, Kelly JS. Sedation in the Intensive Care Setting. In Urman RD, Kaye AD, editors. Moderate and
Deep Sedation in Clinical Practice. Cambridge: Cambridge University Press; 2012. pp. 218–29.
Participants outwith scope of review (n= 10)
Chen J, Zhou JQ, Chen ZF, Huang Y, Jiang H. Efficacy and safety of dexmedetomidine versus propofol for
the sedation of tube-retention after oral maxillofacial surgery. J Oral Maxillofacial Surg 2014;72:285–7.
Coull JT, Jones ME, Egan TD, Frith CD, Maze M. Attentional effects of noradrenaline vary with arousal
level: selective activation of thalamic pulvinar in humans. Neuroimage 2004;22:315–22.
Goodwin HE, Gill RS, Murakami PN, Thompson CB, Lewin JJ, III, Mirski MA. Dexmedetomidine preserves
attention/calculation when used for cooperative and short-term intensive care unit sedation. J Crit Care
2013;28:1113.
Huang Z, Chen YS, Yang ZL, Liu JY. Dexmedetomidine versus midazolam for the sedation of patients with
non-invasive ventilation failure. Intern Med 2012;51:2299–305.
Memis-D, Lu S, Vatan I, Yandim T, Yüksel M, Süt N. Effects of midazolam and dexmedetomidine on
inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth
2007;98:550–2.
Mirski MA, Lewin JJ, III, Ledroux S, Thompson C, Murakami P, Zink EK, et al. Cognitive improvement
during continuous sedation in critically ill, awake and responsive patients: the Acute Neurological ICU
Sedation Trial (ANIST). Intens Care Med 2010;36:1505–13.
Senoglu N, Oksuz H, Dogan Z, Yildiz H, Demirkiran H, Ekerbicer H. Sedation during noninvasive
mechanical ventilation with dexmedetomidine or midazolam: a randomized, double-blind, prospective
study. Curr Ther Res Clin Exp 2010;71:141–53.
Srivastava VK, Agrawal S, Kumar S, Mishra A, Sharma S, Kumar R. Comparison of dexmedetomidine,
propofol and midazolam for short-term sedation in postoperatively mechanically ventilated neurosurgical
patients. J Clin Diag Res 2014;8:GC04–7.
Terao Y, Ichinomiya T, Higashijima U, Tanise T, Miura K, Fukusaki M, et al. Comparison between propofol
and dexmedetomidine in postoperative sedation after extensive cervical spine surgery. J Anesth
2012;26:179–86.
Yu T, Huang Y, Guo F, Yang Y, Teboul JL, Qiu H. The effects of propofol and dexmedetomidine infusion
on fluid responsiveness in critically ill patients. J Surg Res 2013;185:763–73.
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
No relevant outcomes (n= 5)
Kadoi Y, Saito S, Kawauchi C, Hinohara H, Kunimoto F. Comparative effects of propofol vs
dexmedetomidine on cerebrovascular carbon dioxide reactivity in patients with septic shock. Br J Anaesth
2008;100:224–9.
Memis D, Dokmeci D, Karamanlioglu B, Turan A, Ture M. A comparison of the effect on gastric emptying
of propofol or dexmedetomidine in critically ill patients: preliminary study. Eur J Anaesthesiol
2006;23:700–4.
Pandharipande P, Girard TD, Sanders RD, Thompson JL. Comparison of sedation with dexmedetomidine
versus lorazepam in septic ICU patients. Crit Care 2008;12(Suppl. 2):P275.
Sahin N, Kabukou H, Ozkan N, Tirtiz TA. The effects of postoperative dexmedetomidine and midazolam
infusion on haemodynamics and sedation in patients after coronary artery bypass grafting. Eur J
Anaesthesiol 2005;22(Suppl. 35):40.
Singh A, Ambike D, Thatte WS, Das B. Dexmedetomidine versus midazolam infusion for sedation in
mechanically ventilated patients in critical care setting: A randomized controlled trial. Indian J Crit Care
Med 2013;17(Suppl. 1):4.
Published as abstract only (n= 2)
Gupta R, Mehta Y, Ali T, Joby GV. A randomized controlled study to compare the efficacy and safety
of prolonged sedation with dexmedetomidine vs midazolam for mechanically ventilated patients in the
intensive care. Intens Care Med 2013;39.
Riker RR, Ramsay MA, Prielipp RC, Jorden V. Long-term dexmedetomidine for ICU sedation: a pilot study.
Anesthesiology 2001;95.
Foreign-language article requiring translation (n= 11)
Aoki M, Nishimura Y, Baba H, Okawa Y. [Effects of dexmedetomidine hydrochloride on postoperative
sedation in cardiovascular surgery.] Kyobu Geka 2006;59:1181–5.
Cerny V, Samek J, Cichy D. [Postoperative sedation with dexmedetomidine in patients after off pump
coronary artery bypass.] Anesteziol Inten Med 2004;15:21–7.
Eremenko AA, Chernova EV. [Dexmedetomidine use for intravenous sedation and delirium treatment
during early postoperative period in cardio-surgical patients.] Anesteziol Reanimatol 2013;5:4–8.
Eremenko AA, Chemova EV. [Comparison of dexmedetomidine and propofol for short-term sedation in
early postoperative period after cardiac surgery.] Anesteziol Reanimatol 2014;2:37–41.
Fang S, Zhu Y, Xu H, Jiang H. [Dexmedetomidine for sedation during intubation period in postoperative
patients receiving orthognathic surgery in intensive care unit.] Zhongguo Xinyao Yu Linchuang Zazhi
2012;31:454–7.
Iwasaki Y, Nakamura T, Hamakawa T. [Retrospective evaluation of dexmedetomidine for postoperative
sedation in patients for cerebral aneurysm surgery.] Masui 2010;59:1396–9.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Kaneko T. [Postoperative management of carotid endarterectomy with dexmedetomidine – a comparison
with propofol.] Masui 2008;57:696–703.
Karabulut S, Tuncel Z, Kudsioglu T, Coskun FI, Yapici N, Altuntas Y, et al. [Sedation and analgesia after
cardiac surgery: comparison of dexmedetomidine, midazolam/fentanyl and midazolam/dexketoprofen
trometamol.] Gogus-Kalp-Damar Anestezi ve Yogun Bakim Dernegi Dergisi 2014;20.
Moritz RD, Machado FO, Pinto EP, Cardoso GS, Nassar SM. [Evaluate the clonidine use for sedoanalgesia
in intensive care unit patients under prolonged mechanical ventilation.] Revista Brasi Terap Inten
2008;20:24–30.
Wan LJ, Huang QQ, Yue JX, Lin L, Li SH. [Comparison of sedative effect of dexmedetomidine and
midazolam for post-operative patients undergoing mechanical ventilation in surgical intensive care unit.]
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2011;23:543–6.
Yao L, Zhou XM, Zhao JJ. [The role of dexmedetomidine in treatment of serious patients in intensive care
unit.] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2010;22:632–4.
Unable to locate full text (n= 1)
Assad Farhat OM, Abdel-Raouf S, Hussien GZ, Labib D. Comparative study between the effects of
dexmedetomidine versus propofol infusion on human neutrophil functions in cardiac surgical patients in
ICU. Egypt J Anaesth 2010;26:113–22.
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
71

Appendix 5 Characteristics of included studies
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
TA
B
LE
4
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
A
bd
ul
at
if,
20
04
10
9
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
N
R
C
ou
nt
ry
:
Eg
yp
t
St
ar
t/
en
d
da
te
s:
N
R
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
ra
nd
om
is
ed
co
m
pa
ra
tiv
e
st
ud
y
Ra
nd
om
is
at
io
n
m
et
ho
d:
N
R
Le
ng
th
of
fo
llo
w
-u
p:
6
ho
ur
s
So
ur
ce
of
fu
nd
in
g:
N
R
Ty
pe
of
pa
rt
ic
ip
an
ts
:
pa
tie
nt
s
ha
d
es
ta
bl
is
he
d
re
sp
ira
to
ry
fa
ilu
re
re
qu
iri
ng
M
V
us
in
g
pr
es
su
re
su
pp
or
t
ve
nt
ila
tio
n
w
ith
or
w
ith
ou
t
co
nt
in
uo
us
po
si
tiv
e
ai
rw
ay
pr
es
su
re
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
l
A
:
20
l
B:
20
A
na
ly
se
d:
l
A
:
20
l
B:
20
A
ge
(y
ea
rs
),
m
ea
n
(S
D
):
l
A
:
43
(3
.7
)
l
B:
40
(5
.2
)
Se
x,
n
(%
):
l
A
:
m
al
e
10
(5
0)
,
fe
m
al
e
8
(4
0)
,
N
R
2
(1
0)
l
B:
m
al
e
9
(4
5)
,
fe
m
al
e
10
(5
0)
,
N
R
1
(5
)
In
cl
us
io
n
cr
ite
ria
:
pa
tie
nt
s
ha
d
es
ta
bl
is
he
d
re
sp
ira
to
ry
fa
ilu
re
re
qu
iri
ng
M
V
us
in
g
pr
es
su
re
su
pp
or
t
ve
nt
ila
tio
n
w
ith
or
w
ith
ou
t
co
nt
in
uo
us
po
si
tiv
e
ai
rw
ay
pr
es
su
re
Ex
cl
us
io
n
cr
ite
ria
:
ex
cl
us
io
n
cr
ite
ria
in
cl
ud
ed
si
gn
ifi
ca
nt
re
na
lo
r
he
pa
tic
dy
sf
un
ct
io
n,
ca
rd
io
va
sc
ul
ar
in
st
ab
ili
ty
,
co
nc
ur
re
nt
us
e
of
in
ot
ro
pe
s
or
va
so
ac
tiv
e
dr
ug
s,
C
N
S
or
ps
yc
ho
lo
gi
ca
ld
is
or
de
rs
,
us
e
of
m
us
cl
e
re
la
xa
nt
s
to
fa
ci
lit
at
e
ve
nt
ila
tio
n,
pr
eg
na
nc
y
or
m
or
bi
d
ob
es
ity
IC
U
se
tt
in
g:
N
R
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
pr
op
of
ol
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
l
A
:
in
iti
al
i.v
.
lo
ad
in
g
do
se
(1
µg
/k
g)
ov
er
10
m
in
ut
es
,
fo
llo
w
ed
by
co
nt
in
uo
us
i.v
.
in
fu
si
on
(5
µg
/m
l)
at
a
ra
te
of
0.
5
µg
/k
g/
ho
ur
(0
.1
m
l/k
g/
ho
ur
)t
o
be
in
cr
ea
se
d
to
a
m
ax
im
um
of
1
µg
/k
g/
ho
ur
l
B:
i.v
.
in
fu
si
on
(1
0
m
g/
m
l)
st
ar
tin
g
w
ith
a
do
se
of
1
m
g/
kg
/h
ou
r
(0
.1
m
l/h
ou
r)
an
d
in
cr
ea
si
ng
up
to
2
m
g/
kg
/h
ou
r
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
6
ho
ur
s
Ta
rg
et
se
da
tio
n
le
ve
l:
RS
S
sc
or
e
of
2
or
3
Re
sc
ue
m
ed
ic
at
io
n:
1-
m
g
bo
lu
s
of
m
id
az
ol
am
Pa
in
co
nt
ro
l:
N
R
D
ai
ly
in
te
rr
up
tio
n:
N
R
Ph
ys
io
lo
gi
ca
lp
ar
am
et
er
s,
cl
in
ic
al
ad
ve
rs
e
re
sp
ira
to
ry
ef
fe
ct
s
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
C
or
be
tt
,
20
05
11
0
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
1
C
ou
nt
ry
:
U
SA
St
ar
t/
en
d
da
te
s:
O
ct
ob
er
20
02
–
A
pr
il
20
04
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
RC
T
Ra
nd
om
is
at
io
n
m
et
ho
d:
vi
a
a
ra
nd
om
-n
um
be
r
ta
bl
e,
oc
cu
rr
ed
in
th
e
op
er
at
in
g
ro
om
be
fo
re
st
er
na
lc
lo
su
re
,
an
d
th
e
dr
ug
w
as
in
iti
at
ed
af
te
r
by
pa
ss
Le
ng
th
of
fo
llo
w
-u
p:
at
le
as
t
24
ho
ur
s
af
te
r
ex
tu
ba
tio
n
Ty
pe
of
pa
rt
ic
ip
an
ts
:
af
te
r
no
n-
em
er
ge
nt
C
A
BG
su
rg
er
y
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
N
R
A
na
ly
se
d:
l
A
:
43
l
B:
46
A
ge
(y
ea
rs
),
m
ea
n
(S
D
):
l
A
:
63
.5
(1
0.
1)
l
B:
62
.4
(1
0.
7)
Se
x,
n
(%
):
l
A
:
m
al
e,
35
(8
1)
;
fe
m
al
e,
8
(1
9)
l
B:
m
al
e,
38
(8
3)
;
fe
m
al
e,
8
(1
7)
In
cl
us
io
n
cr
ite
ria
:
≥
18
ye
ar
s
of
ag
e
an
d
re
qu
iri
ng
no
n-
em
er
ge
nt
C
A
BG
su
rg
er
y
w
ith
an
ex
pe
ct
ed
M
V
le
ng
th
of
24
ho
ur
s
IC
U
se
tt
in
g:
N
R
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
pr
op
of
ol
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
l
A
:
1
µg
/k
g
(a
ct
ua
lb
od
y
w
ei
gh
t)
lo
ad
in
g
do
se
in
tr
av
en
ou
sl
y
ad
m
in
is
te
re
d
ov
er
15
m
in
ut
es
,
fo
llo
w
ed
by
a
0.
4
µg
/k
g/
ho
ur
i.v
.
in
fu
si
on
l
B:
5
µg
/k
g/
m
in
ut
e
i.v
.
in
fu
si
on
tit
ra
te
d
w
ith
in
th
e
ra
ng
e
of
0.
2–
0.
7
µg
/k
g/
ho
ur
or
5–
75
µg
/k
g/
m
in
ut
e
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
l
A
:
up
to
1
ho
ur
po
st
ex
tu
ba
tio
n
l
B:
di
sc
on
tin
ue
d
be
fo
re
ex
tu
ba
tio
n
Ta
rg
et
se
da
tio
n
le
ve
l:
RS
S
sc
or
e
of
5
fo
r
th
e
fir
st
2
ho
ur
s
po
st
-o
pe
ra
tiv
el
y,
fo
llo
w
ed
by
a
sc
or
e
of
3
or
4
fo
r
th
e
le
ng
th
of
in
tu
ba
tio
n
Pa
tie
nt
sa
tis
fa
ct
io
n,
le
ng
th
of
M
V
an
d
IC
U
st
ay
,
vi
ta
ls
ig
ns
,
ad
ve
rs
e
ev
en
ts
co
nt
in
ue
d
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
TA
B
LE
4
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
(c
o
n
ti
n
u
ed
)
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
So
ur
ce
of
fu
nd
in
g:
N
R
Ex
cl
us
io
n
cr
ite
ria
:
1.
in
ab
ili
ty
to
ob
ta
in
in
fo
rm
ed
co
ns
en
t
2.
do
cu
m
en
te
d
hy
pe
rs
en
si
tiv
ity
to
ei
th
er
dr
ug
or
an
y
co
m
po
ne
nt
of
th
e
dr
ug
s
3.
se
ve
re
hy
po
te
ns
io
n,
de
fin
ed
as
sy
st
ol
ic
bl
oo
d
pr
es
su
re
of
90
m
m
H
g
im
m
ed
ia
te
ly
be
fo
re
in
iti
at
io
n
of
st
ud
y
dr
ug
4.
he
ar
t
ra
te
of
40
be
at
s
pe
r
m
in
ut
e
im
m
ed
ia
te
ly
be
fo
re
in
iti
at
io
n
of
th
e
st
ud
y
dr
ug
5.
re
na
li
ns
uf
fic
ie
nc
y,
de
fin
ed
as
a
cr
ea
tin
in
e
cl
ea
ra
nc
e
of
30
m
l/m
in
ut
e
pe
r
C
oc
kc
ro
ft
–
G
au
lt
6.
he
pa
tic
dy
sf
un
ct
io
n,
de
fin
ed
as
liv
er
fu
nc
tio
n
te
st
s
gr
ea
te
r
th
an
fo
ur
tim
es
th
e
up
pe
r
lim
it
of
no
rm
al
(a
la
ni
ne
tr
an
sa
m
in
as
e
of
28
8
un
its
/l
or
as
pa
rt
at
e
tr
an
sa
m
in
as
e
of
18
4
un
its
/l)
7.
re
qu
ire
m
en
t
fo
r
co
nt
in
ue
d
ne
ur
om
us
cu
la
r
bl
oc
ki
ng
ag
en
ts
po
st
op
er
at
iv
el
y
8.
re
qu
ire
m
en
t
fo
r
ep
id
ur
al
or
sp
in
al
an
ae
st
he
si
a
9.
gr
os
s
ob
es
ity
de
fin
ed
as
10
0%
ov
er
id
ea
l
bo
dy
w
ei
gh
t
10
.
kn
ow
n
hi
st
or
y
of
al
co
ho
lo
r
dr
ug
ab
us
e
11
.
an
y
ne
ur
ol
og
ic
al
im
pa
irm
en
t
or
re
ce
nt
se
ve
re
ce
nt
ra
ln
er
vo
us
sy
st
em
tr
au
m
a
th
at
co
ul
d
po
te
nt
ia
lly
al
te
r
th
e
pa
tie
nt
’s
ab
ili
ty
to
re
as
on
ab
ly
co
m
pl
et
e
a
po
st
-o
pe
ra
tiv
e
qu
es
tio
nn
ai
re
Re
sc
ue
m
ed
ic
at
io
n:
m
id
az
ol
am
w
as
al
lo
w
ed
fo
r
br
ea
kt
hr
ou
gh
an
xi
et
y,
ad
m
in
is
te
re
d
at
1–
2
m
g
ev
er
y
ho
ur
in
th
e
pr
op
of
ol
ar
m
an
d
ev
er
y
2
ho
ur
s
in
th
e
de
xm
ed
et
om
id
in
e
ar
m
Pa
in
co
nt
ro
l:
m
or
ph
in
e
w
as
av
ai
la
bl
e
as
ne
ed
ed
fo
r
pa
in
ev
er
y
ho
ur
in
a
1-
to
4-
m
g
do
se
fo
r
pr
op
of
ol
pa
tie
nt
s
an
d
in
a
1-
to
2-
m
g
do
se
fo
r
de
xm
ed
et
om
id
in
e
pa
tie
nt
s
D
ai
ly
in
te
rr
up
tio
n:
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
El
ba
ra
di
e,
20
04
11
1
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
1
C
ou
nt
ry
:
Eg
yp
t
St
ar
t/
en
d
da
te
s:
N
R
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
ra
nd
om
is
ed
co
nt
ro
lle
d,
pa
tie
nt
-b
lin
de
d
st
ud
y
Ra
nd
om
is
at
io
n
m
et
ho
d:
at
th
e
en
d
of
su
rg
er
y,
pa
tie
nt
s
w
er
e
se
le
ct
ed
ra
nd
om
ly
us
in
g
a
to
ss
in
to
tw
o
eq
ua
lg
ro
up
Le
ng
th
of
fo
llo
w
-u
p:
N
R
So
ur
ce
of
fu
nd
in
g:
N
R
Ty
pe
of
pa
rt
ic
ip
an
ts
:
af
te
r
m
aj
or
th
or
ac
ic
,
ab
do
m
in
al
or
pe
lv
ic
ca
nc
er
su
rg
er
ie
s
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
30
A
na
ly
se
d:
N
R
A
ge
(y
ea
rs
),
m
ea
n
(S
D
):
l
A
:
65
(6
.5
)
l
B:
67
(5
.7
)
Se
x,
n
(%
):
N
R
In
cl
us
io
n
cr
ite
ria
:
ad
ul
t
pa
tie
nt
s
w
ho
w
er
e
ex
pe
ct
ed
to
re
qu
ire
a
m
in
im
um
of
6-
ho
ur
po
st
-o
pe
ra
tiv
e
se
da
tio
n
an
d
ve
nt
ila
tio
n
af
te
r
m
aj
or
th
or
ac
ic
,
ab
do
m
in
al
or
pe
lv
ic
ca
nc
er
su
rg
er
ie
s
Ex
cl
us
io
n
cr
ite
ria
:
ne
ur
os
ur
gi
ca
lp
ro
ce
du
re
s,
kn
ow
n
al
le
rg
y
to
pr
op
of
ol
or
de
xm
ed
et
om
id
in
e,
kn
ow
n
or
su
sp
ec
te
d
pr
eg
na
nc
y,
gr
os
s
ob
es
ity
(o
ve
r
50
%
ab
ov
e
id
ea
lb
od
yw
ei
gh
t)
,
se
ve
re
he
pa
tic
or
re
na
ld
is
ea
se
w
he
re
th
e
ne
ur
ol
og
ic
al
co
nd
iti
on
w
as
di
ff
ic
ul
t
to
ev
al
ua
te
,
sp
in
al
or
ep
id
ur
al
an
ae
st
he
si
a,
hi
st
or
y
of
co
rt
ic
os
te
ro
id
th
er
ap
y
w
ith
in
th
e
la
st
3
m
on
th
s,
or
un
co
nt
ro
lle
d
di
ab
et
es
IC
U
se
tt
in
g:
su
rg
ic
al
IC
U
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
pr
op
of
ol
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
l
A
:
lo
ad
in
g
in
fu
si
on
do
se
of
de
xm
ed
et
om
id
in
e
2.
5
µg
/k
g/
ho
ur
ov
er
10
m
in
ut
es
fo
llo
w
ed
by
m
ai
nt
en
an
ce
in
fu
si
on
at
a
ra
te
of
0.
2–
0.
5
µg
/k
g/
ho
ur
in
to
a
pe
rip
he
ra
lv
ei
n,
w
ith
th
e
do
sa
ge
ad
ju
st
ed
to
ac
hi
ev
e
th
e
de
si
re
d
le
ve
lo
f
se
da
tio
n
l
B:
un
di
lu
te
d
as
a
bo
lu
s
do
se
of
1
m
g/
kg
in
iti
al
ly
,
fo
llo
w
ed
by
an
in
fu
si
on
of
0.
5–
1
m
g/
kg
/h
ou
r,
w
ith
th
e
do
sa
ge
ad
ju
st
ed
to
ac
hi
ev
e
th
e
de
si
re
d
le
ve
lo
f
se
da
tio
n
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
di
sc
on
tin
ue
d
in
pr
ep
ar
at
io
n
fo
r
ex
tu
ba
tio
n
Ta
rg
et
se
da
tio
n
le
ve
l:
re
co
rd
ed
ho
ur
ly
us
in
g
th
e
RS
S
sc
or
e
an
d
co
nt
in
uo
us
ly
us
in
g
th
e
bi
sp
ec
tr
al
in
de
x.
Th
re
e
le
ve
ls
of
se
da
tio
n
w
er
e
co
ns
id
er
ed
:
ad
eq
ua
te
(s
ed
at
io
n
le
ve
lw
as
gr
ad
e
2,
3,
4
or
5)
,
in
su
ff
ic
ie
nt
(s
ed
at
io
n
le
ve
lw
as
1)
an
d
ex
ce
ss
iv
e
(s
ed
at
io
n
le
ve
lw
as
gr
ad
e
6)
Re
sc
ue
m
ed
ic
at
io
n:
th
e
do
se
of
bo
th
dr
ug
s
w
as
ad
ju
st
ed
by
va
ry
in
g
th
e
do
se
by
10
%
in
cr
ea
se
or
de
cr
ea
se
in
in
fu
si
on
ra
te
in
or
de
r
to
m
ai
nt
ai
n
th
e
le
ve
lo
f
se
da
tio
n
w
ith
in
th
e
ra
ng
e
pr
ev
io
us
ly
co
ns
id
er
ed
ad
eq
ua
te
Pa
in
co
nt
ro
l:
al
lp
at
ie
nt
s
re
ce
iv
ed
sh
or
t-
ac
tin
g
fe
nt
an
yl
in
fu
si
on
0.
25
–
0.
5
µg
/k
g/
ho
ur
D
ai
ly
in
te
rr
up
tio
n:
N
R
Se
da
tio
n,
tim
e
in
ad
eq
ua
te
se
da
tio
n
un
de
r
ve
nt
ila
to
r,
ex
tu
ba
tio
n
tim
es
,
bl
oo
d
pr
es
su
re
,
he
ar
t
ra
te
s,
se
ru
m
le
ve
ls
of
co
rt
is
ol
an
d
IL
-6
,
re
sp
ira
to
ry
ad
ve
rs
e
ev
en
ts
co
nt
in
ue
d
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
77
TA
B
LE
4
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
(c
o
n
ti
n
u
ed
)
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
Es
m
ao
gl
u,
20
09
11
2
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
1
C
ou
nt
ry
:
Tu
rk
ey
St
ar
t/
en
d
da
te
s:
N
R
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
RC
T
Ra
nd
om
is
at
io
n
m
et
ho
d:
pa
tie
nt
s
w
er
e
ra
nd
om
ly
di
vi
de
d
in
to
tw
o
gr
ou
ps
us
in
g
co
in
to
ss
Le
ng
th
of
fo
llo
w
-u
p:
N
R
So
ur
ce
of
fu
nd
in
g:
N
R
Ty
pe
of
pa
rt
ic
ip
an
ts
:
pa
tie
nt
s
w
ho
se
pr
eg
na
nc
ie
s
w
er
e
te
rm
in
at
ed
vi
a
ca
es
ar
ea
n
de
liv
er
y
be
ca
us
e
of
ec
la
m
ps
ia
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
l
A
:
20
l
B:
20
A
na
ly
se
d:
l
A
:
20
l
B:
20
A
ge
(y
ea
rs
),
m
ea
n
(S
D
):
l
A
:
25
.1
(4
.8
)
l
B:
26
.8
(7
.1
)
Se
x,
n
(%
):
l
A
:
fe
m
al
e,
20
(1
00
)
l
B:
fe
m
al
e,
20
(1
00
)
In
cl
us
io
n
cr
ite
ria
:
pa
tie
nt
s
w
ho
se
pr
eg
na
nc
ie
s
w
er
e
te
rm
in
at
ed
vi
a
ca
es
ar
ea
n
de
liv
er
y
be
ca
us
e
of
ec
la
m
ps
ia
an
d
w
ho
ne
ed
ed
ve
nt
ila
to
ry
su
pp
or
t
Ex
cl
us
io
n
cr
ite
ria
:
ch
ro
ni
c
hy
pe
rt
en
si
on
;
ca
rd
ia
c,
ne
ur
ol
og
ic
al
,
he
pa
tic
,
re
na
l,
or
en
do
cr
in
al
di
se
as
e;
or
al
le
rg
ic
re
ac
tio
ns
to
th
e
m
ed
ic
in
e
us
ed
du
rin
g
th
e
tr
ea
tm
en
t
or
de
ve
lo
pe
d
ha
em
ol
ys
is
,
el
ev
at
ed
liv
er
en
zy
m
es
an
d
pl
at
el
et
s
IC
U
se
tt
in
g:
N
R
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
m
id
az
ol
am
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
A
:
lo
ad
in
g
do
se
ad
m
in
is
te
re
d
at
1
µg
/k
g
pe
r
20
m
in
ut
es
,
fo
llo
w
ed
by
a
co
nt
in
uo
us
in
fu
si
on
at
0.
7
µg
/k
g/
ho
ur
B:
lo
ad
in
g
do
se
of
10
0
m
g
in
10
0
m
l0
.9
%
N
aC
l
at
0.
05
m
g/
kg
an
d
co
nt
in
ue
d
at
0.
1
m
g/
kg
/h
ou
r
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
N
R
Ta
rg
et
se
da
tio
n
le
ve
l:
RS
S
sc
or
e
2
or
3
cr
ite
ria
Re
sc
ue
m
ed
ic
at
io
n:
pr
op
of
ol
w
as
gi
ve
n
as
a
bo
lu
s
(0
.5
m
g/
kg
)
in
bo
th
gr
ou
ps
Pa
in
co
nt
ro
l:
fe
nt
an
yl
w
as
ad
m
in
is
te
re
d
in
th
e
do
se
of
1
µg
/k
g
D
ai
ly
in
te
rr
up
tio
n:
N
R
Pa
tie
nt
s
re
qu
iri
ng
an
tih
yp
er
te
ns
iv
e,
ar
te
ria
lp
re
ss
ur
e,
IC
U
le
ng
th
of
st
ay
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
H
er
r,
20
03
11
4
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
25
C
ou
nt
ry
:
U
SA
,
C
an
ad
a
St
ar
t/
en
d
da
te
s:
N
R
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
m
ul
tic
en
tr
e,
op
en
-la
be
l,
ra
nd
om
is
ed
st
ud
y
Ty
pe
of
pa
rt
ic
ip
an
ts
:
af
te
r
C
A
BG
su
rg
er
y
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
N
R
A
na
ly
se
d:
l
A
:
14
8
l
B:
14
7
A
ge
(y
ea
rs
),
m
ea
n
(S
D
):
l
A
:
61
.9
(9
.5
)
l
B:
62
.4
(8
.7
)
Se
x,
n
(%
):
l
A
:
m
al
e,
13
7
(9
3)
;
fe
m
al
e,
11
(7
%
)
l
B:
m
al
e,
12
8
(8
7)
;
fe
m
al
e,
19
(1
3)
In
cl
us
io
n
cr
ite
ria
:
ad
ul
ts
w
ho
w
er
e
sc
he
du
le
d
fo
r
C
A
BG
su
rg
er
y
IC
U
se
tt
in
g:
N
R
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
pr
op
of
ol
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
l
A
:
1.
0
µg
/k
g
de
xm
ed
et
om
id
in
e
ov
er
20
m
in
ut
es
as
th
e
lo
ad
in
g
do
se
,
fo
llo
w
ed
by
a
m
ai
nt
en
an
ce
in
fu
si
on
of
0.
4
µg
/k
g/
ho
ur
.
A
ft
er
tr
an
sf
er
to
th
e
IC
U
,
th
e
in
fu
si
on
ra
te
w
as
tit
ra
te
d
in
th
e
ra
ng
e
of
0.
2
–
0.
7
µg
/k
g/
ho
ur
as
ne
ce
ss
ar
y
to
m
ai
nt
ai
n
a
RS
S
sc
or
e
of
≥
3
be
fo
re
ex
tu
ba
tio
n,
≥
2
af
te
r
ex
tu
ba
tio
n
l
B:
no
do
se
or
ra
te
of
pr
op
of
ol
w
as
sp
ec
ifi
ed
by
th
e
pr
ot
oc
ol
.
In
ve
st
ig
at
or
s
w
er
e
to
ld
to
fo
llo
w
th
ei
r
us
ua
lp
ra
ct
ic
e
w
ith
re
ga
rd
to
pr
op
of
ol
-b
as
ed
se
da
tio
n
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
24
ho
ur
s
Ef
fic
ac
y
of
se
da
tio
n
of
de
xm
ed
et
om
id
in
e
co
m
pa
re
d
w
ith
pr
op
of
ol
-b
as
ed
IC
U
se
da
tio
n,
to
ta
l
do
se
of
m
or
ph
in
e
ad
m
in
is
te
re
d
fo
r
pa
in
by
tim
e
pe
rio
d;
tim
e
to
w
ea
ni
ng
;
tim
e
to
ex
tu
ba
tio
n,
ad
ve
rs
e
ev
en
ts
co
nt
in
ue
d
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
79
TA
B
LE
4
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
(c
o
n
ti
n
u
ed
)
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Ra
nd
om
is
at
io
n
m
et
ho
d:
ra
nd
om
is
ed
be
fo
re
su
rg
er
y
by
se
al
ed
en
ve
lo
pe
s
pr
ov
id
ed
by
th
e
st
at
is
tic
ia
n.
In
ve
st
ig
at
or
s
di
d
no
t
kn
ow
th
e
ra
nd
om
is
at
io
n
bl
oc
k
si
ze
Le
ng
th
of
fo
llo
w
-u
p:
24
ho
ur
s
af
te
r
di
sc
ha
rg
e
fr
om
IC
U
So
ur
ce
of
fu
nd
in
g:
N
R
Ex
cl
us
io
n
cr
ite
ria
:
w
om
en
w
ho
w
er
e
pr
eg
na
nt
or
la
ct
at
in
g;
pa
tie
nt
s
w
ho
se
ne
ur
ol
og
ic
al
co
nd
iti
on
or
re
sp
on
se
s
co
ul
d
be
di
ff
ic
ul
t
to
ev
al
ua
te
;
pa
tie
nt
s
w
ho
ha
d
un
st
ab
le
or
un
co
nt
ro
lle
d
di
ab
et
es
,
w
er
e
gr
os
sl
y
ob
es
e,
ha
d
an
ej
ec
tio
n
fr
ac
tio
n
of
30
%
or
w
er
e
ho
sp
ita
lis
ed
fo
r
a
dr
ug
ov
er
do
se
Ta
rg
et
se
da
tio
n
le
ve
l:
l
A
:
RS
S
sc
or
e
of
≥
3
be
fo
re
ex
tu
ba
tio
n,
sc
or
e
of
≥
2
af
te
r
ex
tu
ba
tio
n
l
B:
no
t
sp
ec
ifi
ed
.
In
ve
st
ig
at
or
s
w
er
e
to
ld
to
fo
llo
w
th
ei
r
us
ua
lp
ra
ct
ic
e
w
ith
re
ga
rd
to
pr
op
of
ol
-b
as
ed
se
da
tio
n
Re
sc
ue
m
ed
ic
at
io
n:
l
A
:
pa
tie
nt
s
w
ho
re
ce
iv
ed
de
xm
ed
et
om
id
in
e
co
ul
d
be
gi
ve
n
pr
op
of
ol
if
th
e
in
ve
st
ig
at
or
be
lie
ve
d
th
at
th
ey
sh
ou
ld
be
m
or
e
he
av
ily
se
da
te
d
an
d
th
e
in
fu
si
on
ra
te
w
as
al
re
ad
y
at
th
e
re
co
m
m
en
de
d
m
ax
im
um
of
0.
7
µg
/k
g/
ho
ur
l
B:
no
t
sp
ec
ifi
ed
.
In
ve
st
ig
at
or
s
w
er
e
to
ld
to
fo
llo
w
th
ei
r
us
ua
lp
ra
ct
ic
e
w
ith
re
ga
rd
to
pr
op
of
ol
-b
as
ed
se
da
tio
n
Pa
in
co
nt
ro
l:
on
ly
m
or
ph
in
e
or
no
n-
st
er
oi
da
l
an
ti-
in
fla
m
m
at
or
y
dr
ug
s
w
er
e
al
lo
w
ed
fo
r
pa
in
re
lie
f
in
bo
th
gr
ou
ps
D
ai
ly
in
te
rr
up
tio
n:
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
Ja
ko
b,
20
12
;
M
ID
EX
70
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
44
C
ou
nt
ry
:
ni
ne
Eu
ro
pe
an
co
un
tr
ie
s
St
ar
t/
en
d
da
te
s:
20
07
–
10
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
Ph
as
e
3
m
ul
tic
en
tr
e,
ra
nd
om
is
ed
,
do
ub
le
-b
lin
d
tr
ia
l
Ra
nd
om
is
at
io
n
m
et
ho
d:
by
ce
nt
ra
l
in
te
ra
ct
iv
e
vo
ic
e
re
sp
on
se
sy
st
em
fu
nd
ed
by
th
e
sp
on
so
r
an
d
st
ra
tif
ie
d
fo
r
st
ud
y
ce
nt
re
in
bl
oc
ks
of
fo
ur
Le
ng
th
of
fo
llo
w
-u
p:
45
da
ys
So
ur
ce
of
fu
nd
in
g:
O
rio
n
Ph
ar
m
a,
Es
po
o,
Fi
nl
an
d
Ty
pe
of
pa
rt
ic
ip
an
ts
:
ge
ne
ra
lI
C
U
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
l
A
:
24
9
l
B:
25
2
A
na
ly
se
d:
l
A
:
24
9
l
B:
25
1
A
ge
(y
ea
rs
),
m
ed
ia
n
(IQ
R)
:
l
A
:
65
(5
5–
74
)
l
B:
65
(5
5
–
74
)
Se
x,
n
(%
):
l
A
:
m
al
e,
15
3
(6
1)
;
fe
m
al
e,
96
(3
9)
l
B:
m
al
e,
17
5
(7
0)
;
fe
m
al
e,
76
(3
0)
In
cl
us
io
n
cr
ite
ria
:a
ge
≥
18
ye
ar
s,
in
va
si
ve
M
V
,
cl
in
ic
al
ne
ed
fo
r
lig
ht
to
m
od
er
at
e
se
da
tio
n
us
in
g
m
id
az
ol
am
or
pr
op
of
ol
in
fu
si
on
ex
pe
ct
ed
to
la
st
fo
r
24
ho
ur
s
or
lo
ng
er
af
te
r
ra
nd
om
is
at
io
n,
an
d
ra
nd
om
is
at
io
n
w
ith
in
72
ho
ur
s
of
IC
U
ad
m
is
si
on
an
d
w
ith
in
48
ho
ur
s
of
st
ar
tin
g
co
nt
in
uo
us
se
da
tio
n
Ex
cl
us
io
n
cr
ite
ria
:a
cu
te
se
ve
re
ne
ur
ol
og
ic
al
di
so
rd
er
,m
ea
n
ar
te
ria
lp
re
ss
ur
e
<
55
m
m
H
g
de
sp
ite
ap
pr
op
ria
te
i.v
.v
ol
um
e
re
pl
ac
em
en
t
an
d
va
so
pr
es
so
rs
,h
ea
rt
ra
te
<
50
be
at
s
pe
r
m
in
ut
e,
at
rio
ve
nt
ric
ul
ar
co
nd
uc
tio
n
gr
ad
e
II
or
III
(u
nl
es
s
pa
ce
m
ak
er
in
st
al
le
d)
an
d
us
e
of
al
ph
a-
2
ag
on
is
ts
or
an
ta
go
ni
st
s
w
ith
in
24
ho
ur
s
pr
io
r
to
ra
nd
om
is
at
io
n
IC
U
se
tt
in
g:
N
R
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
m
id
az
ol
am
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
si
x
do
se
le
ve
ls
of
ea
ch
st
ud
y
dr
ug
co
ve
re
d
th
e
fu
ll
do
se
ra
ng
e
(d
ex
m
ed
et
om
id
in
e
0.
2
–
1.
4
µg
/k
g
pe
r
ho
ur
;
m
id
az
ol
am
,
0.
03
–
0.
2
m
g/
kg
pe
r
ho
ur
).
St
ud
y
tr
ea
tm
en
ts
w
er
e
in
fu
se
d
w
ith
ou
t
lo
ad
in
g
do
se
at
a
do
se
m
at
ch
in
g
th
e
pr
er
an
do
m
is
at
io
n
do
se
of
m
id
az
ol
am
fo
r
1
ho
ur
.
Th
er
ea
ft
er
,
st
ud
y
dr
ug
s
w
er
e
tit
ra
te
d
by
th
e
pa
tie
nt
’s
nu
rs
e
st
ep
w
is
e
to
m
ai
nt
ai
n
th
e
ta
rg
et
RA
SS
sc
or
e
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
m
ax
im
um
14
da
ys
fr
om
ra
nd
om
is
at
io
n
Ta
rg
et
se
da
tio
n
le
ve
l:
ta
rg
et
RA
SS
sc
or
e
w
as
de
te
rm
in
ed
be
fo
re
st
ar
tin
g
st
ud
y
tr
ea
tm
en
t
an
d
at
da
ily
se
da
tio
n
st
op
s.
A
ss
es
sm
en
t
of
RA
SS
sc
or
e
w
as
pe
rf
or
m
ed
ev
er
y
2
ho
ur
s
an
d
pr
io
r
to
an
y
do
se
of
re
sc
ue
th
er
ap
y
Re
sc
ue
m
ed
ic
at
io
n:
pr
op
of
ol
Pa
in
co
nt
ro
l:
fe
nt
an
yl
bo
lu
se
s
D
ai
ly
in
te
rr
up
tio
n:
ne
ed
fo
r
re
-s
ed
at
io
n
an
d
co
nt
in
ue
d
ve
nt
ila
tio
n
w
as
as
se
ss
ed
af
te
r
a
da
ily
se
da
tio
n
st
op
an
d
sp
on
ta
ne
ou
s
br
ea
th
in
g
tr
ia
l
Pr
op
or
tio
n
of
tim
e
in
th
e
ta
rg
et
se
da
tio
n
ra
ng
e
(R
A
SS
sc
or
e
0
to
–
3)
w
ith
ou
t
us
e
of
re
sc
ue
th
er
ap
y
of
th
e
to
ta
ld
ur
at
io
n
of
st
ud
y
dr
ug
in
fu
si
on
;
du
ra
tio
n
of
M
V
fr
om
ra
nd
om
is
at
io
n
un
til
fr
ee
fr
om
M
V
(in
cl
ud
in
g
no
n-
in
va
si
ve
)
w
ith
ou
t
re
in
st
itu
tio
n
fo
r
th
e
fo
llo
w
in
g
48
ho
ur
s;
le
ng
th
of
IC
U
st
ay
fr
om
ra
nd
om
is
at
io
n
un
til
m
ed
ic
al
ly
fit
fo
r
di
sc
ha
rg
e;
nu
rs
es
’
as
se
ss
m
en
t
of
ar
ou
sa
l,
ab
ili
ty
to
co
-o
pe
ra
te
w
ith
ca
re
an
d
ab
ili
ty
to
co
m
m
un
ic
at
e
pa
in
us
in
g
V
A
S;
ad
ve
rs
e
ev
en
ts
an
d
se
rio
us
ad
ve
rs
e
ev
en
ts
w
ith
in
ci
de
nc
e
of
>
2%
in
an
y
tr
ea
tm
en
t
gr
ou
p
co
nt
in
ue
d
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
81
TA
B
LE
4
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
(c
o
n
ti
n
u
ed
)
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
Ja
ko
b,
20
12
;
PR
O
D
EX
70
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
33
C
ou
nt
ry
:
si
x
Eu
ro
pe
an
co
un
tr
ie
s
an
d
Ru
ss
ia
St
ar
t/
en
d
da
te
s:
20
07
–
10
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
Ph
as
e
3
m
ul
tic
en
tr
e,
ra
nd
om
is
ed
,
do
ub
le
-b
lin
d
tr
ia
l
Ra
nd
om
is
at
io
n
m
et
ho
d:
by
ce
nt
ra
l
in
te
ra
ct
iv
e
vo
ic
e
re
sp
on
se
sy
st
em
fu
nd
ed
by
th
e
sp
on
so
r
an
d
st
ra
tif
ie
d
fo
r
st
ud
y
ce
nt
re
in
bl
oc
ks
of
fo
ur
Le
ng
th
of
fo
llo
w
-u
p:
45
da
ys
So
ur
ce
of
fu
nd
in
g:
O
rio
n
Ph
ar
m
a,
Es
po
o,
Fi
nl
an
d
Ty
pe
of
pa
rt
ic
ip
an
ts
:
ge
ne
ra
lI
C
U
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
l
A
:
25
1
l
B:
24
9
A
na
ly
se
d:
l
A
:
25
1
l
B:
24
7
A
ge
(y
ea
rs
),
m
ed
ia
n
(IQ
R)
:
l
A
:
65
(5
1–
75
)
l
B:
65
(5
1
–
74
)
Se
x,
n
(%
):
l
A
:
m
al
e,
16
0
(6
4)
;
fe
m
al
e,
91
(3
6)
l
B:
m
al
e,
16
6
(6
7)
;
fe
m
al
e,
81
(3
3)
In
cl
us
io
n
cr
ite
ria
:≥
18
ye
ar
s,
in
va
si
ve
M
V
,c
lin
ic
al
ne
ed
fo
r
lig
ht
to
m
od
er
at
e
se
da
tio
n
us
in
g
m
id
az
ol
am
or
pr
op
of
ol
in
fu
si
on
ex
pe
ct
ed
to
la
st
fo
r
24
ho
ur
s
or
lo
ng
er
af
te
r
ra
nd
om
is
at
io
n,
an
d
ra
nd
om
is
at
io
n
w
ith
in
72
ho
ur
s
of
IC
U
ad
m
is
si
on
an
d
w
ith
in
48
ho
ur
s
of
st
ar
tin
g
co
nt
in
uo
us
se
da
tio
n
Ex
cl
us
io
n
cr
ite
ria
:a
cu
te
se
ve
re
ne
ur
ol
og
ic
al
di
so
rd
er
,m
ea
n
ar
te
ria
lp
re
ss
ur
e
<
55
m
m
H
g
de
sp
ite
ap
pr
op
ria
te
i.v
.v
ol
um
e
re
pl
ac
em
en
t
an
d
va
so
pr
es
so
rs
,h
ea
rt
ra
te
<
50
be
at
s
pe
r
m
in
ut
e,
at
rio
ve
nt
ric
ul
ar
-c
on
du
ct
io
n
gr
ad
e
II
or
III
(u
nl
es
s
pa
ce
m
ak
er
in
st
al
le
d)
,a
nd
us
e
of
al
ph
a-
2
ag
on
is
ts
or
an
ta
go
ni
st
s
w
ith
in
24
ho
ur
s
pr
io
r
to
ra
nd
om
is
at
io
n
IC
U
se
tt
in
g:
N
R
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
pr
op
of
ol
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
si
x
do
se
le
ve
ls
of
ea
ch
st
ud
y
dr
ug
co
ve
re
d
th
e
fu
ll
do
se
ra
ng
e
(d
ex
m
ed
et
om
id
in
e
0.
2
–
1.
4
µg
/k
g/
ho
ur
;
pr
op
of
ol
0.
3–
4.
0
m
g/
kg
/h
ou
r)
.
St
ud
y
tr
ea
tm
en
ts
w
er
e
in
fu
se
d
w
ith
ou
t
lo
ad
in
g
do
se
at
a
do
se
m
at
ch
in
g
th
e
pr
er
an
do
m
is
at
io
n
do
se
of
pr
op
of
ol
fo
r
1
ho
ur
.
Th
er
ea
ft
er
,
st
ud
y
dr
ug
s
w
er
e
tit
ra
te
d
by
th
e
pa
tie
nt
’s
nu
rs
e
st
ep
w
is
e
to
m
ai
nt
ai
n
th
e
ta
rg
et
RA
SS
sc
or
e
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
m
ax
im
um
14
da
ys
fr
om
ra
nd
om
is
at
io
n
Ta
rg
et
se
da
tio
n
le
ve
l:
ta
rg
et
RA
SS
sc
or
e
w
as
de
te
rm
in
ed
be
fo
re
st
ar
tin
g
st
ud
y
tr
ea
tm
en
t
an
d
at
da
ily
se
da
tio
n
st
op
s.
A
ss
es
sm
en
t
of
RA
SS
sc
or
e
w
as
pe
rf
or
m
ed
ev
er
y
2
ho
ur
s
an
d
pr
io
r
to
an
y
do
se
of
re
sc
ue
th
er
ap
y
Re
sc
ue
m
ed
ic
at
io
n:
m
id
az
ol
am
Pa
in
co
nt
ro
l:
fe
nt
an
yl
bo
lu
se
s
D
ai
ly
in
te
rr
up
tio
n:
ne
ed
fo
r
re
se
da
tio
n
an
d
co
nt
in
ue
d
ve
nt
ila
tio
n
w
as
as
se
ss
ed
af
te
r
a
da
ily
se
da
tio
n
st
op
an
d
sp
on
ta
ne
ou
s
br
ea
th
in
g
tr
ia
l
Pr
op
or
tio
n
of
tim
e
in
th
e
ta
rg
et
se
da
tio
n
ra
ng
e
(R
A
SS
sc
or
e
0
to
–
3)
w
ith
ou
t
us
e
of
re
sc
ue
th
er
ap
y
of
th
e
to
ta
ld
ur
at
io
n
of
st
ud
y
dr
ug
in
fu
si
on
;
du
ra
tio
n
of
M
V
fr
om
ra
nd
om
is
at
io
n
un
til
fr
ee
fr
om
M
V
(in
cl
ud
in
g
no
n-
in
va
si
ve
)
w
ith
ou
t
re
in
st
itu
tio
n
fo
r
th
e
fo
llo
w
in
g
48
ho
ur
s;
le
ng
th
of
IC
U
st
ay
fr
om
ra
nd
om
is
at
io
n
un
til
m
ed
ic
al
ly
fit
fo
r
di
sc
ha
rg
e;
nu
rs
es
’
as
se
ss
m
en
t
of
ar
ou
sa
l,
ab
ili
ty
to
co
-o
pe
ra
te
w
ith
ca
re
an
d
ab
ili
ty
to
co
m
m
un
ic
at
e
pa
in
us
in
g
V
A
S;
ad
ve
rs
e
ev
en
ts
an
d
se
rio
us
ad
ve
rs
e
ev
en
ts
w
ith
in
ci
de
nc
e
>
2%
in
an
y
tr
ea
tm
en
t
gr
ou
p
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
M
ac
La
re
n,
20
13
11
6
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
1
C
ou
nt
ry
:
U
SA
St
ar
t/
en
d
da
te
s:
Se
pt
em
be
r
20
09
–
M
ay
20
12
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
pr
os
pe
ct
iv
e,
ra
nd
om
is
ed
,
do
ub
le
-b
lin
d
pi
lo
t
st
ud
y
Ra
nd
om
is
at
io
n
m
et
ho
d:
w
ith
in
24
ho
ur
s
of
qu
al
ify
in
g
fo
r
da
ily
aw
ak
en
in
gs
,
pa
tie
nt
s
w
er
e
ra
nd
om
is
ed
by
a
co
m
pu
te
r-
ge
ne
ra
te
d
ra
nd
om
nu
m
be
rs
ta
bl
e
Le
ng
th
of
fo
llo
w
-u
p:
at
le
as
t
72
ho
ur
s
af
te
r
ex
tu
ba
tio
n
or
tr
ac
he
os
to
m
y
bu
t
be
fo
re
ho
sp
ita
ld
is
ch
ar
ge
Ty
pe
of
pa
rt
ic
ip
an
ts
:
m
ed
ic
al
or
su
rg
ic
al
IC
U
pa
tie
nt
s
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
l
A
:
11
l
B:
12
A
na
ly
se
d:
l
A
:
11
l
B:
12
A
ge
(y
ea
rs
),
m
ea
n
(S
D
):
l
A
:
58
.3
(1
5.
3)
l
B:
57
.8
(9
.3
)
Se
x,
n
(%
):
l
A
:
m
al
e,
6
(5
5)
;
fe
m
al
e,
5
(4
5)
l
B:
m
al
e,
7
(5
8)
;
fe
m
al
e,
5
(4
2)
In
cl
us
io
n
cr
ite
ria
:
cr
iti
ca
lly
ill
pa
tie
nt
s
re
qu
iri
ng
M
V
an
d
re
ce
iv
in
g
a
be
nz
od
ia
ze
pi
ne
in
fu
si
on
w
ith
an
an
tic
ip
at
ed
ne
ed
of
at
le
as
t
12
ad
di
tio
na
lh
ou
rs
of
se
da
tio
n
at
a
Ri
ke
r
SA
S
sc
or
e
of
3
or
4
w
er
e
re
cr
ui
te
d
on
ce
th
ey
qu
al
ifi
ed
fo
r
da
ily
aw
ak
en
in
gs
IC
U
se
tt
in
g:
m
ed
ic
al
an
d
su
rg
ic
al
IC
U
s
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
m
id
az
ol
am
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
l
A
:
de
xm
ed
et
om
id
in
e
w
as
st
ar
te
d
at
0.
15
µg
/k
g/
ho
ur
an
d
ad
ju
st
ed
by
0.
15
µg
/k
g/
ho
ur
to
a
m
ax
im
um
of
1.
5
µg
/k
g/
ho
ur
l
B:
m
id
az
ol
am
w
as
st
ar
te
d
at
1
m
g/
ho
ur
an
d
ad
ju
st
ed
by
1
m
g/
ho
ur
to
a
m
ax
im
um
of
10
m
g/
ho
ur
.
A
ll
in
fu
si
on
s
w
er
e
ad
ju
st
ed
by
in
cr
em
en
ts
of
2
m
l/h
ou
r
to
m
ai
nt
ai
n
bl
in
di
ng
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
at
le
as
t
12
ho
ur
s
Ta
rg
et
se
da
tio
n
le
ve
l:
Ri
ke
r
SA
S
sc
or
e
3
or
4
Re
sc
ue
m
ed
ic
at
io
n:
op
en
-la
be
lm
id
az
ol
am
Pa
in
co
nt
ro
l:
op
en
-la
be
lf
en
ta
ny
l
Po
st
-IC
U
an
xi
et
y,
de
pr
es
si
on
an
d
ac
ut
e
st
re
ss
di
so
rd
er
m
an
ife
st
at
io
ns
;
re
ca
ll,
an
xi
et
y,
de
pr
es
si
on
an
d
ac
ut
e
st
re
ss
di
so
rd
er
;
su
cc
es
sf
ul
ve
nt
ila
to
r
lib
er
at
io
n
(i.
e.
at
le
as
t
72
ho
ur
s
of
tr
ac
he
al
ex
tu
ba
tio
n)
;
ho
ur
ly
an
d
cu
m
ul
at
iv
e
do
se
s
of
co
nv
en
tio
na
l
se
da
tiv
es
an
d
an
al
ge
si
cs
;
pe
rc
en
ta
ge
of
Ri
ke
r
sc
or
es
at
va
rio
us
se
da
tio
n
le
ve
ls
;
pe
rc
en
ta
ge
of
PA
BS
sc
or
es
in
di
ca
tin
g
m
in
im
al
pa
in
(≤
3)
;
de
lir
iu
m
du
rin
g
ea
ch
12
-h
ou
r
nu
rs
in
g
sh
ift
;
IC
U
an
d
ho
sp
ita
ll
en
gt
hs
of
st
ay
;
hy
po
te
ns
io
n,
br
ad
yc
ar
di
a,
or
ta
ch
yc
ar
di
a
co
nt
in
ue
d
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
83
TA
B
LE
4
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
(c
o
n
ti
n
u
ed
)
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
So
ur
ce
of
fu
nd
in
g:
H
os
pi
ra
Ex
cl
us
io
n
cr
ite
ria
:
ag
ed
<
18
ye
ar
s
or
>
85
ye
ar
s;
ad
m
in
is
tr
at
io
n
of
be
nz
od
ia
ze
pi
ne
s
fo
r
pu
rp
os
es
ot
he
r
th
an
se
da
tio
n
(e
.g
.
se
iz
ur
e
co
nt
ro
l);
ad
m
in
is
tr
at
io
n
of
ne
ur
om
us
cu
la
r
bl
oc
ke
rs
fo
r
>
12
ho
ur
s;
ad
m
in
is
tr
at
io
n
of
ep
id
ur
al
m
ed
ic
at
io
ns
;
ac
tiv
e
m
yo
ca
rd
ia
li
sc
ha
em
ia
;
se
co
nd
-
or
th
ird
-d
eg
re
e
he
ar
t
bl
oc
k;
ha
em
od
yn
am
ic
in
st
ab
ili
ty
;
ac
tiv
e
ne
ur
om
us
cu
la
r
di
se
as
e;
C
hi
ld
–
Pu
gh
cl
as
s
C
liv
er
di
se
as
e;
al
co
ho
la
bu
se
w
ith
in
6
m
on
th
s
of
st
ud
y
el
ig
ib
ili
ty
;
ba
se
lin
e
de
m
en
tia
;
so
lid
or
ga
n
tr
an
sp
la
nt
;
pr
eg
na
nc
y;
m
or
ib
un
d
st
at
e
w
ith
pl
an
ne
d
w
ith
dr
aw
al
of
lif
e
su
pp
or
t;
en
ro
lm
en
t
in
an
ot
he
r
th
er
ap
eu
tic
st
ud
y;
or
kn
ow
n
or
su
sp
ec
te
d
se
ve
re
ad
ve
rs
e
re
ac
tio
ns
to
an
y
be
nz
od
ia
ze
pi
ne
s,
de
xm
ed
et
om
id
in
e,
or
cl
on
id
in
e
D
ai
ly
in
te
rr
up
tio
n:
da
ily
aw
ak
en
in
gs
pe
rf
or
m
ed
w
he
n
th
e
fo
llo
w
in
g
co
nd
iti
on
s
m
et
:
pa
tie
nt
ha
em
od
yn
am
ic
al
ly
st
ab
le
,
pa
tie
nt
no
t
re
ce
iv
in
g
ne
ur
om
us
cu
la
r
bl
oc
ka
de
,
an
d
pa
tie
nt
on
70
%
fo
r
fr
ac
tio
n
of
in
sp
ire
d
ox
yg
en
an
d
14
cm
H
2O
fo
r
po
si
tiv
e
en
d-
ex
pi
ra
to
ry
pr
es
su
re
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
M
al
do
na
do
,
20
09
72
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
1
C
ou
nt
ry
:
U
SA
St
ar
t/
en
d
da
te
s:
N
R
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
op
en
-la
be
lR
C
T
Ra
nd
om
is
at
io
n
m
et
ho
d:
ra
nd
om
is
at
io
n
w
as
pe
rf
or
m
ed
th
e
ev
en
in
g
be
fo
re
su
rg
er
y
by
ra
nd
om
dr
aw
in
g
Le
ng
th
of
fo
llo
w
-u
p:
3
da
ys
po
st
-o
pe
ra
tiv
el
y
Ty
pe
of
pa
rt
ic
ip
an
ts
:
fo
llo
w
in
g
ca
rd
ia
c
va
lv
e
su
rg
er
y
En
ro
lle
d:
17
9
el
ig
ib
le
Ra
nd
om
is
ed
:
l
A
:
40
l
B:
38
l
C
:
40
A
na
ly
se
d:
l
A
:
30
l
B:
30
l
C
:
30
A
ge
(y
ea
rs
),
m
ea
n
(S
D
):
l
A
:
55
(1
6)
l
B:
58
(1
8)
l
C
:
60
(1
6)
Se
x,
n
(%
):
l
A
:
m
al
e,
26
(6
5)
;
fe
m
al
e,
14
(3
5)
l
B:
m
al
e,
22
(5
8)
;
fe
m
al
e,
16
(4
2)
l
C
:
m
al
e,
27
(6
8)
;
fe
m
al
e,
13
(3
2)
IC
U
se
tt
in
g:
N
R
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
pr
op
of
ol
l
C
:
m
id
az
ol
am
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
l
A
:
lo
ad
in
g
do
se
:
0.
4
µg
/k
g,
fo
llo
w
ed
by
a
m
ai
nt
en
an
ce
dr
ip
of
0.
2–
0.
7
µg
/k
g/
ho
ur
l
B:
pr
op
of
ol
dr
ip
(2
5–
50
µg
/k
g/
m
in
ut
e)
l
C
:
m
id
az
ol
am
dr
ip
(0
.5
–
2
m
g/
ho
ur
)
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
pa
tie
nt
s
w
er
e
w
ea
ne
d
of
f
pr
op
of
ol
or
m
id
az
ol
am
in
fu
si
on
s
be
fo
re
ex
tu
ba
tio
n,
w
he
re
as
pa
tie
nt
s
re
ce
iv
in
g
de
xm
ed
et
om
id
in
e
w
er
e
ex
tu
ba
te
d
w
hi
le
st
ill
on
th
e
m
ed
ic
at
io
n
an
d
w
er
e
ke
pt
on
th
e
m
ai
nt
en
an
ce
in
fu
si
on
as
de
em
ed
cl
in
ic
al
ly
ne
ce
ss
ar
y
fo
r
a
m
ax
im
um
of
24
ho
ur
s
Ta
rg
et
se
da
tio
n
le
ve
l:
RS
S
sc
or
e
of
3
be
fo
re
ex
tu
ba
tio
n
an
d
of
2
af
te
r
ex
tu
ba
tio
n
Pr
op
or
tio
n
of
pa
tie
nt
s
in
ea
ch
tr
ea
tm
en
t
gr
ou
p
w
ho
re
ce
iv
ed
a
di
ag
no
si
s
of
po
st
-o
pe
ra
tiv
e
de
lir
iu
m
,
le
ng
th
of
st
ay
in
IC
U
,
le
ng
th
of
st
ay
in
ho
sp
ita
l,
us
e
of
po
st
-o
pe
ra
tiv
e
re
sc
ue
m
ed
ic
at
io
ns
,
de
lir
iu
m
co
nt
in
ue
d
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
TA
B
LE
4
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
(c
o
n
ti
n
u
ed
)
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
So
ur
ce
of
fu
nd
in
g:
N
R
In
cl
us
io
n
cr
ite
ria
:
al
lp
at
ie
nt
s
m
ee
tin
g
in
cl
us
io
n
an
d
ex
cl
us
io
n
cr
ite
ria
ad
m
itt
ed
to
a
la
rg
e,
te
rt
ia
ry
-c
ar
e
un
iv
er
si
ty
m
ed
ic
al
ce
nt
re
sc
he
du
le
d
fo
r
el
ec
tiv
e
ca
rd
ia
c
va
lv
e
op
er
at
io
ns
w
er
e
el
ig
ib
le
fo
r
th
is
pr
os
pe
ct
iv
e,
ra
nd
om
is
ed
cl
in
ic
al
tr
ia
l
Ex
cl
us
io
n
cr
ite
ria
:
pr
e-
ex
is
tin
g
di
ag
no
si
s
of
de
m
en
tia
or
sc
hi
zo
ph
re
ni
a,
th
e
pr
eo
pe
ra
tiv
e
us
e
of
ps
yc
ho
tr
op
ic
m
ed
ic
at
io
ns
,
ac
tiv
e
or
re
ce
nt
su
bs
ta
nc
e
ab
us
e
or
de
pe
nd
en
ce
,
ag
ed
le
ss
th
an
18
ye
ar
s
or
ol
de
r
th
an
90
ye
ar
s,
do
cu
m
en
te
d
st
ro
ke
w
ith
in
th
e
la
st
6
m
on
th
s,
ev
id
en
ce
of
ad
va
nc
ed
he
ar
t
bl
oc
k,
pr
eg
na
nc
y
or
an
tic
ip
at
ed
in
tr
ao
pe
ra
tiv
e
de
ep
hy
po
th
er
m
ic
ci
rc
ul
at
or
y
ar
re
st
Re
sc
ue
m
ed
ic
at
io
n:
fo
r
ad
di
tio
na
ls
ed
at
io
n
w
hi
le
in
tu
ba
te
d,
pa
tie
nt
s
re
ce
iv
ed
in
cr
ea
se
d
do
se
s
of
th
e
dr
ug
th
ey
ha
d
be
en
ra
nd
om
ly
as
si
gn
ed
to
Pa
in
co
nt
ro
l:
fe
nt
an
yl
25
–
50
µg
ev
er
y
ho
ur
as
ne
ed
ed
fo
r
pa
in
w
as
th
e
on
ly
op
ia
te
us
ed
in
th
e
fir
st
24
ho
ur
s;
ke
to
ro
la
c,
hy
dr
oc
od
on
e
an
d
ox
yc
od
on
e
w
er
e
al
lo
w
ed
fo
r
pa
in
m
an
ag
em
en
t
af
te
r
th
e
fir
st
24
ho
ur
s
D
ai
ly
in
te
rr
up
tio
n:
N
R
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
M
em
is
,
20
09
11
7
Se
co
nd
ar
y
re
po
rt
s:
no
ne
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
1
C
ou
nt
ry
:
Tu
rk
ey
St
ar
t/
en
d
da
te
s:
N
R
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
RC
T
(p
ilo
t)
Ra
nd
om
is
at
io
n
m
et
ho
d:
an
in
de
pe
nd
en
t
nu
rs
e
pr
ep
ar
ed
se
al
ed
en
ve
lo
pe
s
fr
om
a
co
m
pu
te
r-
ge
ne
ra
te
d
ta
bl
e
be
fo
re
th
e
st
ud
y
st
ar
te
d
Le
ng
th
of
fo
llo
w
-u
p:
N
R
So
ur
ce
of
fu
nd
in
g:
N
R
Ty
pe
of
pa
rt
ic
ip
an
ts
:
al
lp
at
ie
nt
s
fu
lfi
lle
d
cl
in
ic
al
an
d
la
bo
ra
to
ry
cr
ite
ria
of
se
pt
ic
sh
oc
k
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
l
A
:
20
l
B:
20
A
na
ly
se
d:
l
A
:
20
l
B:
20
A
ge
(y
ea
rs
),
m
ea
n
(r
an
ge
):
l
A
:
60
(3
1–
80
)
l
B:
54
(2
5
–
78
)
Se
x,
n
(%
):
l
A
:
m
al
e,
14
(7
0)
;
fe
m
al
e,
6
(3
0)
l
B:
m
al
e,
13
(6
5)
;
fe
m
al
e,
7
(3
5)
In
cl
us
io
n
cr
ite
ria
:
al
lp
at
ie
nt
s
fu
lfi
lle
d
cl
in
ic
al
an
d
la
bo
ra
to
ry
cr
ite
ria
of
se
pt
ic
sh
oc
k
Ex
cl
us
io
n
cr
ite
ria
:
kn
ow
n
al
le
rg
y
to
pr
op
of
ol
or
de
xm
ed
et
om
id
in
e,
pa
tie
nt
s
w
ith
kn
ow
n
or
su
sp
ec
te
d
br
ai
n
de
at
h,
un
st
ab
le
ha
em
og
lo
bi
n
le
ve
ls
(c
ha
ng
e
in
ha
em
og
lo
bi
n
le
ve
lo
f
>
0.
5
g/
dl
),
si
gn
ifi
ca
nt
ar
rh
yt
hm
ia
s,
ac
ut
e
m
yo
ca
rd
ia
li
sc
ha
em
ia
(c
on
tin
uo
us
ST
se
gm
en
t
an
al
ys
is
),
pa
tie
nt
s
re
qu
iri
ng
co
nt
in
uo
us
re
na
l
re
pl
ac
em
en
t
th
er
ap
y,
pr
eg
na
nc
y
an
d
ag
ed
<
18
ye
ar
s
IC
U
se
tt
in
g:
N
R
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
pr
op
of
ol
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
l
A
:
lo
ad
in
g
do
se
at
1
µg
/k
g
ov
er
10
m
in
ut
es
,
fo
llo
w
ed
by
a
m
ai
nt
en
an
ce
do
se
of
0.
2–
2.
5
µg
/k
g
pe
r
ho
ur
in
to
a
pe
rip
he
ra
l
or
ce
nt
ra
lv
ei
n
ov
er
a
24
-h
ou
r
in
fu
si
on
l
B:
lo
ad
in
g
do
se
of
1
m
g/
kg
ov
er
15
m
in
ut
es
,
fo
llo
w
ed
by
a
m
ai
nt
en
an
ce
of
1
to
3
m
g/
kg
pe
r
ho
ur
ov
er
a
24
-h
ou
r
in
fu
si
on
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
24
ho
ur
s
Ta
rg
et
se
da
tio
n
le
ve
l:
RS
S
sc
or
e
of
be
lo
w
2
Re
sc
ue
m
ed
ic
at
io
n:
N
R
Pa
in
co
nt
ro
l:
al
fe
nt
an
il
w
as
in
fu
se
d
at
0.
25
–
1.
0
µg
/k
g/
m
in
ut
e
D
ai
ly
in
te
rr
up
tio
n:
N
R
In
do
cy
an
in
e
gr
ee
n
pl
as
m
a
di
sa
pp
ea
ra
nc
e
ra
te
,
m
or
ta
lit
y,
ha
em
od
yn
am
ic
pa
ra
m
et
er
s,
ad
ve
rs
e
ev
en
ts
co
nt
in
ue
d
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87
TA
B
LE
4
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
(c
o
n
ti
n
u
ed
)
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
Pa
nd
ha
rip
an
de
,
20
07
10
2
Se
co
nd
ar
y
re
po
rt
s:
Fi
ne
,
20
08
;1
13
an
d
Pa
nd
ha
rip
an
de
,
20
10
11
8
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
2
C
ou
nt
ry
:
U
SA
St
ar
t/
en
d
da
te
s:
A
ug
us
t
20
04
–
A
pr
il
20
06
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
do
ub
le
-b
lin
d
RC
T
Ra
nd
om
is
at
io
n
m
et
ho
d:
pa
rt
ic
ip
an
ts
w
er
e
ra
nd
om
is
ed
us
in
g
co
m
pu
te
r-
ge
ne
ra
te
d,
pe
rm
ut
ed
bl
oc
k
ra
nd
om
is
at
io
n
(k
no
w
n
on
ly
to
in
ve
st
ig
at
io
na
lp
ha
rm
ac
is
ts
)
an
d
st
ra
tif
ie
d
by
si
te
Le
ng
th
of
fo
llo
w
-u
p:
un
til
di
sc
ha
rg
e
fr
om
ho
sp
ita
lo
r
de
at
h,
an
d
su
rv
iv
or
s
w
er
e
ob
se
rv
ed
fo
r
vi
ta
ls
ta
tu
s
un
til
1
ye
ar
af
te
r
en
ro
lm
en
t
So
ur
ce
of
fu
nd
in
g:
H
os
pi
ra
Ty
pe
of
pa
rt
ic
ip
an
ts
:
m
ed
ic
al
an
d
su
rg
ic
al
IC
U
pa
tie
nt
s
En
ro
lle
d:
N
R
Ra
nd
om
is
ed
:
l
A
:
54
l
B:
52
A
na
ly
se
d:
l
A
:
52
l
B:
51
A
ge
(y
ea
rs
),
m
ed
ia
n
(IQ
R)
:
l
A
:
60
(4
9–
65
)
l
B:
59
(4
5
–
67
)
Se
x,
n
(%
):
l
A
:
m
al
e,
30
(5
8)
;
fe
m
al
e,
22
(4
2)
l
B:
m
al
e,
23
(4
5)
;
fe
m
al
e,
28
(5
5)
In
cl
us
io
n
cr
ite
ria
:
ad
ul
t
m
ed
ic
al
an
d
su
rg
ic
al
IC
U
pa
tie
nt
s
re
qu
iri
ng
M
V
fo
r
lo
ng
er
th
an
24
ho
ur
s
Ex
cl
us
io
n
cr
ite
ria
:
ne
ur
ol
og
ic
al
di
se
as
e
th
at
w
ou
ld
co
nf
ou
nd
th
e
di
ag
no
si
s
of
de
lir
iu
m
,
ac
tiv
e
se
iz
ur
es
,
C
hi
ld
–
Pu
gh
cl
as
s
B
or
C
liv
er
di
se
as
e,
m
or
ib
un
d
st
at
e
w
ith
pl
an
ne
d
w
ith
dr
aw
al
of
lif
e
su
pp
or
t,
fa
m
ily
or
ph
ys
ic
ia
n
re
fu
sa
l,
al
co
ho
la
bu
se
,
ac
tiv
e
m
yo
ca
rd
ia
l
is
ch
ae
m
ia
,
se
co
nd
-
or
th
ird
-d
eg
re
e
he
ar
t
bl
oc
k,
se
ve
re
de
m
en
tia
,
be
nz
od
ia
ze
pi
ne
de
pe
nd
en
cy
,
pr
eg
na
nc
y
or
la
ct
at
io
n,
an
d
se
ve
re
he
ar
in
g
di
sa
bi
lit
ie
s
or
in
ab
ili
ty
to
un
de
rs
ta
nd
En
gl
is
h
to
al
lo
w
de
lir
iu
m
ev
al
ua
tio
ns
IC
U
se
tt
in
g:
m
ed
ic
al
an
d
su
rg
ic
al
IC
U
s
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
lo
ra
ze
pa
m
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
th
e
st
ud
y
dr
ug
in
fu
si
on
w
as
st
ar
te
d
at
1
m
l/h
ou
r
(0
.1
5
µg
/k
g/
ho
ur
de
xm
ed
et
om
id
in
e
or
1
m
g/
ho
ur
lo
ra
ze
pa
m
)
an
d
tit
ra
te
d
by
th
e
be
ds
id
e
nu
rs
e
to
a
m
ax
im
um
of
10
m
l/h
ou
r
(1
.5
µg
/k
g/
ho
ur
de
xm
ed
et
om
id
in
e
or
10
m
g/
ho
ur
lo
ra
ze
pa
m
)
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
m
ax
im
um
12
0
ho
ur
s
Ta
rg
et
se
da
tio
n
le
ve
l:
se
da
tio
n
le
ve
lw
as
as
se
ss
ed
us
in
g
th
e
RA
SS
.
Bo
th
th
e
ph
ys
ic
ia
n
go
al
RA
SS
sc
or
es
an
d
th
e
nu
rs
e
go
al
RA
SS
sc
or
es
w
er
e
re
co
rd
ed
tw
ic
e
da
ily
at
th
e
tim
e
of
th
e
st
ud
y
as
se
ss
m
en
ts
.
N
o
sp
ec
ifi
c
RA
SS
sc
or
e
w
er
e
re
po
rt
ed
Re
sc
ue
m
ed
ic
at
io
n:
if
10
m
l/h
ou
r
of
th
e
st
ud
y
dr
ug
di
d
no
t
re
su
lt
in
ad
eq
ua
te
se
da
tio
n
or
if
pa
tie
nt
s
re
qu
ire
d
fr
eq
ue
nt
in
te
rm
itt
en
t
do
se
s
of
fe
nt
an
yl
fo
r
pa
in
,a
co
nt
in
uo
us
in
fu
si
on
of
fe
nt
an
yl
w
as
pe
rm
itt
ed
.I
f
a
pa
tie
nt
ex
pe
rie
nc
ed
su
dd
en
an
d
ur
ge
nt
le
ve
ls
of
ag
ita
tio
n
th
at
ha
d
th
e
po
te
nt
ia
lt
o
ca
us
e
ha
rm
to
th
e
pa
tie
nt
or
st
af
f,
a
pr
op
of
ol
bo
lu
s
of
25
–
50
m
g
w
as
al
lo
w
ed
,w
hi
le
th
e
st
ud
y
dr
ug
or
fe
nt
an
yl
in
fu
si
on
s
w
er
e
tit
ra
te
d
up
w
ar
ds
Pa
in
co
nt
ro
l:
in
te
rm
itt
en
t
do
se
s
of
fe
nt
an
yl
D
ai
ly
in
te
rr
up
tio
n:
th
e
de
ci
si
on
to
pe
rf
or
m
da
ily
ce
ss
at
io
n
of
se
da
tiv
es
an
d
sp
on
ta
ne
ou
s
br
ea
th
in
g
tr
ia
ls
w
as
co
ns
id
er
ed
pa
rt
of
th
e
m
an
ag
in
g
te
am
s’
pr
ot
oc
ol
an
d
no
t
m
an
da
te
d
as
pa
rt
of
th
e
st
ud
y
pr
ot
oc
ol
D
el
iri
um
-f
re
e
an
d
co
m
a-
fr
ee
da
ys
,
ef
fic
ac
y
of
th
e
tw
o
se
da
tio
n
re
gi
m
en
s
in
ac
hi
ev
in
g
cl
in
ic
al
ly
in
di
vi
du
al
is
ed
ta
rg
et
se
da
tio
n
go
al
s,
le
ng
th
s
of
st
ay
w
ith
ve
nt
ila
tio
n,
in
th
e
IC
U
,
an
d
in
th
e
ho
sp
ita
l,
al
on
g
w
ith
ne
ur
op
sy
ch
ol
og
ic
al
te
st
in
g
af
te
r
IC
U
di
sc
ha
rg
e,
28
-d
ay
m
or
ta
lit
y
an
d
12
-m
on
th
su
rv
iv
al
fr
om
en
ro
lm
en
t
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
Ri
ke
r,
20
09
71
Se
co
nd
ar
y
re
po
rt
s:
Ri
ke
r,
20
08
;1
19
Sh
eh
ab
i,
20
10
;5
2
an
d
La
ch
ai
ne
,
20
12
11
5
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
68
C
ou
nt
ry
:
A
rg
en
tin
a,
A
us
tr
al
ia
,
Br
az
il,
th
e
U
SA
an
d
N
ew
Ze
al
an
d
St
ar
t/
en
d
da
te
s:
M
ar
ch
20
05
–
A
ug
us
t
20
07
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
do
ub
le
-b
lin
d
RC
T
Ra
nd
om
is
at
io
n
m
et
ho
d:
ce
nt
ra
l
ra
nd
om
is
at
io
n
us
in
g
an
in
te
ra
ct
iv
e
vo
ic
e-
re
sp
on
se
sy
st
em
an
d
co
m
pu
te
r-
ge
ne
ra
te
d
sc
he
du
le
Le
ng
th
of
fo
llo
w
-u
p:
48
ho
ur
s
af
te
r
ce
ss
at
io
n
of
st
ud
y
dr
ug
Ty
pe
of
pa
rt
ic
ip
an
ts
:
ge
ne
ra
lI
C
U
En
ro
lle
d:
l
A
+
B:
42
0
Ra
nd
om
is
ed
:
l
A
:
25
0
l
B:
12
5
A
na
ly
se
d:
l
A
:
24
4
l
B:
12
2
A
ge
(y
ea
rs
),
m
ea
n
(S
D
):
l
A
:
61
.5
(1
4.
8)
l
B:
62
.9
(6
2.
8)
Se
x,
n
(%
):
l
A
:
m
al
e,
12
5
(5
1)
;
fe
m
al
e,
11
9
(4
9)
l
B:
m
al
e,
57
(4
7)
;
fe
m
al
e,
65
(5
3)
In
cl
us
io
n
cr
ite
ria
:
ag
ed
≥
18
ye
ar
s,
in
tu
ba
te
d
an
d
m
ec
ha
ni
ca
lly
ve
nt
ila
te
d
fo
r
<
96
ho
ur
s
pr
io
r
to
st
ar
t
of
st
ud
y
dr
ug
,
an
d
an
an
tic
ip
at
ed
ve
nt
ila
tio
n
an
d
se
da
tio
n
du
ra
tio
n
of
≥
3
da
ys
IC
U
se
tt
in
g:
N
R
Se
da
tiv
e
ag
en
ts
:
l
A
:
de
xm
ed
et
om
id
in
e
l
B:
m
id
az
ol
am
Ro
ut
e/
do
se
/f
re
qu
en
cy
:
op
tio
na
lb
lin
de
d
lo
ad
in
g
do
se
s
(u
p
to
1
µg
/k
g
de
xm
ed
et
om
id
in
e
or
0.
05
m
g/
kg
m
id
az
ol
am
)
co
ul
d
be
ad
m
in
is
te
re
d
at
th
e
in
ve
st
ig
at
or
’s
di
sc
re
tio
n.
Th
e
st
ar
tin
g
m
ai
nt
en
an
ce
in
fu
si
on
do
se
of
bl
in
de
d
st
ud
y
dr
ug
w
as
0.
8
µg
/k
g/
ho
ur
fo
r
de
xm
ed
et
om
id
in
e
an
d
0.
06
m
g/
kg
/h
ou
r
fo
r
m
id
az
ol
am
,
co
rr
es
po
nd
in
g
to
th
e
m
id
-p
oi
nt
of
th
e
al
lo
w
ab
le
in
fu
si
on
do
se
ra
ng
e
Le
ng
th
of
in
fu
si
on
of
st
ud
y
dr
ug
:
un
til
ex
tu
ba
tio
n
or
to
a
m
ax
im
um
of
30
da
ys
Ta
rg
et
se
da
tio
n
le
ve
l:
RA
SS
sc
or
e
ta
rg
et
ra
ng
e
of
−
2
to
1
Pe
rc
en
ta
ge
of
tim
e
w
ith
in
th
e
ta
rg
et
se
da
tio
n
ra
ng
e
(R
A
SS
sc
or
e
−
2
to
1)
du
rin
g
th
e
do
ub
le
-b
lin
d
tr
ea
tm
en
t
pe
rio
d,
pr
ev
al
en
ce
an
d
du
ra
tio
n
of
de
lir
iu
m
,
us
e
of
fe
nt
an
yl
an
d
op
en
-la
be
lm
id
az
ol
am
,
nu
rs
in
g
sh
ift
as
se
ss
m
en
ts
,
ad
ve
rs
e
ev
en
ts
co
nt
in
ue
d
DOI: 10.3310/hta20250 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 25
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Cruickshank et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
TA
B
LE
4
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
st
u
d
ie
s
(c
o
n
ti
n
u
ed
)
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
So
ur
ce
of
fu
nd
in
g:
H
os
pi
ra
Ex
cl
us
io
n
cr
ite
ria
:
tr
au
m
a
or
bu
rn
s
as
ad
m
itt
in
g
di
ag
no
se
s,
di
al
ys
is
of
al
lt
yp
es
,
pr
eg
na
nc
y
or
la
ct
at
io
n,
ne
ur
om
us
cu
la
r
bl
oc
ka
de
ot
he
r
th
an
fo
r
in
tu
ba
tio
n,
ep
id
ur
al
or
sp
in
al
an
al
ge
si
a,
ge
ne
ra
la
na
es
th
es
ia
24
ho
ur
s
pr
io
r
to
or
pl
an
ne
d
af
te
r
th
e
st
ar
t
of
st
ud
y
dr
ug
in
fu
si
on
,
se
rio
us
ce
nt
ra
ln
er
vo
us
sy
st
em
pa
th
ol
og
y
(a
cu
te
st
ro
ke
,
un
co
nt
ro
lle
d
se
iz
ur
es
,
se
ve
re
de
m
en
tia
),
ac
ut
e
he
pa
tit
is
or
se
ve
re
liv
er
di
se
as
e
(C
hi
ld
–
Pu
gh
cl
as
s
C
),
un
st
ab
le
an
gi
na
or
ac
ut
e
m
yo
ca
rd
ia
li
nf
ar
ct
io
n,
le
ft
ve
nt
ric
ul
ar
ej
ec
tio
n
fr
ac
tio
n
<
30
%
,
he
ar
t
ra
te
<
50
be
at
s
pe
r
m
in
ut
e,
se
co
nd
-
or
th
ird
-d
eg
re
e
he
ar
t
bl
oc
k,
or
sy
st
ol
ic
bl
oo
d
pr
es
su
re
<
90
m
m
H
g
de
sp
ite
co
nt
in
uo
us
in
fu
si
on
s
of
tw
o
va
so
pr
es
so
rs
be
fo
re
th
e
st
ar
t
of
st
ud
y
dr
ug
in
fu
si
on
Re
sc
ue
m
ed
ic
at
io
n:
pa
tie
nt
s
in
ei
th
er
gr
ou
p
no
t
ad
eq
ua
te
ly
se
da
te
d
by
st
ud
y
dr
ug
tit
ra
tio
n
co
ul
d
re
ce
iv
e
op
en
-la
be
lm
id
az
ol
am
bo
lu
s
do
se
s
of
0.
01
–
0.
05
m
g/
kg
at
10
-
to
15
-m
in
ut
e
in
te
rv
al
s
un
til
ad
eq
ua
te
se
da
tio
n
(R
A
SS
sc
or
e
of
ra
ng
e
−
2
to
1)
w
as
ac
hi
ev
ed
w
ith
a
m
ax
im
um
do
se
of
4
m
g
in
8
ho
ur
s
Pa
in
co
nt
ro
l:
fe
nt
an
yl
bo
lu
s
do
se
s
(0
.5
–
1.
0
µg
/k
g)
co
ul
d
be
ad
m
in
is
te
re
d
as
ne
ed
ed
ev
er
y
15
m
in
ut
es
D
ai
ly
in
te
rr
up
tio
n:
a
da
ily
ar
ou
sa
la
ss
es
sm
en
t
w
as
pe
rf
or
m
ed
th
ro
ug
ho
ut
th
e
tr
ea
tm
en
t
pe
rio
d,
du
rin
g
w
hi
ch
pa
tie
nt
s
w
ith
in
th
e
RA
SS
sc
or
e
ra
ng
e
of
−
2
to
1
w
er
e
as
ke
d
to
pe
rf
or
m
fo
ur
ta
sk
s.
Pa
tie
nt
s
w
er
e
co
ns
id
er
ed
aw
ak
e
w
ith
su
cc
es
sf
ul
co
m
pl
et
io
n
of
th
e
as
se
ss
m
en
t
w
he
n
th
ey
co
ul
d
pe
rf
or
m
th
re
e
of
fo
ur
ta
sk
s.
If
th
e
pa
tie
nt
’s
RA
SS
sc
or
e
w
as
>
1
at
th
e
tim
e
of
a
sc
he
du
le
d
as
se
ss
m
en
t,
st
ud
y
m
ed
ic
at
io
n
w
as
tit
ra
te
d
un
til
a
RA
SS
sc
or
e
of
−
2
to
1
w
as
ac
hi
ev
ed
an
d
th
en
th
e
ar
ou
sa
la
ss
es
sm
en
t
w
as
pe
rf
or
m
ed
.
If
pa
tie
nt
s
w
er
e
ov
er
se
da
te
d
to
a
RA
SS
va
lu
e
of
−
3
to
−
5,
st
ud
y
dr
ug
w
as
in
te
rr
up
te
d
un
til
a
RA
SS
sc
or
e
of
−
2
to
0
w
as
ac
hi
ev
ed
an
d
th
en
th
e
ar
ou
sa
la
ss
es
sm
en
t
w
as
pe
rf
or
m
ed
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
St
u
d
y
d
et
ai
ls
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s
In
te
rv
en
ti
o
n
ch
ar
ac
te
ri
st
ic
s
Su
m
m
ar
y
o
f
o
u
tc
o
m
es
Fi
rs
t
au
th
or
,
ye
ar
:
Ru
ok
on
en
,
20
09
69
Se
co
nd
ar
y
re
po
rt
s:
Ta
ka
la
,
20
07
12
5
La
ng
ua
ge
:
En
gl
is
h
Pu
bl
ic
at
io
n
ty
pe
:
fu
ll
te
xt
N
um
be
r
of
ce
nt
re
s:
2
C
ou
nt
ry
:
Fi
nl
an
d
an
d
Sw
itz
er
la
nd
St
ar
t/
en
d
da
te
s:
N
R
Pr
os
pe
ct
iv
e/
re
tr
os
pe
ct
iv
e
da
ta
co
lle
ct
io
n:
pr
os
pe
ct
iv
e
St
ud
y
de
si
gn
:
m
ul
tic
en
tr
e,
pr
os
pe
ct
iv
e,
ra
nd
om
is
ed
,
do
ub
le
-b
lin
d,
do
ub
le
du
m
m
y,
ac
tiv
e
co
m
pa
ra
to
r
st
ud
y
Ra
nd
om
is
at
io
n
m
et
ho
d:
N
R
Le
ng
th
of
fo
llo
w
-u
p:
45
da
ys
So
ur
ce
of
fu
nd
in
g:
O
rio
n
Ph
ar
m
a,
H
el
si
nk
i,
Fi
nl
an
d
Ty
pe
of
pa
rt
ic
ip
an
ts
:
ge
ne
ra
lI
C
U
En
ro
lle
d:
l
A
+
B
+
C
:
95
Ra
nd
om
is
ed
:
l
A
:
41
l
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l
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l
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l
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m
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l
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l
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l
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Appendix 6 Dosage and administration of
sedative agents
TABLE 5 Dosage and administration of sedative agents
Study
Dose and frequency of study drugs
Dexmedetomidine Comparator
Abdulatif et al.,
2004109
Loading dose (1 µg/kg) i.v. over 10 minutes,
followed by continuous i.v. infusion (5 µg/ml) at
a rate of 0.5 µg/kg/hour (0.1ml/kg/hour) to be
increased to a maximum of 1 µg/kg/hour
Propofol: i.v. infusion (10mg/ml) starting with a
dose of 1mg/kg/hour (0.1ml/hour) and
increasing up to 2mg/kg/hour
Corbett et al.,
2005110
Loading dose 1 µg/kg (actual body weight)
intravenously administered over 15 minutes,
followed by a 0.4 µg/kg/hour i.v. infusion
Propofol: 5 µg/kg/minute i.v. infusion titrated
within the range of 0.2–0.7 µg/kg/hour or
5–75 µg/kg/minute
Elbaradie et al.,
2004111
Loading infusion dose of dexmedetomidine
2.5µg/kg/hour over 10 minutes followed by
maintenance infusion at a rate of
0.2–0.5µg/kg/hour into a peripheral vein, with
the dosage adjusted to achieve the desired level
of sedation
Propofol: undiluted as a bolus dose of 1mg/kg
initially, followed by an infusion of
0.5–1mg/kg/hour, with the dosage adjusted to
achieve the desired level of sedation varying the
dose by 10% increase or decrease in infusion
rate in order to maintain the level of sedation
within the range previously considered adequate
Esmaoglu et al.,
2009112
Loading dose 1 µg/kg per 20 minutes, followed
by a continuous infusion at 0.7 µg/kg/hour
Midazolam: loading dose of 100mg in 100ml of
0.9% NaCl at 0.05mg/kg and continued at
0.1mg/kg/hour
Herr et al., 2003114 Loading dose of 1.0µg/kg over 20 minutes,
followed by a maintenance infusion of
0.4µg/kg/hour. After transfer to the ICU, the
infusion rate was titrated in the range of
0.2µg/kg/hour to 0.7µg/kg/hour as necessary to
maintain a RSS score of ≥3 before extubation,
≥2 after extubation
Propofol: no dose or rate of propofol was
specified by the protocol. Investigators were told
to follow their usual practice with regard to
propofol-based sedation
Jakob et al.,
201270; MIDEX
Six dose levels of each study drug covered
the full dose range (dexmedetomidine,
0.2–1.4 µg/kg/hour; midazolam,
0.03–0.2mg/kg/hour). Study treatments were
infused without loading dose at a dose matching
the pre-randomisation dose of midazolam for
1 hour. Thereafter, study drugs were titrated by
the patient’s nurse stepwise to maintain the
target RASS score
Midazolam: six dose levels of each study drug
covered the full dose range (dexmedetomidine,
0.2–1.4 µg/kg per hour; midazolam,
0.03–0.2mg/kg/hour). Study treatments were
infused without loading dose at a dose matching
the pre-randomisation dose of midazolam for
1 hour. Thereafter, study drugs were titrated by
the patient’s nurse stepwise to maintain the
target RASS score
Jakob et al.,
201270; PRODEX
Six dose levels of each study drug covered
the full dose range (dexmedetomidine,
0.2–1.4 µg/kg per hour; propofol, 0.3–4.0mg/kg
per hour). Study treatments were infused
without loading dose at a dose matching the
pre-randomisation dose of propofol for 1 hour.
Thereafter, study drugs were titrated by the
patient’s nurse stepwise to maintain the target
RASS score
Propofol: six dose levels of each study drug
covered the full dose range (dexmedetomidine
0.2–1.4 µg/kg per hour; propofol 0.3–4.0mg/kg
per hour). Study treatments were infused
without loading dose at a dose matching the
pre-randomisation dose of propofol for 1 hour.
Thereafter, study drugs were titrated by the
patient’s nurse stepwise to maintain the target
RASS score
MacLaren et al.,
2013116
Dexmedetomidine was started at
0.15 µg/kg/hour and adjusted by 0.15 µg/kg/hour
to a maximum of 1.5 µg/kg/hour
Midazolam: midazolam was started at 1mg/hour
and adjusted by 1mg/hour to a maximum of
10mg/hour. All infusions were adjusted by
increments of 2ml/hour to maintain blinding
continued
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TABLE 5 Dosage and administration of sedative agents (continued )
Study
Dose and frequency of study drugs
Dexmedetomidine Comparator
Maldonado et al.,
200972
Loading dose of 0.4 µg/kg, followed by a
maintenance drip of 0.2–0.7 µg/kg/hour
Propofol: propofol drip (25 µg/kg/minute–
50 µg/kg/minute)
Midazolam: midazolam drip (0.5mg/hour–
2mg/hour)
Memis et al.,
2009117
Loading dose at 1µg/kg over 10 minutes, followed
by a maintenance dose of 0.2–2.5µg/kg per hour
into a peripheral or central vein over a 24-hour
infusion
Propofol: loading dose of 1mg/kg over
15 minutes, followed by a maintenance dose of
1–3mg/kg per hour over a 24-hour infusion
Pandharipande
et al., 2007102
Started at 1ml/hour (0.15 µg/kg per hour
dexmedetomidine) and titrated by the bedside
nurse to a maximum of 10ml/hour
(1.5 µg/kg/hour dexmedetomidine)
Lorazepam: started at 1ml/hour (1mg/hour
lorazepam) and titrated by the bedside nurse to
a maximum of 10ml/hour (10mg/hour lorazepam)
Riker et al., 200971 Optional blinded loading doses (up to 1µg/kg
dexmedetomidine) could be administered at the
investigator’s discretion. The starting maintenance
infusion dose of the blinded study drug was
0.8µg/kg/hour per hour for dexmedetomidine or
responding to the mid-point of the allowable
infusion dose range of 4mg in 8 hours
Midazolam: optional blinded loading doses
(0.05mg/kg midazolam) could be administered
at the investigator’s discretion. The starting
maintenance infusion dose of blinded study
drug was 0.06mg/kg/hour for midazolam,
corresponding to the mid-point of the allowable
infusion dose range of 4mg in 8 hours
Ruokonen et al.,
200969
Infused without a loading dose at 0.8 µg/kg/hour
for 1 hour and then adjusted stepwise at 0.25,
0.5, 0.8, 1.1 and 1.4 µg/kg/hour
Propofol: infused at 2.4mg/kg/hour for 1 hour
and then adjusted stepwise at 0.8, 1.6, 2.4,
3.2 and 4.0mg/kg/hour
Midazolam: depending on standard care at time
of randomisation, midazolam was given either
as i.v. boluses (1–2mg), starting at three boluses
per hour for 1 hour, and thereafter one to four
boluses per hour and, if not sufficient, as
continuous infusion of 0.2mg/kg/hour, or as a
continuous infusion at 0.12mg/kg/hour for
1 hour, followed by adjustments at 0.04, 0.08,
0.12, 0.16 and 0.20mg/kg/hour. The initial dose
could be reduced, if considered necessary by the
treating clinician
Shah et al.,
2014120
Loading dose of injection with 1 µg/kg over
10 minutes, followed by a maintenance infusion
of 0.2–0.7 µg/kg/hour. The rate of the
maintenance infusion was adjusted to achieve
the desired level of sedation
Propofol: started at 5 µg/kg/minute
(0.3mg/kg/hour). The infusion rate was
increased by increments of 5–10 µg/kg/minute
(0.3–0.6mg/kg/hour) until the desired level
of sedation was achieved. A minimum period of
5 minutes between adjustments was allowed for
the onset of peak drug effect
Shehabi et al.,
2013121
Infusion at a starting dose of 1 µg/kg/hour
without a loading dose. Bolus administration of
dexmedetomidine was strictly prohibited
owing to the risk of severe bradycardia and sinus
arrest. If required, sedation could be
supplemented with propofol. Dexmedetomidine
infusion was administered between a minimum
of 0 µg/kg/hour and maximum of 1.5 µg/kg/hour
specified by the treating clinician and titrated to
achieve the desired level of sedation
Midazolam and/or propofol: the primary sedative
agent was at the discretion of the treating
clinician and could be midazolam and/or
propofol or other agents deemed necessary
but not dexmedetomidine. Clonidine and
remifentanil could not be administered. Selected
agents could be given by infusion or boluses and
titrated by bedside nurses, including cessation
when necessary, to achieve the default light
sedation or level of sedation deemed clinically
appropriate and specified by treating clinician
Srivastava et al.,
201455
Loading dose of 0.7 µg/kg over a period of
10 minutes followed by maintenance of
0.2 µg/kg/hour, with dosage increments titrated
up to 0.7 µg/kg/hour
Clonidine: i.v. infusion of clonidine 1 µg/kg/hour
and titration was achieved with dosage
increments up to 2 µg/kg/hour
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TABLE 5 Dosage and administration of sedative agents (continued )
Study
Dose and frequency of study drugs
Dexmedetomidine Comparator
Tasdogan et al.,
2009122
Loading dose at 1 µg/kg over 10 minutes,
followed by a maintenance 0.2 to 2.5 µg/kg per
hour into a peripheral or central vein over a
24-hour infusion
Propofol: loading dose of 1mg/kg over
15 minutes, followed by a maintenance of
1mg/kg to 3mg/kg per hour over a
24-hour infusion
Venn and
Grounds, 2001123
Loading dose of dexmedetomidine was
2.5 µg/kg/hour over 10 minutes, followed by a
maintenance infusion of 0.2–2.5 µg/kg/hour into
a peripheral or central vein
Propofol: propofol was given undiluted as an
infusion of 1–3mg/kg/hour after a loading dose
infusion of up to 1mg/kg over 10 minutes,
if required
i.v., intravenous.
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Appendix 7 Subgroup analyses: primary and
secondary outcomes
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